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Preface
The work contained in this dissertation was conducted in the department of
Chemical Engineering at Michigan Technological University from May 2016 to February
2020. This dissertation was written by Dylan Gregory Turpeinen. All experiments and
measurements discussed within this dissertation were performed by Dylan Gregory
Turpeinen with the assistance of collaborators who are listed in the following paragraphs.
Chapter 3 discusses the results of analyte detection using printed graphene
biosensors. All the sheet resistivity results from printing the graphene ink onto paper and
non-paper substrates were obtained by myself in Dr. Julie King’s laboratory. I received
help in changing ink properties such as ink viscosity and number of printing coats by
Clara Peterson (UG). I custom-made different graphene ink during an internship with XG
Sciences under Dr. Hiroyuki Fukushima and Thomas Ritch. Design, fabrication, and
testing of antibody-functionalized graphene sensors was performed by myself under the
direction of Dr. Caryn Heldt. 3-D printing wax barriers onto the graphene paper sheets
was performed by Matthew Weiss (UG) and Cameron Miller (UG) under my supervision.
During development and testing of the sensors, the work was presented in poster format
at the 2017 American Institute of Chemical Engineers (AIChE) national meeting in
Minneapolis, MN. The work discussed in Chapter 3 will not be published as no
significant, positive results were obtained for analyte detection.
Chapter 4 expands upon the previously published work using gold nanoparticles
(AuNPs) for virus detection. From Dr. Xue Mi’s AuNP/virus assay, we were able to
detect porcine parvovirus (PPV) and bovine viral diarrhea virus (BVDV) using
unmodified 15 nm AuNPs aggregated by mannitol. Ellie Lucier (UG) had significant
contribution to the work discussed in Chapter 4, from running the experimental assay and
collecting dynamic light scattering (DLS) results for my analysis. I learned how to
synthesize and characterize various shapes and sizes of AuNPs while at the National
University of Singapore working in Dr. James Chen Yong Kah’s lab in collaboration with
Nural ‘Ain Azman (Ph.D. candidate) and Malvin Wei Cherng Kang (Ph.D. candidate).
The results obtained during development of the virus detection assay was presented at the
2019 American Chemistry Society (ACS) national meeting in oral presentation format in
xii

Orlando, FL, and at the 2019 AIChE national meeting in poster format in Orlando, FL.
The results obtained and discussed in Chapter 4 showed no improvement to limits of
detection of PPV and BVDV than the previously tested 15 nm AuNPs, and will be
published.
Chapter 5 is about the design and testing of a continuous virus purification
technique based on an aqueous two-phase system (ATPS). Using Pratik Joshi’s (Ph.D.
candidate) batch-mode ATPS work to find an optimized ATPS for purification of PPV, I
designed and tested the possibility of the ATPS to be ran continuously without loss in
purification performance. Pratik trained me in forming ATPSs and how to determine the
composition of the phases using phase diagrams he generated for the PEG/citrate system.
With help from Erin Browne (UG), we constructed a continuous ATPS using a static inline mixer and tubular separator to achieve mixing and separation of the phases. Human
immunodeficiency virus type 1 group antigen labelled with green fluorescent protein
virus-like particles (HIV VLPs) were donated by Dr. David O’Hagan and Dr. Savita
Nikam from Esperovax for testing the continuous purification system. The COMSOL
Multiphysics modeling of the helical mixer was performed and analyzed by Dr. Hassan
Masoud from the Mechanical Engineering Department at Michigan Technological
University. Results obtained during the development of the ATPS process was presented
in poster format at the 2019 ACS national meeting in Orlando, FL. The results contained
in Chapter 5 are also currently in preparation for submission to the Separation and
Purification Technology journal.
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Abstract
Viruses are responsible for many human diseases that lead to suffering and death.
Acquired immunodeficiency syndrome (AIDS), influenza, and coronavirus disease 2019
(COVID-19) have claimed the lives of millions of people. Two methods have been
created to reduce the suffering caused by these diseases. The first is the manufacturing of
vaccines that prevent disease and the second is the development of virus detection tests
that lead to treatment. The work summarized in this dissertation discusses the
development of a continuous virus purification process using an aqueous two-phase
system for use in vaccine manufacturing. Additionally, two novel virus detection
methods were developed using graphene biosensors and a gold nanoparticle aggregation
assay.
This dissertation contains results obtained from a novel continuous viral particle
purification technique. The biomanufacturing industry would greatly benefit by switching
from traditional batch processes to continuous processing. The reduction in costs and
increase in productivity of continuous unit operations are driving the desire for
continuous biomanufacturing processes. Switching to continuous processing would
eliminate the current downstream processing challenges of viral-based biotherapeutics
including limited yield and throughput. The method developed here was a
chromatography-free separation technique aimed to increase throughput, purity, and yield
of viral particles. The technique utilized an aqueous two-phase system (ATPS) to
partition viral particles to a different phase than contaminant proteins. The ATPS
consisted of poly(ethylene glycol) (PEG) and sodium citrate to separate viral particles
from contaminant proteins from cell culture media. The ATPS was scaled-up from 1 g
batch systems and run continuously for porcine parvovirus (PPV) and human
immunodeficiency virus-like particles (HIV VLPs). Results from the purification of both
viruses showed >70% recovery with a majority of the contaminating proteins and DNA
being removed. This system has the potential to be further scaled-up for full-scale
continuous biomanufacturing of vaccines.
This dissertation also contains results from the development of two viral detection
methods. The first detection method used a graphene ink-based paper biosensor to
xv

electrochemically detect the presence of biomolecules. These graphene biosensors were
created with the goal of being lab-on-a-chip devices for rapid detection in low-resource
areas without the need of expensive laboratory equipment. The biosensors initially
showed promise for portable, inexpensive, and rapid detection of proteins via electrical
resistance changes at the sensor surface, but ultimately could not be applied to virus
particles. The second detection test utilized osmolyte-induced gold nanoparticle
(AuNP)/virus complex aggregation to detect whole viral particles. The AuNP aggregation
assay was previously developed to detect two model viruses, PPV and bovine viral
diarrhea virus (BVDV), using one size of AuNPs. The AuNP assay was capable of
nanomolar level detection of both viruses. Optimization of this previously established
virus detection method was performed by utilizing various sizes of AuNPs to lower the
limit of detection (LOD). Results from using other sizes of AuNPs showed no
improvement to the LOD.

xvi

1 Introduction and chapter summaries
1.1 Introduction
Viruses are difficult-to-detect microorganisms capable of infecting living cells
and causing numerous communicable diseases. Communicable diseases caused by a wide
variety of viruses claim the lives of millions of people each year around the world. Every
year, an estimated one billion people get sick and 290,000-650,000 people die due to
influenza [1]. Acquired immunodeficiency syndrome (AIDS) resulted in 770,000 deaths
and 1.7 million new cases in 2018 [2]. The novel coronavirus causing coronavirus disease
2019 (COVID-19) has already claimed the lives of 500,000 people, with 10 million cases
worldwide [3]. These communicable viral diseases and nearly 20 others are responsible
for extreme human suffering and death. However, with either prophylactic or early
treatment, these harmful effects can be decreased. To have as early treatment as possible,
rapid virus detection techniques are necessary. A non-specific virus detection method
would be helpful in confirming the presence of any disease-causing virus without the
need to test for individual viruses with time-consuming multiple tests. In addition to
detecting a disease as early as possible, vaccination remains as one of the best methods of
preventing deaths caused by infectious diseases [4]. However, the challenge of
developing early detection tests and manufacturing large quantities of vaccines still
exists. To help in reducing human suffering and death caused by diseases, my research
shown in the dissertation focused on developing two novel virus detection methods and
one vaccine manufacturing method.
The work contained in this dissertation explored two different methods for virus
detection. The first method utilized graphene/cellulose biosensors to electrochemically
detect the presence of biomolecules on the sensor surface. The graphene biosensor
initially showed promise for portable, inexpensive, and rapid detection of proteins via
electrical resistance changes at the sensor surface, but ultimately could not be applied to
virus particles. The second method utilized osmolyte-induced gold nanoparticle
(AuNP)/virus complex aggregation to detect viral particles. The AuNP aggregation assay
was previously developed to detect two model viruses, porcine parvovirus (PPV) and
1

bovine viral diarrhea virus (BVDV), using one size of AuNPs. The AuNP assay was
capable of nanomolar level detection of both viruses, which is significantly more
sensitive than standard commercially available ELISA kits. Optimization of this
previously established virus detection assay was attempted by utilizing various sizes of
AuNPs to lower the limit of detection of the assay.
This dissertation also contains results from developing a novel virus purification
technique that has the potential to be used in large scale manufacturing of vaccines. To
create a safe and effective vaccine, the viral product during downstream processing must
be purified from contaminants while maintaining high titer. To aid in supplying the world
with critical vaccines, the recovery of viral products from downstream processes must
also be increase beyond the currently accepted 30% [5]. The developed virus purification
method utilizes an aqueous two-phase system (ATPS) of poly(ethylene glycol) and
sodium citrate to partition viral particles to a different phase than contaminant proteins
with high recovery (>70%) and purity. The ATPS was scaled-up and run continuously for
PPV and human immunodeficiency virus-like particles (HIV VLPs). This system has the
potential to be further scaled-up for full-scale continuous biomanufacturing of vaccines.

1.2 Chapter summaries
Chapter 2 of this dissertation begins with a literature review of current analyte
detection strategies and vaccine manufacturing processes. Each section discusses
conventional methods that have their limitations, and current research aimed at breaking
through those limitations. The graphene biosensor literature review focuses on the
different electrochemical detection techniques, and the advantages and disadvantages of
each technique used to detect proteins and viruses. The gold nanoparticle literature
review focuses on how functionalized particles have been used for virus detection, and
how attempts have been made to use more simple, non-functionalized particle systems.
The virus purification literature review focuses on the traditional batch processes used to
purify viruses for use in vaccines, and the development of semi-continuous processes.
Chapter 3 discusses the graphene biosensors project aimed at designing and
testing an inexpensive paper-based sensor for the electrochemical detection of analytes at
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the sensor surface. The ultimate goal of the graphene biosensors was to create a point-ofcare device for the detection of a malaria biomarker, plasmodium falciparum
topoisomerase I (pfTopI). The biosensors were created from a sheet of blended
cellulose/graphene nanoplatelets from XG Sciences. From previous experiments
performed and published in 2013, it was shown that an increase in the protein
concentration present on the sensor surface caused an increase in electrical resistivity due
to an altered electron flow path. This increase in resistivity was also found to be
dependent on the protein’s molecular weight. In 2012, XG Sciences’ manufacturing
process of the graphene/cellulose sheets was changed, which caused a project shift to
flexographic printing of graphene ink onto various paper and non-paper substrates.
Printing the graphene ink onto various substrates allowed us to tune printing parameters
such as ink viscosity, number of coats, and ink composition to achieve conditions for
analyte detection during testing. Due to the new biosensor creation method, protein
detection on the surface of the graphene-ink printed biosensors needed to be confirmed
before application to virus particle detection. XG Sciences’ standard graphene
nanoplatelet ink was printed on common copier paper and on qualitative chromatography
filter paper to attempt to mimic the cellulose/graphene biosensors previously created. The
graphene ink was also printed onto highly hydrophobic poly(ethylene terephthalate)
(PET) and various grades of Tyvek. An additional optimization strategy was altering the
composition of the ink to various grades of graphene nanoplatelets to induce different
resistivity changes as proteins were applied. The graphene-ink printed biosensors were
tested for their ability to detect the presence of proteins in a buffer solution compared to
the buffer solution alone as a control. Although numerous combinations of graphene ink
types and printing substrates were tested, no combination led to a statistically significant
difference in resistivity change when the target protein was applied to the sensor surface,
compared to when protein-free solutions were applied. To enhance the electrochemical
signal due to analyte presence, the graphene surface was functionalized with antibodies to
specifically bind antigens to the sensor surface. Testing the functionalized graphene
sensors resulted in the same conclusion that antigen presence could not be distinguished
from buffer-only application. Although the number of tests performed covered a large
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experimental area, there could exist a combination of parameters not tested which would
lead to accurate detection of analytes. As another possible system for analyte detection, a
gold nanoparticle virus detection assay was developed and tested in the Heldt lab.
Chapter 4 discusses the gold nanoparticle (AuNP)-virus assay to detect two
different viruses at the lowest concentration possible. The goal of the AuNP-virus assay
was to find an optimal size ratio between AuNPs and virus particles to enhance
electrostatic interactions for binding and signal enhancement using dynamic light
scattering (DLS). With an optimal size ratio determined, the assay could be applied to
practical applications such as rapid surface cleanliness tests for hospital rooms or
equipment. This assay is possible due to the unique ability of osmolytes (mannitol and
glycine) to preferentially aggregate virus particles, by decreasing the hydration layer
around the virus while leaving proteins un-aggregated in solution. Unmodified, citratecapped AuNPs are electrostatically bound to the positive patches present on virus
surfaces and aggregated in the presence of mannitol and glycine. By performing serial
dilutions of the non-enveloped porcine parvovirus (PPV), the limit of detection was 106
MTT50/mL [6]. To test the non-specific nature of the assay, a larger enveloped bovine
viral diarrhea virus (BVDV) was detected to a limit of 104 MTT50/mL [6]. Both of these
virus detection tests were performed alongside a control test of various concentrations of
a model bovine serum albumin (BSA) protein, which showed no ability to be detected.
This AuNP-virus assay demonstrates the ability to detect virus particles at lower
concentrations than conventional immunodetection methods with unmodified,
nonfunctionalized AuNPs. In an attempt to improve the limit of detection of the
AuNP/virus assay, AuNPs of different diameters were synthesized and applied in the
assay to find an optimal ratio of diameters between the virus particles and AuNPs.
Chapter 5 discusses the continuous aqueous two-phase system (ATPS) used to
purify and recover virus particles directly from crude cell lysate supernatant. An ATPS is
a type of liquid-liquid extraction technique; which is formed by mixing two components
above critical concentrations, where they separate into two distinct phases over time. The
ATPS used here was a mixture of poly(ethylene glycol) (PEG) and trisodium citrate. This
project was the developmental beginning of a continuous ATPS. The future goal of the
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continuous ATPS will be to scale up and run the process for up to a week to purify
various novel vaccine candidates. Batch-mode ATPS experiments performed in the Heldt
lab showed ≥80% of virus particles can be recovered in a different phase than
contaminant proteins [7]. Using the batch-mode results, a bench-scale continuous process
was designed and tested for the ability to recover and purify PPV in the PEG-rich phase.
The continuous process was optimized by designing and evaluating a mixer capable of
mixing the viscous PEG, citrate, and virus streams to allow for proper partitioning of
virus particles to the PEG-rich phase and proteins to the citrate-rich phase. Proper mixing
and phase separation were confirmed for the various mixers tested by comparing batchmode and continuous-mode physical property measurements of the PEG-rich and citraterich phases after separation to confirm proper ATPS formation. PPV and a human
immunodeficiency gag-GFP virus-like particle (HIV gag-GFP VLP) were tested in the
continuous ATPS for the ability to recover and purify the viral product in the PEG-rich
phase with contaminating proteins in the citrate-rich phase. More than 70% of the viral
product was recovered in the PEG-rich phase with high protein purity visualized with
SDS-PAGE gels and more than 70% DNA removal. These results indicate that
continuous ATPS could be used as a continuous downstream purification method.
Chapter 6 concludes the dissertation with key findings from each project and
provides future work theories for further development.
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2 Literature review
2.1 Analyte detection systems
2.1.1 Current virus detection methods
Currently, there are three main ways viruses are detected. The first, and oldest,
way is to grow host cells via conventional cell culture methods and infect the cells with a
virus-containing sample to confirm cell death and presence of a virus [8-11]. The second,
and most common today, is the method of polymerase chain reaction (PCR) where
specific nucleic acid sequences from the virus are amplified and detected [12]. The third,
also common, method is using enzyme-linked immunosorbent assays (ELISAs) where a
system of antibodies is used to capture and detect a specific virus [13]. Virus detection
methods using biosensors are being developed and have promise of becoming more
clinically relevant as they are less expensive, faster, and can be used at the point-of-care
[14].
2.1.1.1 Cell culture
Cell culture for virus detection has been regarded as the gold standard method
since the beginning of clinical diagnosis of viral diseases [15]. The earliest use of
laboratory cell culture was used for the detection of influenza virus using various cell
lines including Vero cells, primary epithelial cells of human adenoid, primary rhesus
monkey kidney (PMK) cells, and Madin-Darby canine kidney (MDCK) cells [9, 10]. The
most conventional method of virus detection is growing host cells, infecting them with
virus-containing samples, waiting for virus propagation, and checking for any cytopathic
effect (CPE) within the cells. This method was used to detect influenza virus from
various specimen locations including the lungs and throats of patients [10]. This
traditional technique was also used to detect the presence of human adenovirus in a 5-7
day cell culture in HEp-2 cells [16]. Although the cell culture methods are well
understood and has been used for a long time, the major drawback is the amount of time
it takes to perform. This length of time between detection and treatment could mean the
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difference between life and death for the patient. Another drawback to this technique is
the variability in cell lines from lab to lab, which makes it difficult for standardization
around the world [17].
2.1.1.2 Polymerase chain reaction
PCR is a type of nucleic acid test (NAT) that is used to make millions of copies of
a specific sequence of nucleic acid in order to increase the copy number for detection
[12]. Once the nucleic acid of interest is replicated to a certain level, the detection is
achieved by co-amplification of fluorescence or luminescent dyes [18]. It is widely used
today to detect numerous infectious agents, including up to six different infectious
diseases for blood donations in the United States [19, 20]. The PCR technique has been
used for the rapid detection of yellow fever virus in under three hours including sample
preparation, which is a significant improvement on the five or more days necessary for
detection using traditional cell culture methods [21]. PCR has also been used to bring the
detection time of influenza A virus strain H3N2 down to approximately three hours,
which is much faster than the minimum three days necessary for traditional cell culture
techniques [22]. Most recently, PCR has been critical for the detection of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2); however, several hours are still
needed to prepare and test the samples [23]. While PCR has an advantage of decreased
detection time compared to traditional cell culture methods, PCR requires skilled
laboratory technicians and is considerably expensive for the necessary reagents [18].
2.1.1.3 Enzyme-linked immunosorbent assays
The use of ELISAs has also helped replace the time-consuming traditional virus
detection techniques. ELISAs are plate-based assays in which immobilized antibodies are
used to capture antigens (viruses) of interest, and secondary, enzyme- or fluorescentlinked antibodies are used for detection. Detection is achieved when a substrate is added
to the enzyme-linked antibody to form a measurable product, or fluorescence is measured
from fluorescent-linked antibodies [24]. In addition to NATs, ELISAs are used for blood
donation screening for up to seven different infectious diseases in the United States,
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including Hepatitis B and C, human immunodeficiency virus (HIV), and Zika virus [19,
20]. In the lab, an ELISA was used to detect H5 hemagglutinin from avian influenza
virus in as little as 31 minutes, which is much faster than the days needed for traditional
cell culture methods and faster than a commercially-available ELISA kit of 260 minutes
– without loss of detection at just 0.23 ng/mL [25]. Although more rapid than traditional
cell culture techniques, ELISAs require complex sample preparations, skilled laboratory
personnel, and monoclonal antibodies used in the kits are expensive [18]. An ideal virus
detection technique would be as rapid as possible, sensitive, inexpensive, and easy to
perform.
2.1.2 Electrochemical biosensors
Biosensors is a broad term used to describe devices that combine a biological
component with physicochemical detectors to detect an analyte of interest [26].
Biosensors are attractive alternatives to the current virus detection methods because they
have the potential to simultaneously possess all the characteristics of an ideal detection
system. Biosensors have three main components, a biological receptor, a transducer, and
a detector, shown in Figure 2.1 [27, 28]. The biological receptor in the case of viral
biosensors can be enzymes, antibodies, or nucleic acid that sense the presence of an
analyte, and the transducer transforms the molecular interactions between the receptor
and analyte to a quantifiable signal measured by the detector [17, 27]. Three main
categories of biosensors exist: electrochemical, piezoelectric, and optical [17, 27]. This
review will focus on electrochemical biosensors for virus detection applications.
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Figure 2.1: Main components of an electrochemical biosensor [28]
2.1.2.1 Types of electrochemical biosensors
Electrochemical biosensors are the most common and longest-used type of
biosensors to date [29, 30]. Three common groups of electrochemical biosensors exist,
differing by the electrochemical property being measured: amperometric/voltammetric
[31-34], potentiometric [35, 36], and impedimetric/conductometric [37-41]. Each of these
have been explored for their virus detection ability using various biological receptors
including oligonucleotides, cells, enzymes, and antibodies – discussed later in section
2.1.2.2.
2.1.2.1.1 Amperometric/voltammetric
Within the amperometric category exists two subtypes of measurement strategies:
amperometry and voltammetry. Amperometry is when the current changes are measured
at a constant voltage, and voltammetry is when the current changes are measured with
controlled changes in voltage [28]. The second measurement strategy is more commonly
known as cyclic voltammetry. Amperometric biosensors work by measuring the current
change from the oxidation or reduction (redox) of an electroactive species and sensing
element which is linearly dependent on the analyte concentration applied [42]. Regardless
of the measurement strategy (amperometry or voltammetry), the resulting signal from the
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redox reaction of electroactive species in a biochemical reaction being monitored is
correlated to the analyte concentration [29].
For a redox reaction occur, mediated or non-mediated pathways exist for electron
transfer between the electroactive species and the sensing element. A mediator is an
artificial electron transferring agent which facilitates the electron transfer between the
analyte and electrode [30]. Commonly used mediators include ferrocene and its
derivatives [43-45], methylene blue [46, 47], and N-methyl phenazine [48-50]. One
graphitized mesoporous carbon-methylene blue mediated nanocomposite biosensor was
fabricated for detecting the hepatitis C virus (HCV) core antigen using cyclic
voltammetry measurements [47]. The methylene blue was able to effectively transfer
electrons from the redox reaction occurring from the reduction of a horse radish
peroxidase (HRP) antibodies immobilized on the sensor surface, shown in Figure 2.2.
While this sensor exhibited a wide linear range of detection from 0.25 pg/mL to 300
pg/mL with a limit of detection (LOD) of 0.01 pg/mL, multiple complex steps were
necessary for device creation which could limit the widespread use of the sensor [47].

Figure 2.2: Methylene blue (MB)-mediated electron transfer during the redox reaction
between the gold electrode surface and HRP [47]
One mediator-free sensor was created to detect the human immunodeficiency
virus type 1 (HIV-1) p24 antigen down to 0.0064 ng/mL in the range of 0.01 to 60.00
ng/mL [33]. As a mediator was not used in the HIV-1 biosensor, the sensitivity was in the
ng/mL range which is higher than the HCV biosensor which had a detectable range in the
pg/mL. While these example sensors show low limits of detection and good linear ranges,
they are limited by their complex fabrication and testing methods requiring equipment
capable of generating cyclic voltammograms [51]. These sensors also utilized sensor
ligands for the biological receptor to specifically capture the analyte of interest, which
will be further discussed in section 2.1.2.3.
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2.1.2.1.2 Potentiometric
Potentiometric biosensors operate by measuring the potential at a working
electrode with respect to a reference electrode during an electrochemical reaction [30].
Contrary to amperometric biosensors, potentiometric biosensors operate at zero current
and monitor the accumulation of charge at an electrode surface. The reaction produces a
readable signal caused by a difference in ionic concentration of a target analyte that is
reduced during an electrochemical reaction [29]. The Nernst Equation governs the
relationship between the concentration of an analyte/its reduced species, and the
potential, allowing the concentration to be determined by the measurement of the
potential [28]. Equation 2.1 shows the Nernst Equation:
𝐸𝐸 = 𝐸𝐸0 −

𝑅𝑅𝑅𝑅

𝑛𝑛𝑛𝑛

𝐶𝐶 −

ln � 𝐶𝐶𝑋𝑋 �
𝑋𝑋

(2.1)

where E (volts) is the electrode potential at zero current, E0 (volts) is the standard
reduction potential of the cell, R is the universal gas constant (8.314 J/(mol·K)), T (K) is
the temperature, n is the number of electrons transferred, F is Faraday’s constant (96,485
C/mol), CX- (mol/L) is the concentration of the reduced species at the electrode, and CX
(mol/L) is the concentration of the non-reduced species at the electrode [28, 52].
One example of the potentiometric technique was used to detect poliovirus in the
presence of a contaminating adenovirus mixture to the un-optimized concentration of
0.644 nM (3.10 × 1011 particles/mL) [36]. The group observed significant changes in
potential versus the reference electrode when poliovirus alone was present on the sensor
surface compared to when a mixture of poliovirus and adenovirus was applied [36]. This
is a significant result in the detection of poliovirus as the sensor did not require the use of
a biological receptor to capture the virus. The group accomplished this by creating a
poliovirus-templated alkanethiol self-assembled monolayer (SAM) onto a gold surface,
where only poliovirus could attach during sample testing due to the specific size, shape,
and hydrophobicity of the cavity, shown in Figure 2.3 [47].

Figure 2.3: Fabrication of poliovirus-templated alkanethiol SAM on a gold surface [36]
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Another potentiometric biosensor was used to detect the non-structural protein 1
(NS1) from the Dengue serotype 2 virus using egg yolk immunoglobulin (IgY) as the
biological receptor [35]. This sensor was able to quickly detect NS1 with an LOD of 0.09
µg/mL with a linear range of 0.10-10 µg/mL in samples containing real serum [35].
Again, although these sensors show promise for viral detection, sensor fabrication
contains complex steps and the necessary equipment (a potentiostat) is complex and
requires trained personnel to operate and interpret the output.
2.1.2.1.3 Impedimetric/conductometric
Impedimetric biosensors detect analytes by measuring the change in impedance
caused by a biochemical reaction or analyte binding events occurring at/on an electrode
surface [51]. Impedance describes the opposition to the flow of electrical current, similar
to electrical resistance [53]. However, impedance is used when alternating current (AC)
is used to drive the flow of electrons instead of direct current (DC). Impedimetric
biosensors utilize electrochemical impedance spectroscopy (EIS) where small amplitude
sine wave perturbations are used over a wide frequency range to produce changes in
impedance as a function of the change in frequency [51]. The resulting impedance versus
frequency output is known as the electrochemical impedance spectrum. It is also
important to note that conductance is the inverse of resistance, meaning conductance
describes the ability of a material to allow the flow of electrical current.
Conductometric biosensors are considered sub-sets of impedimetric sensors as
they assume an ideal resistor system is applicable [28, 53]. Conductometric biosensors
measure the electrical conductance across electrodes due to the presence of an analyte or
solution [28, 54]. Typically, conductivity changes across electrodes are attributed to a
change in ionic strength of the medium/analyte during an enzymatic reaction, but
conductivity changes can also occur due to binding of analytes to the biosensor or
electrode surface [40, 41]. A few advantages over amperometric and potentiometric
sensors exist: conductometric sensors do not require a reference electrode, complex
electrical equipment, and they can be readily downsized to reduce costs [28, 55]. These
advantages make conductometric devices more portable and less complex to use.
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Although conductometric sensors have many advantages, they have rarely been explored
for their ability to detect viruses and are mostly used to detect small molecules such as
arginine and phenol [55-57] and heavy-metal ions in water [58, 59].
One of the only examples of a conductometric biosensor for virus detection was
created for the detection of bovine viral diarrhea virus (BVDV). The biosensor used antiBVDV antibodies as the biological receptor for specific detection of BVDV, and
polyaniline as the sensor transducer which provided signal amplification during detection
[41]. Signal measurement was accomplished by using a multimeter to monitor the change
in resistance across a copper wafer surface when different concentrations of BVDV were
applied to the sensor surface. In under ten minutes, 102 cell culture infective dose
(CCID)/mL BVDV was detected in antigen-spiked blood serum, which is favorable when
compared to the three or more hours of assay time using a commercially available ELISA
kit with comparable titer detection ability [41].
When considering all the electrochemical techniques discussed, conductometric
biosensors have the highest potential to be portable and rapid as they only require the use
of a multimeter to record the resistance across electrodes or sensor surfaces. Multimeters
can be found in handheld configurations, meaning a new sensor and multimeter can be
brought to the point-of-care and used to detect the presence of virus when needed.
2.1.2.2 Biological receptors
A biological receptor (bioreceptor) is the part of a biosensor that captures a
specific analyte of interest. The bioreceptors can be whole cells, oligonucleotides,
enzymes, or antibodies immobilized onto the sensor surface. The two most popular
choices for electrochemical biosensors are immobilized antibodies and complementary
oligonucleotides, due to their superior specificity for the target analyte.
2.1.2.2.1 Aptamers
Aptamers are short (20-100 nucleotides) single-stranded DNA or RNA (ssDNA or
ssRNA) oligonucleotides that are specific to the analyte of interest to be detected by a
biosensor [28, 60]. Immobilization of aptamers onto biosensor surfaces or electrodes is
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achieved via covalent attachment, physical absorption, electrostatic/hydrophobic
interactions, or π-π stacking [60-63]. Although the immobilization of oligonucleotides
does not specifically require complex chemistry pathways for immobilization onto the
surface of electrodes, as is required with antibodies, groups still choose to covalently bind
the aptamers to their sensor or electrode surfaces. The non-covalent bond pathway of
immobilization is possible because the oligonucleotide strands have the ability to π-π
stack with commonly-used carbon-based substrates for electrode and sensor creation [64,
65]. This immobilization strategy can reduce sensor preparation steps, leading to faster
sensor creation and less chance of fabrication errors. However, it is common for the 5’or 3’-end of aptamers to be modified with biotin for later attachment to a streptavidinfunctionalized surface [60]. Thiolated aptamers are also commonly immobilized on gold
nanoparticle-coated substrates and electrodes which allow them to self-assemble onto a
gold surface [31, 66]. Regardless of how the aptamer is immobilized, when an aptamer is
immobilized onto a sensor or electrode surface, the result is an aptasensor.
An aptasensor can detect the interaction between the immobilized aptamer and a
target oligonucleotide strand via any of the electrochemical strategies discusses
previously. For example, one amperometric aptasensor was created by immobilizing
thiolated tetrahedral-structured ssDNA probes onto a gold electrode via Au-S bonds for
the detection of avian influenza A (H7N9) [31]. This aptasensor was able to specifically
detect H7N9 to a LOD of 100 fM, even in the presence of other influenza viruses H1N1
and H3N2. Aptasensors offer an attractive virus detection technique due to the highly
specific binding events between aptamer probes and target, complementary
oligonucleotides. However, the stability of oligonucleotides is of concern, as probe
functionality can be reduced with changes in pH, temperature, and ionic strength of the
sample and sensor environment [67].
2.1.2.2.2 Antibodies
Antibodies are the most common bioreceptors due to their highly specific nature
and sensitivity to target antigens [29]. When an antibody is immobilized onto a sensor or
electrode surface, an immunosensor is created. Immobilization of antibodies is
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accomplished by electrostatic interactions between the Fc region and sensor surface [35,
68, 69], streptavidin-biotin binding [33], and through carbodiimide-assisted
amidation/amine-reactive crosslinking chemistry [70-77]. Carbodiimide-assisted
amidation and amine-reactive crosslinking chemistry are the most widely used
immobilization technique to form a covalent bond between the biosensor surface and
primary amine on the antibody. Carbodiimide-assisted amidation reactions are used to
create reactive N-hydroxysuccinimide ester (NHS) groups by reacting carboxylic acid
groups located on a biosensor surface with 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide·HCl (EDC) linkers. NHS-amine reactive crosslinking chemistry is
performed between NHS esters and primary amines as shown in Figure 2.4. In this well
understood chemical pathway, NHS esters react with primary amines in near-physiologic
pH (7.2 - 9) to create stable amide bonds [78]. The immobilization chemical pathway
from a reactive carboxylic acid group to a stable amide bond to a primary amine located
on the antibody is used to immobilize antibodies to biosensor surfaces to create highly
specific and sensitive devices for target antigens.

Figure 2.4: NHS-amine reactive crosslinking chemical pathway to produce a stable amide
bond between a primary amine and NHS ester [78]
One amperometric immunosensor was developed using 1-pyrenebutyric acid Nhydroxysuccinimide ester (PSE) as a linker between graphene oxide sheets and rotavirusspecific antibodies. The PSE linker was used to non-covalently functionalize the
graphene oxide sheets through π-π stacking of the pyrene group on PSE and the sp2
hybridized carbon in the graphene sheets, shown in Figure 2.5 [72]. Rotavirus-specific
antibodies were then crosslinked to the PSE by forming a stable amide bond between
primary amines on the antibody and the NHS group on the PSE. A cyclic voltammogram
(CV) was collected from the antibody-functionalized graphene electrode and was
compared to a CV collected from the application of rotavirus to the antibody15

functionalized graphene electrode, showing a change in current due to increased
resistance from rotavirus-bound antibodies. The immunosensor detected rotavirus with an
LOD of 102 plaque-forming units (pfu)/mL [72].

Figure 2.5: Rotavirus immunosensor fabrication pathway [72]
Another biosensor was created for the detection of the M1 protein from influenza
virus by immobilizing polyclonal anti-M1 antibodies onto a boron-doped diamond
electrode via the same EDC-NHS chemistry pathway [77]. Electrical impedance
spectroscopy was used to detect the presence of decreasing concentrations of M1 protein
to an LOD of 50 fg/mL (40 virions) in only six minutes. The immunosensor was
compared to other detection methods for influenza including PCR, ELISA, and other
biosensors, showing superior testing time and comparable virion detection limits [77].
With low limits of detection being reported, immunosensors developed by
immobilizing antibodies to detect specific antigens show promise for being rapid,
sensitive, and specific diagnostic tools. However, antibodies are extremely sensitive to
their environment, as any change in pH or temperature can change their function due to
denaturing. Additionally, immobilizing an antibody and restricting their structure to one
conformation could lead to a loss of biological function and a loss of detection ability
[28, 79].
2.1.2.3 Graphene-based biosensors
This section of the biosensors review focuses on the material used to create the
biosensor. Since electrochemical biosensors are being reviewed, the sensor surface must
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be conductive to allow the transport of electrons. Common materials for device and
electrode creation include gold [31, 33, 35-37, 66, 68], graphene [39, 40, 72, 75], and
other carbon-based materials [32, 38, 45]. Graphene is a popular material to construct
biosensors because of its excellent electron transfer ability, high mechanical strength, and
high surface area available for functionalization [80]. Graphene surfaces have the
potential to replace the solid support surfaces used in conventional ELISA. Using a
conductive surface for an ELISA can provide a faster detection method via electrical
detection when compared to traditional methods, which were discussed in section 2.1.1.3.
In a conventional ELISA, antibodies are immobilized onto a solid plastic support such as
the polystyrene walls of a 96-well plate. In this type of system, the antibody that is
immobilized on the surface has no way of producing a measurable electrical signal.
Therefore, additional antibodies and labels are needed to produce a detectable signal,
typically a color change from enzymatic reduction reactions. The most common way to
develop a signal is with a sandwich ELISA, shown in Figure 2.6. To create this system, a
primary antibody is immobilized onto a solid surface (Figure 2.6A). An antigen specific
to the primary antibody is applied, which binds to the primary antibody (Figure 2.6B).
After washing, a secondary antibody is attached to the other end of the antigen, which is
bound to the primary antibody (Figure 2.6C). The last antibody attached is the detecting
antibody labeled with a luminescent enzyme or a fluorescent tag to induce a color change
after addition of the enzyme’s substrate (Figure 2.6D) [81, 82]. Instead of relying on a
colorimetric readout of antigen-antibody interactions inside of a plastic well,
electrochemical biosensors can be used to quantify the antigen presence via electrical
signal on a conductive surface, such as graphene.

Figure 2.6: Schematic of a sandwich ELISA. A) Immobilization of the primary antibody
to the substrate, B) antigen-primary antibody binding, C) antigen-secondary antibody
binding, and D) detecting antibody/label complex binding to the secondary antibody [82]
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A sandwich ELISA was constructed on a graphene-sheet coated carbon electrode
for the amperometric detection of the H5 gene from avian influenza H5N1 [83]. The
graphene sheets were modified with PSE, functionalized with a streptavidin linker to bind
a biotin-and fluorescein-labelled PCR H5 gene DNA strand, and finally an antifluorescein HRP detecting antibody was applied, as seen in Figure 2.7. As a proof-ofconcept device, the amperometric response for the H5 gene was above the negative
control response down to 0.2659 ng/µL, showing promise for a portable, on-site
screening point-of-care detection device after further device optimizations [83]. Although
this device shows promise for viral gene detection, it does not detect the influenza virus
directly, as a PCR-amplified gene was used and diluted as the target analyte, which slows
down detection time.

Figure 2.7: Fabrication schematic of the graphene-enhanced electrochemical biosensor
for the detection of the H5 viral gene [83]
Another sandwich ELISA system was created for the detection of
carcinoembryonic antigen (CEA). This amperometric immunosensor was fabricated in
the same way as previously discussed on a graphene/gold nanoparticle nanocomposite
surface [84]. The immunosensor showed two linear ranges of CEA detection between
0.5-50 ng/mL and 250-2000 ng/mL with LODs of 0.28 ng/mL and 181.5 ng/mL,
respectively [84]. Although this device does not detect a virus particle, it shows the
potential application of virus detection with substitutions of the antibodies, while leaving
the electrochemical detection technique the same.
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In my work, a sandwich ELISA system was created to detect the presence of
mouse immunoglobulin G (IgG) antigen and tested using the conductometric sensing
strategy. Despite the drawbacks of using a multiple antibody-based system, the sandwich
ELISA immunosensor system was chosen to produce the most specific sensors possible.
To detect the analytes of choice, the conductometric sensing strategy was chosen as it
does not require sophisticated equipment or training to obtain or analyze results, making
the sensors easier to transition out of a laboratory setting. The sandwich ELISA system
was developed on a graphene biosensor to allow for an electrical signal readout across
two electrodes when the target analyte is applied. The goal of the conductometric
sandwich ELISA biosensor was to be used for the direct detection of viral particles,
which is currently missing from the literature.
2.1.3 Gold nanoparticles used for analyte detection
Although electrochemical biosensors offer an inexpensive, specific, and rapid
method to detect analytes, other methods of detection exist that do not require additional
fluorescent enzyme labels, electrochemical reactions, or solid sensor surfaces. For
example, colorimetric assays based on the aggregation of metal nanoparticles have been
developed to detect and quantify analytes [85-87]. The developed colorimetric assays
provide rapid and sensitive detection of a variety of viruses and proteins, based on the
aggregation or de-aggregation of nanoparticles.
2.1.3.1 AuNP properties and aggregation
Gold nanoparticles (AuNPs) are used for biosensing due to their unique
physicochemical and optical properties [88, 89]. Among the most important properties of
AuNPs are their biocompatibility, controllable size, surface modification capability, and
their intrinsic surface plasmon resonance (SPR) [89]. SPR is a result of the cloud of free
electrons present near the surface of AuNPs. The natural oscillations of the free electrons
on the surface of the AuNPs are called surface plasmons, which exist at the gold metaldielectric interface [90]. The surface plasmons can be excited by light, and when
coupling occurs between the incident light and the surface plasmons, electromagnetic
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waves in the visible range are given off [88, 90]. This resonant oscillation between the
incident light and surface plasmons is called SPR [91]. SPR is the property responsible
for the AuNPs color in liquid solution, which is bright red, corresponding to a wavelength
of 519 nm for 16 nm particles. A red-shift in the absorbance wavelength occurs as the
AuNPs size increases and the liquid solution begins to show as a blue color, seen in
Figure 2.8.

Figure 2.8: 2-150 nm AuNPs color in liquid solution [92]
The wavelength spectrum of the particles is measured using ultraviolet-visible
(UV-Vis) spectrophotometry. When AuNPs of the same size aggregate, there is also a
red-shift due to reduced inter-particle separation [93, 94]. This can be seen in Figure 2.9
as AuNPs of diameter 16.3 nm (Figure 2.9A-C) are aggregated in the presence of 100
mM NaCl (Figure 2.9D-F) [93]. The aggregation of the AuNPs is quantified by the
aggregation index (AI) shown in Equation 2.2 [95]
𝐴𝐴𝐴𝐴 =

𝜆𝜆𝑚𝑚𝑚𝑚𝑚𝑚+60𝑛𝑛𝑛𝑛
𝜆𝜆𝑚𝑚𝑚𝑚𝑚𝑚

(2.2)

where λmax is the absorbance at the maximum wavelength and λmax+60nm is the absorbance
at a wavelength of 60 nm added to the maximum wavelength. This equation is used to
determine the aggregation extent of AuNPs in two ways. First, the UV-Vis peak
absorbance decreases as AuNPs aggregate, and second, the UV-Vis peak broadens as
AuNPs aggregate. These two phenomena can be seen by comparing the UV-Vis spectrum
curves in Figure 2.9A and D, where the peak absorbance is higher and sharper in Figure
2.9A. A larger AI corresponds to a high extent of aggregation [93]. The aggregation of
AuNPs can also be measured using dynamic light scattering (DLS), which gives the
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hydrodynamic diameter (DH) of nanoparticles in a liquid medium. The change in DH
(ΔDH) before and after aggregation can be calculated using Equation 2.3
Δ𝐷𝐷𝐻𝐻 = 𝐷𝐷𝐻𝐻,𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 − 𝐷𝐷𝐻𝐻,𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏𝑏

(2.3)

where DH, after is the hydrodynamic diameter (nm) after inducing aggregation, and DH,
before

is the hydrodynamic diameter (nm) before inducing aggregation.
The red-shift and diameter increase resulting from AuNPs aggregation can be

used to develop a colorimetric assay by creating conditions that bring analyte-covered
AuNPs together and then quantifies them by AI or diameter increase. For example, the
ΔDH from Figure 2.9 is 922.2 nm – 16.3 nm = 905.9 nm.

Figure 2.9: Example of AuNP aggregation resulting in a red-shift. A) UV-Vis spectrum
of 16.3 nm AuNP, B) hydrodynamic diameter measurement of AuNP, C) TEM image of
16.3 nm AuNP, D) UV-Vis spectrum of aggregated 16.3 nm AuNP, E) hydrodynamic
diameter measurement of aggregated AuNP, and F) TEM image of aggregated AuNP
[93]
One AuNP assay was developed to detect clinical samples of hepatitis C virus
(HCV) RNA based on the aggregating effects of cationic and anionic AuNP binding [94].
Citrate-capped AuNPs were functionalized with a thiolated-ssDNA probe specific to
HCV RNA. When denatured, complementary HCV RNA strands were added, basepairing between the probe and HCV RNA strand occurred, leaving negatively charged
RNA phosphate backbone strands un-bound. Finally, when cationic AuNPs were added,
the particles bound to the folded HCV RNA complexes did not allow the cationic and
anionic AuNPs to come into contact and aggregate. In contrast, when cationic AuNPs
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were added to samples containing non-complementary HCV RNA strands, the anionic
AuNPs were able to bind to the phosphate backbone of the RNA probe. This binding
reduced the inter-particle distance between cationic and anionic AuNPs, leading to
aggregation and a visible color change. The aggregation and anti-aggregation were
characterized by UV-Vis absorption peak changes. These results were directly compared
to PCR and ELISA techniques, which agreed favorably with both conventional tests. This
assay allowed for the detection of unamplified HCV RNA from clinical samples in ~30
minutes with a 94.1% specificity with a limit of detection of 4.57 IU/µL [94]. However,
one drawback to this type of assay is the need to functionalize the AuNPs with nucleic
acid probes, which tend to be expensive.
2.1.3.2 Modified, functionalized AuNPs
Modified AuNPs, commonly through antibody and nucleic acid functionalization,
have been used extensively for the detection of analytes. These types of AuNP assays are
specific and sensitive due to the use of specific targeting receptors for the analyte of
interest. As discussed for bioreceptor immobilization, the modification of AuNPs is very
similar. Thiolated probes can be readily bound to the AuNP surface, and antibody
immobilization onto AuNPs is achieved through EDC-NHS chemistry. Additionally,
antibodies can be passively adsorbed to the surface of citrate-capped AuNPs through
ionic and hydrophobic interactions [96]. This was done to conjugate 13 nm AuNPs with
anti-influenza A H3N2 HA mouse monoclonal antibodies (mAbs) for the un-amplified
detection of influenza A virus H3N2 [96]. When the virus was in the presence of the
AuNP-mAb complexes, aggregation lead to a red-shift in the absorbance spectrum due to
decreased intra-particle distance. This aggregation was confirmed using DLS, where a
ΔDH of 116 nm (21 to 137 nm) was measured. This assay had a limit of detection of 7.8
hemagglutination units (HAU) with a detection time of only 30 minutes [96]. Another
AuNP assay based on DLS measurements was developed to detect influenza A virus
H1N1. The AuNPs were conjugated with mAbs specific to the influenza A virus using a
3,3’-dithiobis(sulfosuccinimidyl propionate) bifunctional linker to covalently bind the
mAbs to the AuNPs. AuNPs with diameters of 30, 60, and 80 nm were used to evaluate
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the size dependence of the influenza assay, revealing that a different AuNP size did not
affect the assay performance [97]. By optimizing the concentration of AuNPs, a limit of
detection of <100 TCID50/mL was achieved, which is 1-2 orders of magnitude better than
conventional ELISA kits and only requires ~30 minutes of detection time [97]. Another
virus assay was developed using peptide-functionalized AuNPs for the detection of
Newcastle disease virus (NDV) [98]. The AuNPs were functionalized with NDV-specific
peptides via strong sulfur-gold bonds. Using optical density measurements with different
virus concentrations for varying degrees of aggregation, a limit of detection of 0.125
HAU was found in 20 minutes [98]. These virus detection assays show the aggregation of
AuNPs as the detection pathway, but anti-aggregation of AuNPs can also be used.
The anti-aggregation method was highlighted in a gold nanostar (AuNS) assay for
the detection of enterovirus 71 (EV71) that causes hand, foot, and mouth disease
(HFMD) [99]. In this assay, 105 nm AuNS were conjugated with a receptor protein with
a known affinity to EV71 through passive adsorption. Aggregation was prevented in
samples that contained EV71 because the receptor protein binding sites were filled,
which prevented nonspecific interactions with contaminant proteins present in the sample
media [99]. Raman spectroscopy peak intensities after the addition of decreasing
concentrations of EV71 were measured, leading to a limit of detection of 107 pfu/mL in
only 15 minutes [99].
Functionalized AuNPs lead to the rapid detection of various viruses with low
limits of detection. However, preparation steps to functionalize and wash the AuNPs
increase overall testing time. Increased testing time can cause stability issues because
ligand-functionalized AuNPs are temperature and the external-environment dependent.
2.1.3.3 Unmodified AuNPs
To overcome the potential stability issues of functionalized AuNPs, unmodified
AuNPs can be used for analyte detection assays. Using unmodified AuNPs reduces the
complexity of analyte detection assays, as there are no AuNP pre-treatment
functionalization steps. The detection strategy of analytes with unmodified AuNPs is the
same as functionalized AuNPs, which is achieved through observing absorbance peak
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shifts after aggregation or quantifying the aggregation with DLS. There are also
opportunities to develop assays for naked-eye detection of aggregation through a color
change of the testing liquid. Most of the developed unmodified AuNP assays are all
centered around keeping the AuNPs dispersed in solution to keep the solution color red.
This is achieved by adding complementary ssRNA/ssDNA primers to the sample tube,
which contains the target virus’ RNA/DNA, leading to stable dsRNA/DNA formation
that keeps the testing solution red.
This technique was used to detect unamplified BVDV-RNA by naked-eye [100].
In this assay, BVDV probes were added to testing tubes that contained unmodified
AuNPs and either non-complementary BVDV-RNA or complementary BVDV-RNA.
When NaCl was added to samples containing non-complementary BVDV-RNA, no
aggregation was observed because the BVDV probes stabilized the unmodified AuNPs
through electrostatic interactions between the negatively charged backbone of the probe
and citrate shell around the AuNPs [100]. When NaCl was added to samples containing
complementary BVDV-RNA, salt-induced AuNP aggregation occurred because the
probes hybridized to the BVDV-RNA, and NaCl was free to aggregate the un-stabilized
AuNPs. By using a fixed concentration of AuNPs and probes, BVDV concentration was
varied to show a LOD of 80 TCID50/mL by UV-Vis, and 200 TCID50/mL by naked-eye
[100]. Despite these promising results, a purified RNA sample was used for detection
because unmodified AuNPs can also passively bind to other contaminants in clinical
samples, including other DNA fragments and proteins.
Another assay using unmodified AuNPs was developed for the detection of
Dengue virus using a similar detection pathway [101]. Instead of inducing aggregation of
unmodified AuNPs with NaCl, this assay found that the addition of a neutral-charge
peptide nucleic acid (PNA) caused aggregation because PNA removed the chargerepulsion between AuNPs thus reducing the interparticle distance [101]. The PNA was
the probe for the target Dengue DNA. In the presence of the Dengue DNA, hybridization
occurred, which left the AuNPs un-aggregated in solution. This assay showed a LOD of
Dengue DNA at 0.12 µM [101]. However, this study used a purified ideal Dengue DNA
sample that did not originate from the full Dengue virus. This limits the actual application
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of these types of assays because the target nucleic acids are located inside the capsid of
the virus, which must be extracted prior to detection. While the extraction of the target
nucleic acids is possible prior to an AuNP assay, this could result in assay complications
because AuNPs non-specifically bind to other biomolecule fragments. One possible
solution to avoid this pre-treatment extraction step is to develop an AuNP assay to detect
whole viral particles.
Only a limited number of unmodified AuNP assays exist for the detection of
whole viral particles. One assay utilized sialic acid-stabilized AuNPs (SA-AuNPs) for the
detection of influenza B Victoria and Yamagata [102]. Influenza viral proteins
(hemagglutinin) are known to bind to sialic acid, which is present on the surface of lung
epithelial cells [103]. By using SA-AuNPs, influenza virus was detected as
hemagglutinin-sialic acid binding occurred, aggregating the nanoparticles. The
aggregation caused peak broadening of the absorption spectrum at 610 nm, and a change
in absorbance at this wavelength was calculated with a decreasing volume of the
influenza virus added. A LOD of only 0.09 volume % of influenza virus was achieved
[102]. Another viral particle detection assay was developed for human papillomavirus
type 16 virus-like particles (HPV16 VLPs) using unmodified citrate-capped AuNPs to
explore the interaction between VLPs and AuNPs [104]. In this study, AuNP-VLP
complexes formed mainly through hydrophobic interactions, which hindered the saltinduced aggregation of un-complexed AuNPs. To test that hydrophobic interactions were
the dominant driving force for complex formation, a higher and higher concentration of
ethanol was added to the VLP-AuNP mixture showing that aggregation was increased
with higher ethanol concentration. VLP solubility increased at higher ethanol
concentrations, resulting in less VLPs complexing with AuNPs, leaving more AuNPs to
be aggregated by 70 mM NaCl [104].
As shown in these whole viral particle detection assays with AuNPs, there is some
mechanism for the viral particles to aggregate and decrease the interparticle distance
between virus-AuNPs complexes. Another option for aggregating viral particles is using
osmolytes.

25

2.1.4 Osmolytes
Osmolytes are water-soluble, naturally-occurring molecules that are produced by
cells to enhance protein stability by combating osmotic stress and other environmental
stresses [105, 106]. Osmolytes are classified into three groups, carbohydrates/polyols
(sucrose, mannitol), amino acids (glycine), and methylamines (TMAO). Additionally,
osmolytes can be classified as protecting or denaturing osmolytes. Protecting osmolytes
do not affect the native protein structures and promote protein folding and denaturing
osmolytes denature proteins into unfolded states [105, 107]. Although the exact
mechanism of osmolyte action on protein folding/unfolding is not fully understood, it has
been shown that protecting osmolytes are preferentially excluded from the protein surface
and do not directly interact with the protein’s amide backbone, whereas denaturing
osmolytes interact with the protein backbone directly, causing protein unfolding [107,
108]. The theory of protecting osmolytes causing protein stabilization is called the
osmophobic effect, which states that there is an unfavorable interaction between
osmolytes and the protein peptide backbone [109]. In the unfolded state, the peptide
backbone is more readily exposed to osmolyte resulting in a high free energy that is
reduced by protein folding back to its native state [109]. Another important action of
osmolytes is their ability to alter the water structure around biomolecules. Protecting
osmolytes are excluded from the surface of proteins, and they interact with water
molecules near the surface, increasing protein stability due to increased intra-protein side
chain interactions [105, 110]. This is the solvation effect of osmolytes. Since the
osmolytes pull water molecules away from the surface of proteins, the protein surface
becomes slightly more hydrophobic, which is stabilized by intra-protein side chain
interactions [105, 110].
2.1.4.1 Preferential virus aggregation
Protecting osmolytes have been used for the preferential aggregation of both
enveloped and non-enveloped viral particles [111, 112]. To test the aggregation ability of
protecting osmolytes, 18-26 nm non-enveloped porcine parvovirus (PPV) was filtered
through a 0.2 µm filter that would not normally retain the PPV in water or PBS. Over
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80% of PPV was removed by the filter using 1.0 M glycine, mannitol, alanine, and
trehalose, which aggregated the PPV and allowed for removal by the filter [111]. Even in
the presence of model contaminating proteins, BSA and lysozyme, 1.0 M mannitol and
alanine were able to remove 85.1% and 80.2% of the PPV, respectively, with less than
5% protein removal [111]. The theory for this preferential virus aggregation versus
protein aggregation with osmolytes is based on the relative hydrophobicity between
viruses and proteins and the physical structure of the two macromolecules [6, 111]. When
osmolytes are introduced into the solutions containing PPV or proteins, there is a partial
dehydration layer around the biomolecules resulting in free energy that must be
minimized. For proteins, their relatively more hydrophilic and flexible nature allows the
excess free energy to be minimized by increased protein side chain interactions resulting
in protein structure compaction and stabilization [6, 111, 113]. Since viruses are
relatively more hydrophobic and rigid than proteins, the dehydrated and hydrophobic
exposed patches are minimized by virus-virus aggregation [111]. This same preferential
aggregation phenomenon was confirmed using an enveloped, 60-80 nm Sindbis virus
heat resistant strain (SVHR) [112]. In this work, 0.3 M proline and mannitol were able to
remove over 80% of SVHR using a 0.2 µm filter while leaving BSA and lysozyme
proteins in solution with less than 23% removed [112]. These studies highlight the ability
of protecting osmolytes to preferentially aggregate viral particles and not proteins.
2.1.4.2 Osmolyte-induced AuNP aggregation virus assay
The ideas of preferential virus aggregation, AuNP complexation with viral
particles, and decreased intra-AuNP distance leading to a color change and measurable
change in complex diameter have been combined to develop a general viral particle
detection assay, shown in Figure 2.10 [6]. When an osmolyte solution was added to
virus/AuNP complexes, aggregation occurred if a high enough concentration of virus was
present (Figure 2.10, top left side pathway). When osmolyte was added to
protein/AuNP complexes, aggregation did not occur because the osmolyte preferentially
aggregated viruses, not proteins (Figure 2.10, bottom left side pathway). To test salt’s
ability to aggregate virus/AuNP complexes, NaCl was added to AuNP/virus complexes
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where aggregation occurred at low enough virus concentration because the virus could
not protect the AuNPs from salt-induced aggregation (Figure 2.10, top right pathway).

Figure 2.10: Scheme of virus detection using osmolyte-induced aggregation of virusAuNP complexes [6]
In this assay, AuNPs and viral particles were complexed, aggregated using
protecting osmolytes, and the aggregation was quantified by DLS for decreasing titers of
PPV and BVDV before and after osmolyte addition. As a control, model proteins BSA
and thyroglobulin were complexed with AuNPs, and their aggregation extent due to
osmolyte addition was compared to the aggregation of virus-AuNP complexes. As
expected, the virus-AuNP complexes aggregated with the addition of 1 M mannitol, and
protein-AuNP complexes did not aggregate. PPV was detected in the range of 105 to 108
MTT50/mL with a LOD of 106 MTT50/mL [6]. BVDV was detected in the range of 103 to
107 MTT50/mL with a LOD of 104 MTT50/mL [6].
To expand upon this AuNP virus detection assay, I synthesized different sizes of
AuNPs and used them in the same AuNP/virus assay to improve the LOD, discussed in
Chapter 4.
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2.2 Purification of viral particles
2.2.1 Vaccine manufacturing process
Vaccination is one of the most effective methods of preventing and eradicating
deadly viral diseases. Millions of lives are saved every year due to vaccination, but
producing vaccines is a difficult undertaking. Vaccine manufacturing is challenging
because a high concentration (titer) of viral particles must be produced and purified while
ensuring the safety and efficacy throughout the manufacturing process to meet regulatory
guidelines. Viruses are complex biomolecules that are susceptible to their environment
and the processes they are put through in the vaccine manufacturing process [114]. These
manufacturing processes are separated into two broad sections: upstream production
where the viral particles are generated in flasks and bioreactors (Figure 2.11, Upstream),
and downstream purification where the viral particles are separated from contaminants
using various unit operations (Figure 2.11, Downstream). Common unit operations for
upstream production of viral products are batch-mode and perfusion (continuous)
bioreactors. Common unit operations for the downstream purification of products are
centrifuges, filtration units, and chromatography columns.

Figure 2.11: Vaccine biomanufacturing train from upstream production through
downstream purification [115, 116]
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2.2.1.1 Conventional upstream vaccine production
Perhaps the most well-known and recognizable vaccine is the seasonal influenza
vaccine. This vaccine has been historically produced in embryonated hens’ eggs, which
act as mini bioreactors after being inoculated with the seasonal influenza strain. Many
issues exist with this egg-based influenza vaccine platform, such as the need for over 400
million eggs every year for enough doses, the fact that some influenza strains are highly
pathogenic and could kill the embryos, and if a downstream purification run fails a large
batch of doses must be discarded [117]. To address these issues, the shift to animal cellculture techniques has been successfully implemented. However, a large majority of
influenza vaccine doses are still created in eggs today [117, 118]. The slow transition
from producing influenza vaccines in eggs to cell-culture bioreactors is due to the large
infrastructure already in place to support the egg-based system, including collaborations
between academic and industrial laboratories to ensure the next batch of vaccine will
contain appropriate antigenic variants [119]. The current role of large-scale animal cell
culture bioreactors is to augment and support the growing demand of the influenza
vaccine, not to fully replace the well-established egg-based vaccine production network.
However, with further developments and implementation, the reliance on egg-based
platforms for the flu vaccine could be fully realized. Numerous cell lines have been
considered and researched to produce influenza vaccines. These cell lines include human
embryonic kidney (HEK) cells [120], Madin-Darby canine kidney (MDCK) cells [118,
120], Vero cells [120], and Spodoptera frugiperda (Sf9) insect cells [120], summarized in
Table 2.1 [121]. Most of the approved vaccines are produced using MDCK and Vero cell
lines because they have been extensively characterized and their growth kinetics are wellunderstood from numerous studies [117].
One study directly compared MDCK and Vero cells for the production of the
influenza virus for vaccines in a lab-scale bioreactor [122]. The adherent MDCK and
Vero cells were grown on microcarriers inside of a 5 L stirred tank bioreactor (STR) and
infected with influenza A Wisconsin strain at ~1.8×106 cells/mL with a MOI of 0.001.
The cells were also grown on microcarriers in a 2 L wave bioreactor and infected at
~1.1×106 cells/mL with a MOI of 0.018. To compare the ability of MDCK and Vero cells
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to produce influenza virus, a virus productivity value was calculated from quantifying the
HA produced during infection per cell. In the STR, MDCK and Vero cells produced
10,000 virions/cell and 4,976 virions/cell, respectively. In the wave reactor, MDCK and
Vero cells produced 33,255 virions/cell and 3,990 virions/cell, respectively [122]. This
study demonstrated that MDCK cells can produce higher titer of influenza virus
compared to Vero cells, which shows why current cell-based influenza vaccines are
produced from MDCK cell lines. However, there is still a need to increase the
productivity of cell lines to produce even more viral particles to meet the demand and
replace egg-based methods.
Table 2.1: Selected list of approved influenza vaccines from cell-culture derived systems
Vaccine
Approved
Approval
Cell Line
Vaccine Type
Name
Region
Year
Optaflu/
MDCK
Trivalent subunit
EU/USA
2007/2012
Flucelvax
33016
(H1N1, H3N2, B)
Monovalent
Celtura
Germany
MDCK
2009
(H1N1)
Monovalent
Celvapan
EU
Vero
2009
(H1N1 or H5N1)
Trivalent inactivated
2010
Preflucel
EU
Vero
(H1N1, H3N2, B)
Quadrivalent subunit
Flublok
USA
Sf9
2013
(updated annually)
Flucelvax
Tetravalent subunit (H1N1,
EU/USA
MDCK
2016
Quadrivalent
H3N2, Victoria, Yamagata)
As mentioned, upstream production of viral particles is achieved in a bioreactor.
A bioreactor is used to grow host cells which are inoculated with a virus to allow for
virus propagation as the cells grow. The classical and commonly used mode for
bioreactor operation is batch cultivation where cells and media are introduced into the
bioreactor and left to grow and collected after many days of virus replication, shown in
Figure 2.12A [123]. Bioreactors are equipped with various sensors and probes to monitor
the temperature, dissolved oxygen level, pH, and other properties to maintain cell health
over time. The six phases of cell concentration occur over time within a batch-mode
operated bioreactor, as shown on the growth curve in Figure 2.12B [124]. The lag phase
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is the short amount of time where cells adapt to their new environment and do not grow.
The acceleration phase is when cell growth begins as cells uptake nutrients from the
surrounding media and continues at a constant rate through the growth phase. The decline
phase starts when the cells utilize all available nutrients, and growth stops through the
stationary phase. The death phase begins when cells lose viability and lyse, or break apart
[124]. The most critical phase to consider is the growth phase where cells are growing,
producing virus particles, and all other biomolecules during normal cell growth.

Figure 2.12: A) Schematic of a bioreactor [123] and B) growth curve of cells within a
batch-mode bioreactor [124]
While upstream studies focus on increasing the productivity of cell lines for the
desired viral product, additional biomolecules are generated during cell growth. These
biomolecules are considered impurities that must be separated from the viral product
during downstream purification, so knowing the composition of what exits the bioreactor
after growth is important for designing downstream purification methods. These
biomolecules include both process- and product-related impurities. Process-related
impurities include proteins from serum-based media and compounds added for cell lysis.
Product-related impurities include host cell proteins (HCP), host cell DNA (hcDNA), and
cell debris after cell lysis.
The amount and type of impurities vary based on the type of expression system
used to produce the viral product. For example, in the case of the egg-based vaccines, the
allantoic fluid from the eggs is collected, which contains high concentrations of
32

ovalbumin protein, tissue compounds, and other solids from chicken growth [125]. In
contrast, the flu vaccine produced using serum-free media with MDCK or Vero cells
have considerably less solids and protein content [125]. Regardless of the expression
system or compounds added upstream, the downstream purification train is responsible
for removing all impurities to below regulatory-approved concentrations prior to the final
formulation of the drug product.
2.2.1.2 Conventional downstream purification processes
The downstream purification train starts directly after the bioreactor harvest step
and is called clarification. Clarification aims to remove cells, cell debris, and aggregates.
The clarification step varies for each viral product, and different unit operations are used
to achieve this removal [125]. The clarification step is a very important step in the
purification train as a low solid content stream to other downstream unit operations
allows them to operate more efficiently. Numerous unit operations are available for the
clarification step, such as low-speed and high-speed centrifuges and various filtration
units. The unit operation used for clarification depends on the viral product’s
physicochemical properties, including size, shape, isoelectric point, and stability. A very
common clarification step is using a low-speed centrifuge to pellet cells and cell debris
from the reactor harvest and collecting the supernatant which contains the virus and other
soluble impurities. This process was used to clarify a rotavirus vaccine produced in Vero
cell culture by centrifuging the harvest at 2,831 × g for 30 minutes and 4,424 × g for 10
minutes at 4°C [126]. Another centrifuge-based clarification step (1,000 × g for 10 min at
4°C) was applied to rotavirus VLPs after a freeze-thaw cycle to lyse the cells [127].
Although neither study directly reported the virus recovery after the primary clarification
step, centrifugation was adequate to remove cell debris, which allowed for additional
purification steps with filtration and chromatography units. The major drawbacks to a
centrifuge-based clarification step are the difficulty of scale-up and continuous operation
[125, 128]. At the production level scale, the only way to process more harvest is to use
additional centrifuges, which leads to increased capital costs and labor costs [125]. These
challenges lead to the development of different clarification steps using filtration units.
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Tangential flow filtration (TFF) and dead-end filtration (DEF) are attractive
options for the clarification of viral products. Although DEF units are easy to implement
at any scale, disadvantages include virus adsorption on the filter surfaces, potential
leachables in the product stream, and rapid fouling from cake formation [125]. TFF units
have numerous advantages, including simple design and operation, variable flow rate
options, and can be operated continuously. As opposed to the conventional perpendicular
feed flow of DEF, TFF utilizes a feed flow parallel to the membrane surface, which
allows constant cake formation on the filter surfaces, leading to steady-state filtrate flux,
shown in Figure 2.13 [129].

Figure 2.13: A) Feed and product streams in TFF and B) filtrate flux rate profile through
filtration time using TFF [129]
The TFF technique has been used extensively at the pilot and production scales
[126, 130-132]. This size-based separation technique has received attention because viral
particles are in the size range of nanometers, whereas cells and aggregates are in the
micrometer range [131]. In one study, a 0.65 µm TFF membrane was used for the
primary clarification of 5 L of influenza VLPs produced in a stirred-tank bioreactor with
High Five (Hi5) insect cells [133]. The primary harvest clarification was successful based
on maintaining 100% HA content before and after clarification, as well as high turbidity
reduction [133]. Although the study did not pursue the 0.65 µm filter further for scale-up,
the potential exists to use the membrane for similar viruses on a large scale. Another
study demonstrated the large-scale recovery of tetanus toxin and toxoid for the
diphtheria-tetanus-pertussis (DTP) vaccine using the TFF technique in a cGMP setting
34

[132]. The conventional primary clarification technique utilizes centrifugation, which
shows losses greater than 25%. At a pilot-scale working volume of 400 L, the tetanus
toxin broth was clarified by a microfiltration TFF membrane with a pore size of 0.22 µm
at >96% recovery. The study also showed that 60,000 L of broth could be processed by
the same filter before irreversible fouling occurred [132]. These studies highlight the
potential and direct application of TFF for use in the primary clarification of viral
products for use in vaccines, which is important in the downstream purification train.
The step after clarification in the downstream purification train is the main
purification section, which aims to separate the target viral product from other soluble
impurities. In the main purification section, the physicochemical properties of the virus
are of great importance in designing purification techniques. These physicochemical
properties include the isoelectric point (pI), size, envelope presence, and hydrophobicity
which are extensively exploited for use in chromatographic separations [5]. The
purification strategies used include ultracentrifugation, ultrafiltration, biphasic extraction
systems, and chromatography [5].
Historically, and especially in monoclonal antibody (mAb) production,
chromatography has been used as the main unit operation in downstream purification.
Chromatography has many different techniques, including size-exclusion, ion exchange,
hydrophobic interaction, and affinity. For example, Protein A affinity chromatography
has been used for the primary capture step in many production-scale mAb processes
[134]. While these chromatography techniques have been used for efficient purification
of mAbs, the relatively large size of viral particles limits their adsorption to the column
resins leading to decreased purification efficiency and flow rates [135]. To address these
issues in viral particle purification, new chromatography resins are being developed and
tested including monoliths and larger-pore resins. The main advantage of using a
monolith-based resin is the ability to flow at 10-20 times higher than conventional resin
columns because mass transfer within porous resin beads is dominated by convection,
rather than diffusion [136].
One monolithic column chromatography technique was used for the purification
of HIV-1 gag virus-like particles from host cell impurities, including extracellular
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vesicles [137]. With a 1 mL monolith column, 41.9 ± 9.6% of the VLPs were recovered
with a 90.6% total protein and 98.2% total dsDNA depletion, comparable to the 48.1%
VLP recovery using a standard method of density gradient ultracentrifugation [137]. This
process only took 47 minutes and resulted in 2000 doses of the purified VLP. Although
not tested during the study, 8 L and 40 L monolith columns are commercially available,
leading to possible scale-up opportunities for full-scale production [137]. Another study
evaluated the ability of an 8 mL convective interaction media (CIM) quaternary amine
(QA) monolith column to purify Vero cell-derived influenza A and B viruses. At
physiological pH, the influenza viruses are negatively charged and bind to the QA
monolith, which were eluted with 0.5 M NaCl. The four different influenza strains had
recoveries between 70.8 ± 32.3% and 87 ± 30.8% [138]. Protein removal was between
93.3 ± 0.4% and 98.6 ± 0.2% and hcDNA removal was between 76.4% and 99.9% [138].
2.2.1.3 Continuous-mode downstream purification
While there have been advances in the downstream purification of viral particles
using conventional techniques like filtration and chromatography, another optimization is
necessary to boost the productivity of these unit operations. Switching to the continuous
operation for these unit operations would increase throughput and productivity while
simultaneously reducing the size of equipment [139, 140]. A reduction in the size of
equipment would reduce the facility size of a manufacturing suite, leading to increased
capital cost savings [139]. The first attempts of making the downstream purification train
continuous was using chromatography for mAbs and a limited number of viruses. In one
process for the continuous purification of influenza virus, simulated moving bed (SMB)
chromatography was used and compared directly to conventional batch chromatography
[141]. SMB chromatography utilizes countercurrent flow between target analytes (solids)
and the mobile phases through an arrangement of many columns and valves, shown in
Figure 2.14 [141, 142]. The size-exclusion SMB process continuously moves the inlet
and outlet ports along a bed, which allows for increased resolution between solids with
similar retention times [143]. Using this size-exclusion SMB technique, 70% of influenza
H1N1 produced in adherent MDCK cells was recovered, compared to 80% recovery
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using a conventional batch process [141]. Total protein reduction was 60% for the
continuous SMB process compared to an 80% reduction in the batch process. The
productivity was calculated to be 3.8 times higher for the continuous SMB process,
which ultimately leads to the ability to use smaller columns compared to a batch process
[141].

Figure 2.14: Four-zone (column) open loop SMB chromatography process [141]
Another SMB process, an open-loop, two-column SMB process, was used for the
quasi-continuous purification of adenovirus serotype 5 (Ad5) [144]. This open-loop, twocolumn SMB process recovered 86% of Ad5 compared to 57% from a single column
batch process. Host cell protein removal was 89%, and host cell DNA removal was 90%
for the continuous process, which was comparable to the 94% removal of HCP and 94%
removal of host cell DNA in the batch process [144]. This study calculated a productivity
increase of 6-fold and a 51% increase in Ad5 recovery, which gives strong evidence that
quasi-continuous chromatography has the potential to be in a novel downstream
processing train.
In addition to SMB, periodic countercurrent chromatography (PCC) has been
explored as a continuous purification process. Although no study could be found for the
purification of viral particles, PCC has been applied to the purification of therapeutic
proteins [140]. The PCC technique utilizes several columns equal to the number of
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chromatographic steps necessary for the separation: loading, washing, eluting, and
regeneration. A common number of columns is three to allow for loading, eluting, and
regeneration, shown in Figure 2.15 [140]. There are six steps in a full cycle:
1. The first column is loaded until breakthrough
2. The first, loaded column is connected to the second column to begin loading
3. The first column is eluted, and the second column is loaded until breakthrough
4. The first column is regenerated, and the second column is connected to the third
column to begin loading
5. The second column is eluted, and the third column is loaded until breakthrough
6. The second column is regenerated, and the third column is connected to the first
column

Figure 2.15: Schematic of three-column PCC cycle [140]
This three-column PCC process was used to purify a mAb from a proprietary
CHO cell line [140]. The PCC process ran uninterrupted for 30 days, with the continuous
recovery of mAb between 70-110%. Compared to a batch chromatography process, the
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three-column PCC had a resin capacity of 120%, buffer usage of 75%, and column
volume of 3.9% [140]. These comparisons to the batch process highlight the ability of a
PCC process to greatly reduce facility size with smaller columns and buffer tanks.
Although these continuous chromatography processes show promise for use in a
continuous downstream processing train, several drawbacks exist. First, these processes
are not truly continuous, as they require either discontinuous loading onto different
columns, or interrupted outlets from valve switches. These issues could lead to the
necessity of holding tanks, which increases facility size. Additionally, many
chromatographic processes were not designed or optimized for use in viral particle
purification, as shown with the limited studies. Lastly, chromatography steps account for
up to 60% of downstream processing costs in mAb manufacturing, as Protein A resin can
cost over $1,000,000 for a 1-meter diameter column [145]. For these reasons,
chromatography-free downstream processing trains may be an attractive option.
2.2.2 Aqueous two-phase systems
The use of aqueous two-phase systems (ATPSs) could be one solution to
replacing chromatography-intensive downstream processing trains. An ATPS is a liquidliquid extraction technique that can partition biomolecules of different properties to
different liquid phases for separation. ATPSs are scalable, do not require labels, are
biocompatible, and can be easily operated continuously [146, 147].
2.2.2.1 Formation and characterization
ATPSs are formed by mixing two phase-forming components that are rich in
water above certain critical concentrations. The phase-forming components can be watersoluble polymers, salts, sugars, or alcohols [147]. When two of these components are
mixed above certain critical concentrations, they separate into two phases – like how oil
and water separate when mixed. Phase separation is dominated by three main forces:
gravitational, buoyant, and frictional, which act on the phase droplets formed as they
coalesce [148]. The density of each phase-forming component affects the gravitational
force, and rheological properties such as dynamic viscosity affect the buoyant and
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frictional forces [148]. The interfacial tension also plays an important role in the
separation of the phases. In the case of a polymer-salt system, the large difference in
viscosity plays a major role in phase separation as the salt phase coalesces in the
polymer-rich phase and must travel downward through the viscous polymer. For this
reason, polymer-salt systems tend to have higher separation times than salt-salt and other
less viscous systems. This phenomenon is important when an ATPS is designed for
biomolecule separation where a rapid separation is desired; different systems can have
vastly different biomolecule separation efficiency.
A phase diagram is used to show the different regions of an ATPS. A phase
diagram is specific for each biphasic system of two phase-forming components and can
change with temperature, pH, ionic strength, and molecular weight of components. A
phase diagram for a polymer-salt system is shown in Figure 2.16 [7]. The binodal curve
on the phase diagram separates the one-phase and two-phase region and is found by
titrating the two phases until a turbid mixture, indicative of a two-phase mixture, is
formed [7]. Any system formed on a unique tie line within the two-phase region will
separate into phases with the same concentration of polymer and salt. For example, the
ATPS formed on system point (S) will separate with a polymer-rich top phase at point
(T), and a salt-rich bottom phase at point (B). This is true for any system formed on the
same tie line connecting points T and B. Tie lines are described by their length (TLL),
which is calculated by the length between points T and B [147].
A particular system point can be uniquely identified by the tie line ratio (TLR)
calculated as the ratio of lengths between the system point (S) and the top point (T) to the
system point (S) and the bottom point (B). Although each system point along a tie line
eventually separates into the same top and bottom phase composition, there are
differences in mixture properties, especially dynamic viscosity in a polymer-salt system.
At low TLR, a higher volume of polymer is present, which makes the total mixture more
viscous than a high TLR system on the same tie line. This consideration is important
when designing an ATPS where easy fluid processability is necessary, such as in a
continuous system. Another important consideration for different systems along tie lines
is the differences in biomolecule partitioning.
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Figure 2.16: Phase diagram of a polymer-salt ATPS [7]
2.2.2.2 Theories of biomolecule partitioning
When biomolecules are introduced into an ATPS, their partitioning is governed
by numerous factors. Phase forming component concentrations, ionic strength, system
temperature and pH, and biomolecule properties all affect partitioning to different phases.
These factors are all combined into an overall partitioning coefficient, K, which is the
concentration ratio between biomolecules in the top phase over the bottom phase at
equilibrium (K=CT/CB), shown in Equation 2.4:
ln 𝐾𝐾 = ln 𝐾𝐾𝑒𝑒 + ln 𝐾𝐾ℎ + ln 𝐾𝐾𝑎𝑎 + ln 𝐾𝐾𝑠𝑠 + ln 𝐾𝐾𝑐𝑐 + ln 𝐾𝐾𝑜𝑜

(2.4)

where Ke is the contribution of partitioning due to electrochemical factors, Kh is the
hydrophobic factor, Ka is the affinity factor, Ks is the biomolecule size factor, Kc is the
biomolecule conformation factor, and Ko is all other factors such as external
environmental factors [149]. Although it is most accurate to consider all of these factors
for partitioning behavior [150], the Ke and Kh factors are the ruling factors for
partitioning in polymer-salt systems [148, 149].
Two leading and debated theories for biomolecule partitioning exist. The first is
based on the excluded volume theory of polymers, which states that the presence of a first
molecule (polymer) disallows the presence of a second molecule (biomolecule) [151].
This mechanism suggests the presence of large-chain polymer molecules geometrically
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block biomolecules’ partition to the polymer-rich phase, making them partition to the
opposite, less sterically-hindered phase [152, 153]. This effect was demonstrated by
comparing the PEG-rich recovery trends as PEG MW increased using protein from E.
coli cell lysate during the production of plasmid DNA [153]. As PEG MW was increased
from 600 to 4000 Da, protein recovery in the PEG-rich phase always decreased,
independent of system pH and lysate load, suggesting the cause of the partitioning was
due to an increased steric hindrance of higher MW PEG [153]. However, this effect was
directly the opposite in a partitioning study using porcine parvovirus (PPV) with PEG
MW from 3000 to 12000 [154]. In this study with PPV particles, an increase in the PEG
MW lead to a higher recovery of PPV in the PEG-rich phase [154]. The second
biomolecule partitioning theory is based on electrostatic and hydrophobic interactions
between the biomolecules and phase-forming components. This theory suggests that
biomolecules are salted-out from the salt-rich phase to the interface and then hydrophobic
interactions pull the biomolecules from the interface to the PEG-rich phase [7, 154, 155].
2.2.2.3 Purification of proteins, enzymes, nucleic acids
ATPSs have been studied extensively for the purification of proteins [156-164],
enzymes [165, 166], and nucleic acids [153, 167-169]. These systems have been run in
both batch-mode and continuous-mode with varying degrees of success, summarized in
Table 2.2.
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Table 2.2: Summary of selected batch-mode (B) and continuous-mode (C) ATPSs for the
purification of proteins, enzymes, and nucleic acids

a

ATPS

Type

Biomolecule

PEG 3350/citrate
PEG 3350/citrate
PEG 600/citrate/sulfate
PEG 1000/citrate

B
B
B
C

Human IgG from CHO cells
Human IgG from CHO cells
Plasmid DNA from E. coli
Α-lactalbumin from whey

Recovery
(%)
99
97
91
86

Purity
(%)
76
72
17
86
Pure
by
SDS
Pure
by
SDS
Pure
by
SDS

PEG 1450/phosphate
then PEG 300/phosphate

B

Plasmid DNA from E. coli

89

PEG 600/sulfate

B

Plasmid DNA from E. coli

67

PEG 1500/phosphate

B

mAb 2F5

95

PEG 550/phosphate

C

Ascorbic oxidoreductase from
curcubita maxima

236a

34b

[165]

PEG 3350/phosphate

C

Human IgG from CHO cells and
PER.C6 cells

99

[160]

PEG 1000/phosphate

C

50

5.8c

[161]

PEG 6000/dextran
500000

C-phycocyanin from spirulina
maxima

80%
(CHO)
100%
(PER.C6)

B

mAb anti-CD34 from hybridoma cells

84

99.9

[164]

PEG 1000/phosphate

C

Whey protein isolate

90

PEG 1000/phosphate

C

Invertase from spent yeast

31

Pure
by
SDS
-

Ref
[156]
[157]
[167]
[158]
[168]
[153]
[159]

[163]
[166]

recovery of enzyme activity
purification factor (ratio of enzyme activity after purification to activity in crude extract)
c
purity index (A620/A280)
b

A commonly studied application of batch-mode ATPSs is for the harvest and
primary recovery steps of monoclonal antibody (mAb) manufacturing. This was
demonstrated in a study where an ATPS of PEG 3350/6000 Da and dextran 500,000 was
used to purify anti-CD34 mAbs produced in hybridoma cells [164]. In this study, a PEGrich mAb recovery of 84 ± 7% with 0.1 ± 0.2% of total cells was achieved in an ATPS of
PEG 6000/dextran 500,000 with 150 mM NaCl at pH 3 [164]. This study showed that the
conventional clarification step of centrifugation or microfiltration can be skipped by
using a one-step ATPS for the primary recovery of mAbs directly from the bioreactor
harvest. However, one consideration not addressed in the study is the subsequent
downstream purification steps since the purified mAbs are left in a viscous PEG-rich
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phase that could pose processing issues. This issue was addressed by introducing a backextraction step after the first stage of ATPS to partition an IgG product from a PEG-rich
phase to a citrate-rich phase for easier processing [156]. The first stage was a system of
PEG 3350-citrate with 15% NaCl to recover 99% of the human IgG in the PEG-rich. The
second stage introduced fresh citrate to decrease the NaCl concentration to 5%, which
back-extracted the IgG product to the citrate-rich phase with 99% recovery and an overall
HPLC purity of 76% [156].
Another option to avoid the desired product from being left in a viscous PEG-rich
phase was demonstrated by combining an ATPS with hydrophobic interaction
chromatography (HIC). A bottom phase from ATPS that was compatible with the loading
step of hydrophobic interaction chromatography (HIC) was designed to eliminate any
buffer-exchange steps between ATPS and HIC [157]. The bottom phase was 10 w/w%
PEG 3350 and 12 w/w% citrate at pH 6, which recovered 97% IgG and 28% overall
protein [157]. The citrate-rich bottom phase was directly loaded onto the HIC column and
resulted in 99% IgG recovery and 91% purity. While this study shows promise for
developing an integrated downstream purification train, these unit operations were all
performed in batch-mode. To boost the productivity of purification processes, they could
be run in continuous-mode.
The design of continuous ATPSs for biomolecule purification has resulted in the
implementation of various devices, such as column contactors and mixer-settler units, to
achieve phase mixing and separation [170]. Coming from the chemical industry and
traditional liquid-liquid extraction processes, column contactors, such as spray columns,
perforated rotating disk contactors (PRDCs), and pulsed cap columns, have been
implemented in various continuous ATPSs. A PRDC is constructed by enclosing
perforated disks attached to a central rotating shaft, shown in Figure 2.17. PRDCs have
advantages of high throughput, enhanced mass transfer, and ease of continuous operation.
The disadvantages of PRDCs are column flooding and poor separation efficiency at high
flow rates [170].
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Figure 2.17: Perforated rotating disk contactor for PEG-citrate continuous ATPS
One PRDC was used for an attempted purification of α-toxin (a zincmetalloenzyme, which can cause hemolysis and necrosis) from Clostridium perfringens
broth [171]. In this system, PEG 8000 and phosphate were used as the polymer-salt phase
forming components inside a 170 mm column with a 32 mm diameter and six perforated
disks. A phosphate salt solution containing the α-toxin flowed into the top of the PRDC,
and the PEG solution flowed in through the bottom of the column. Optimum conditions
for continuous extraction of α-toxin were not found, due to column flooding, highlighting
the possible issue of using PRDCs in continuous ATPS processes [171].
Another option for continuous ATPS operation is using mixer-settler units. These
types of units achieve proper ATPS formation and separation with a mixing stage (either
static or dynamic) and a settling stage (settling tank). This type of continuous ATPS setup
has the advantage of being easily constructed and tested compared to column contactors.
However, the optimization of mixing and settling in a continuous fashion may be difficult
to achieve [170]. One mixer-settler based ATPS process was designed and tested for the
partitioning of whey protein isolate (WPI). This simple design utilized a static glass-bead
filled mixer followed by separation tubing and, lastly, by a separation tank for phase
separation, shown in Figure 2.18. In this continuous ATPS prototype, up to 90%
recovery of WPI was achieved, which showed the great potential of ATPS to be run in
continuous-mode with a mixer-settler unit for recovery of biomolecules [163]. Another
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mixer-settler setup for continuous ATPS was used to partition Cerrena unicolor laccase
in a PEG 6000/phosphate system. Over 5 hours of continuous operation, with 1 hour to
reach steady-state, 60% of laccase was recovered in the bottom phosphate-rich phase
[172]. These studies show the potential use of mixer settler units to recover proteins and
enzymes, but few studies have been developed for continuous virus recovery.

Figure 2.18: Continuous ATPS utilizing static mixer and continuous separator for whey
protein isolate partitioning [163]
2.2.2.4 Purification of virus and virus-like particles
Viruses and virus-like particles (VLPs) have seldomly been used in ATPSs, due
to complex partitioning behavior. Additionally, viruses and VLPs used in continuous
ATPSs have not been studied like proteins and enzymes. However, ATPSs have the
potential to be used as a viral particle purification technique, as evidenced by the studies
of ATPSs with other biomolecules. The vaccine and gene therapy manufacturing
industries would benefit greatly by implementing an optimized ATPS for high recovery
and purification of viral particles produced upstream. However, the partitioning behavior
of viral particles in various ATPSs must be explored and understood prior to industrial
implementation. Batch-mode ATPSs used for the purification of viral particles are
summarized in Table 2.3.
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Table 2.3: Summary of batch mode ATPSs for the purification of viral particles
ATPS

Biomolecule

PEG 400/phosphate
PEG 6000/citrate

Rotavirus VLPs from High Five insect cells
FMDV from BHK-21 cells

Recovery
(%)
85
73

PEG 12000/citrate

PPV from PK-13 cells

79

PEG 12000/citrate

HRV from HeLa cells

36

PEG 8000/phosphate

Bacteriophage T4 from E. coli

38

PEG 12000/citrate

PPV from PK-13 cells

64

PEG 400/phosphate
PEG 300/phosphate

Human B19 parvo VLPs from Sf9 cells
Adenoviral vectors from HEK-293 cells

64
90

PEG 8000/sulfate

Adeno-associated virus from HEK-293 cells

95

PEG 400/phosphate

Bacteriophage M13 from E. coli

80

Purity
(%)
89-94
90
Pure
by
SDS
Pure
by
SDS
Pure
by
SDS
91
Pure
by
SDS
-

Ref
[173]
[174]
[7]
[7]
[175]
[154]
[176]
[177]
[178]
[179]

To address the challenges of complex partitioning behavior of viral particles in
ATPS, one study aimed to assess the partitioning behavior of PPV and human rhinovirus
(HRV) at various tie lines in a PEG 12000/citrate ATPS [7]. By using two non-enveloped
viruses with different pI but similar size within the same system, partitioning behavior
was compared at a constant system pH of 7. When PPV was used in the ATPS, 79%
recovery was obtained at high purity (by SDS), but only 36% of HRV was recovered [7].
The explanation for this was that, at a system pH of 7, PPV is negatively charged (pI 5),
which is readily salted-out of the citrate-rich phase to the interface where it is then pulled
to the PEG-rich phase via hydrophobic interactions [7]. However, HRV with a pI of 6.9
has a net zero charge at the system pH, which is not readily salted-out by the citrate-rich
phase, lowering the PEG-rich phase recovery. The main outcome from this study was that
virus physicochemical properties, such as surface charge and hydrophobicity, play a key
role in partitioning behavior in ATPSs and must be considered when designing a new
process for a different virus.
One potential issue with using ATPSs for the purification of complex viral
particles is inactivation by high concentrations of phase forming components. This was
demonstrated in one study for the attempted purification of bacteriophage T4 in a PEG
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8000/phosphate system. In this system, high concentrations of PEG and phosphate
negatively impacted the infectivity of bacteriophage T4, making quantification via an
infectivity assay (plaque assay) unreliable [175]. To solve this challenge, different ATPS
components would need to be screened with bacteriophage T4 alone prior to using them
in a full ATPS.
One of the best examples of an ATPS with viral particles was the purification of
foot-and-mouth disease virus (FMDV) from clarified HEK-293 cell lysate [174]. This
1000-g ATPS utilized a three-stage extraction process to use the first two stages for
contaminant protein removal, and the third stage for back-extraction to a citrate-rich
phase. Overall, the PEG was removed, 72% of FMDV was recovered, and 90% of the
total protein content was removed [174]. This recovery greatly exceeds the currently
acceptable industrial viral particle recovery of <30% [180]. To further improve this
process, it could be transformed into a continuous three-stage ATPS, possibly using a
mixer-settler unit for each stage.
Another ATPS process was used for the purification of rotavirus VLPs as a
potential vaccine candidate [173]. Rotavirus VLPs were produced in High Five insect
cells using the baculovirus expression system, extracted from cells via disruption, and
purified using a PEG 400/phosphate ATPS. The ATPS purification strategy was directly
compared to a standard CsCl gradient strategy, showing that 85% of VLPs could be
recovered using ATPS, which compared favorably to the CsCl gradient technique with
only 2% VLP recovery [173]. The purity of recovered VLPs was 89-94%, which was
similar to a purity of 91% by the CsCl gradient. Additionally, the ATPS technique only
required two hours of processing time, whereas CsCl gradient purification required more
than 24 hours [173]. However, this two-hour processing time could be lowered by
removing the centrifuge step in the phase separation process by possibly converting it to a
continuous ATPS.
Since the literature on viral particles used in ATPSs is limited, my work focused
on developing and testing a continuous ATPS for the purification of viral particles,
discussed in Chapter 5. The numerous benefits that continuous unit operations bring to
industry are driving the biomanufacturing industry to implement continuous operations.
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Since ATPSs can be easily scaled up and run in continuous-mode, the future of
downstream processing trains may be ATPS-based.
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3 Flexographic-printed graphene biosensors for
electrochemical analyte detection
3.1 Introduction
In this chapter, results from testing graphene ink printed biosensors are
summarized. The graphene biosensor project first started by fabricating sensors using
pre-made graphene/cellulose paper sheets from XG Sciences. The XG Science paperbased sensors lead to the rapid and specific detection of four different proteins applied to
the sensor surface via the conductometric detection technique [40]. With this first
publication, the graphene biosensors were on track for being applied to detect other
analytes, specifically a malaria biomarker. After 2012, XG Sciences changed their
production method for the graphene/cellulose blended paper. This change in production
method lead to the failure of biosensors constructed from it. Due to this, we began
printing our own graphene biosensors onto various paper and non-paper substrates using
XG Sciences’ graphene-based ink. By starting with a graphene ink that could be applied
to any surface desired, there was an opportunity to fully customize the graphene
biosensors for analyte detection. These optimizations included different printing
substrates, anilox ink roll size, number of printing coats, and different ink properties. The
goal of printing custom graphene ink devices was to restore the electrochemical protein
detection ability lost from XG Sciences’ graphene/cellulose paper, and to use the sensors
as point-of-care (POC) devices for other analytes of interest.
Paper-based POC biosensors have been developed to provide inexpensive,
disposable, and rapid detection of various diseases. Not only do these devices benefit
developing countries, they can also benefit rural parts of developed countries, as they do
not require extensive lab equipment or long periods of time. The major advantages of
such devices is the simple testing and results read-out, and the ability of wicking aqueous
samples through the paper to transport necessary reactants/sample buffers to different
areas of the device without the use of pumps [181, 182]. For example, one
immunochromatographic strip on nitrocellulose was used to detect foot-and-mouth
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disease virus (FMDV) by creating a visible test line using gold nanoparticles in five
minutes, similar to an at-home pregnancy test [183]. With rapid POC devices, results can
be obtained for diagnosis without a patient ever leaving the test site, reducing follow-up
exams [28, 184].
These POC devices need a way to quantify the biomolecule they are designed to
detect. The most common technique for quantification of the analyte is through
electrochemical detection, discussed in section 2.1.2. Using electrochemical detection, it
is possible for the biological information to be processed to an electric signal [28].
However, for these electrochemical techniques to be implemented, a conductive species
must be used in the construction of the sensors to carry the electric signal. Our graphenebased sensors avoid this issue by being intrinsically conductive. When an analyte is
applied to the graphene sensor surface, a change in the electrical properties of the device
can be directly measured.
In this chapter, each sub-section of results will be in order of logical optimizations
tested to restore the sensors’ ability to detect the presence of protein on the surface.

3.2 Biosensor testing and theory
A circuit board with permanent copper leads was used for rapid testing of up to
five graphene biosensor sheets, with the full sensor testing arrangement shown in Figure
3.1. To test a graphene biosensor sheet, the amperage was recorded at constant volts
(typically between 5-10 mV) for the dry sheet and buffer-only application as starting
baselines. Using a micropipet, 10 µL of the lowest concentration of protein (0.01 mg/mL)
was applied to the surface. The amperage was recorded after 30 seconds, 40 seconds, and
50 seconds and averaged for the amperage change resulting from that protein
concentration. The solution was wicked from the surface and increasing concentration of
protein (0.1 – 5 mg/mL) was applied to measure the resulting change in amperage.
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Figure 3.1: Graphene biosensor testing lab set-up
To quantify the presence of varying protein concentration on the surface of the
graphene biosensor, sheet resistivity (SR) was calculated from measured amperage
changes at constant voltage across a 1-cm wide graphene sheet, shown in Figure 3.2. The
SR (Ω/sq) was calculated using Equation 3.1
𝑆𝑆𝑆𝑆 =

𝑉𝑉∙𝑊𝑊
𝐼𝐼∙𝐿𝐿

(3.1)

where V (volts) is the constant potential difference applied across the copper leads, W
(cm) is the width of the graphene sheet, I (amps) is the resulting current through the
graphene sheet, and L (cm) is the distance between electrodes where the potential is
applied (constant, 1 cm).

Figure 3.2: Five sheets of two-terminal graphene/cellulose biosensors applied to reusable
circuit board
The Langmuir Isotherm was used to explain and model the change in SR with an
increase in the concentration of protein adsorbed to the sensor surface. The Langmuir
Isotherm has a few basic assumptions: 1) the surface for adsorbing is perfectly flat and
homogeneous, 2) the adsorbing material (protein) adsorbs into an immobile state, 3) all
binding sites on the surface are energetically equivalent and require the same binding
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energy, 4) each binding site binds exactly one species of adsorbing material, and 5) there
are no intra-site interactions between adjacent sites [185]. A simple graphical
representation of the Langmuir Isotherm where a solid surface (grey box) with binding
sites (black curves) is adsorbing an analyte of interest (red circles) can be seen in Figure
3.3. As seen in Figure 3.3, the adsorption rate slows as the concentration of adsorbate
increasing due to the limited number of binding sites become filled. In the case of the
biosensors, the red circles are proteins and the binding sites are individual graphene
nanoplatelet sheets. By measuring the SR change as protein concentration increases, we
can obtain a Langmuir Isotherm curve like Figure 3.3.

Figure 3.3: Langmuir Isotherm representation with solid surface binding sites adsorbing
an analyte of interest
The Langmuir Isotherm used to relate the SR change to protein concentration can
be seen in Equation 3.2
𝐶𝐶

Δ𝑆𝑆𝑆𝑆

=

𝐶𝐶

Δ𝑆𝑆𝑅𝑅𝑚𝑚𝑚𝑚𝑚𝑚

𝐾𝐾

+ Δ𝑆𝑆𝑅𝑅 𝑑𝑑

𝑚𝑚𝑚𝑚𝑚𝑚

(3.2)

where ΔSR (Ω/sq) is the change in SR at the protein concentration point compared to the
buffer-only application, ΔSRmax (Ω/sq) is the maximum change in SR between a protein
application step (typically the highest concentration) and buffer-only application step
during sample testing, C (mg/mL) is the protein concentration applied, and Kd (mg/mL)
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is the equilibrium dissociation constant. The data collected from a tested graphene sheet
can be normalized by ΔSRmax to compare with other sheets by Equation 3.3
𝐶𝐶

Θ

= 𝐶𝐶 + 𝐾𝐾𝑑𝑑

(3.3)

where Θ = ΔSR/ΔSRmax. Using Equation 3.3, Kd is determined for an analyte applied to
the surface during testing. The dissociation constant is a measure of the sensitivity of the
sensor, which is dependent on the analyte size. A lower Kd value corresponds to a higher
amount of protein bound to the sensor surface, increasing the sensitivity of the sensor,
shown in Figure 3.4 [186]. The Kd represents the equilibrium adsorption between the
ligand graphene surface (L) and protein (P). When a protein adsorbs to the graphene
surface, a complex between the ligand and protein (P∙L) is formed.

Figure 3.4: Dissociation constant (Kd) definition and chemical equilibrium between
graphene surface ligand (L) and protein (P) absorbate [186]

3.3 Results and discussion
3.3.1 Results from 2013 graphene biosensor publication
Graphene biosensors constructed and tested prior to 2012 lead to the stacked
graphene nanoplatelet paper sensor publication in 2013 by Heldt et al [40]. These
biosensors were two-terminal sensors constructed on standard glass slides, seen in Figure
3.5. The graphene/cellulose biosensors were able to detect and distinguish between
various proteins present on the sensor surface including bovine serum albumin (BSA),
chicken egg white lysozyme (LYS), bovine hemoglobin (HEM), and bovine fibrinogen
(FIB). These proteins had a range of isoelectric points, hydrophobicity, and molecular
weights. Increasing concentrations of each protein was applied to the graphene sensor
surface and the electrical surface resistivity (SR) was measured.
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Figure 3.5: Two-terminal graphene/cellulose biosensor constructed on glass slide [40]
By fitting the SR versus protein concentration data to the Langmuir Isotherm, the
equilibrium dissociation constant (Kd) was determined for each protein. The main finding
was that the Kd was a function of the protein molecular weight due to protein adsorption
to the graphene surface, seen in Figure 3.6. One of the major issues with the
graphene/cellulose sensors is the swelling effect when liquid is applied to the sensor
surface. Due to the swelling, SR increased by more than three times, likely due to the
stacked graphene nanoplatelets separation during liquid application, which reduced the
graphene-to-graphene contacts.

Figure 3.6: Equilibrium dissociation constant as a function of molecular weight for LYS,
HEM, BSA, and FIB [40]
3.3.2 XG Sciences’ graphene paper manufacturing change
In 2013, XG Sciences changed their graphene/cellulose paper manufacturing
process. Due to this change, the lab began to see inconsistencies in protein detection
compared to the results obtained from the stacked graphene sensor publication.
Biosensors created with paper after 2013 resulted in limited increase in SR with
increasing protein concentration. As a control, the buffer used to dissolve the BSA,
phosphate buffered saline (PBS), was applied to the sensor surface to compare increases
in SR between the protein and buffer, seen in Figure 3.7. Without the ability to
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distinguish between PBS and BSA applications on the sensor surface, the sensors do not
work.

Figure 3.7: Graphene (November 2014 batch) sensor ability to distinguish between PBS
and BSA applications
Between 2014 and 2016, work was done by previous graduate student, Soontorn
Tuntithavornwat, to chemically alter the graphene paper with treatment of 2 w/w%
glutaraldehyde (GA), 1 w/w% zinc nitrate (ZN), and 1 w/w% poly(vinyl alcohol) (PVA)
to improve the wet and dry strength of the paper. This strength improvement was
hypothesized to decrease the swelling effect of buffer application to the surface, which
should improve sensitivity of SR measurements with protein application. Treatment with
the GA, ZN, and PVA mixture improved the wet strength thirteen times (from 0.5 mPa to
7.2 mPa) while maintaining protein sensing ability, seen in Figure 3.8. However, tests
comparing protein application versus buffer-only application were not performed to
confirm the sensing ability of the treated sensors was specific to protein.

Figure 3.8: BSA sensing ability of GA/ZN/PVA-treated graphene sensors
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3.3.3 Graphene ink printing for sensor creation and protein detection
When I joined the Heldt lab in May 2016, we looked for an alternative method to
creating the graphene sensors, as the paper received from XG Sciences post-2013 was not
performing the same way as paper pre-2013. This alternative method was printing XG
Sciences’ graphene ink onto various paper and non-paper substrates. The flexographic
printing method was chosen because it can use water-based and non-water-based inks and
is compatible with a variety of printing substrates. The flexographic proofer (Figure
3.9A) used to print the graphene ink lines (Figure 3.9B) was purchased from Harper
Scientific. Many variables affect the print quality when using the flexographic printing
method, including anilox size, ink properties, substrate type, and number of coats. A vital
ink property that affects flexographic printing is the ink viscosity. A suitable ink viscosity
was determined to be 518 cS, measured with a Zahn cup number 5. The viscosity of the
ink was measured prior to every experiment to keep the viscosity constant across
substrates. The other printing parameters were changed to determine proper feature
formation and sensor detecting ability.

Figure 3.9: A) Flexographic proofer used to print B) graphene ink lines
3.3.3.1 Determination of necessary printing coats
First, the number of coats needed on a paper substrate was determined with SR
measurements. Low SR was desired to confirm when enough ink was applied to the
substrate surface to allow for proper electron transport across the printed graphene ink.
One, two, and three coats of ink were printed on copy paper, and SR was recorded with
applying PBS on the surface multiple times, seen in Figure 3.10. Three coats (or passes)
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was necessary on copy paper to achieve a minimum SR variation across PBS
applications, so all future sensors were made from three passes of ink.

Figure 3.10: SR change with one, two, and three coats of graphene ink on a paper
substrate
3.3.3.2 Anilox sizing for paper and non-paper substrates
The next optimization step was to determine the size of anilox needed to transfer
ink to the paper substrate to print the necessary features. We received two anilox sizes:
75/26 and 70/36. The numbers that define an anilox size have specific meanings. The first
number is used to define the transfer volume of ink to a substrate surface. The transfer
volume is given in units of billion cubic microns (BCM) of ink per square inch of
substrate (BCM/in2). The second number is used to define the number of cells per inch
(LPI) across a straight line on the anilox, also called cell finesse. A larger LPI means
more cells per inch, resulting in a smaller cell volume. To determine which anilox
performed the best with unmodified graphene ink, three coats of ink were printed onto
standard copy paper and SR was measured with increasing BSA concentration on three
individual 1 cm lengths of paper. Both anilox produced similar SR measurements, but
anilox 70/36 had less variation across sheets tested, and produced a higher ΔSR (SR5
mg/mL BSA

- SRbuffer), seen in Figure 3.11. From this result, anilox 70/36 was chosen for all

future printing onto paper substrates.
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Figure 3.11: SR measurements using anilox 70/36 and 75/26 comparison with increasing
BSA concentration
A different size anilox was needed for printing onto non-paper substrates due to
the surface roughness and porosity differences between substrates. We received anilox
size 120/20 and 200/14 to print onto poly(ethylene terephthalate) (PET) and Tyvek type
1079. These substrates were chosen for controls as they are non-porous, non-swelling,
and hydrophobic. Printing with these two anilox showed that only one coat of graphene
ink was needed on the surface of each substrate, likely due to the low surface roughness
compared to the paper substrates. To determine which anilox roll produced the best
graphene sensor sheets, an increasing concentration of BSA was applied to sensors
constructed from each roll and substrate type. The criteria for “best sensors” were
achieving low SR, low SR variance, plus low and consistent Kd values. Ten sensors were
constructed from each anilox roll on PET and tested with increasing BSA concentration
applications from 0 to 5 mg/mL, seen in Figure 3.12. Kd values were calculated for each
sensor, and the average Kd/standard deviation were found for each anilox. Sensors from
anilox 200/14 gave a Kd of 1.64 ± 0.46 μM, and sensors from anilox 120/20 gave a Kd of
1.64 ± 0.35 μM. Both anilox rolls produced sensors that performed similarly for BSA
detection, however, anilox 120/20 produced sensors that started at a lower SR. Tests on
the PET substrate alone was not enough to determine which anilox was best. The same
anilox were tested on another non-paper substrate, Tyvek.
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Figure 3.12: SR values with increasing BSA concentration from sensors constructed
using PET with anilox A) 200/14 and B) 120/20
Five sensors constructed from printing graphene ink onto Tyvek type 1079 were
tested for their ability to detect BSA, shown in Figure 3.13. The Kd from sensors made
with anilox 200/14 was 1.76 ± 0.72 μM, and 1.89 ± 0.63 μM for anilox 120/20. While
comparing Kd values between anilox rolls was inconclusive, considering dry device SR
values between anilox for both PET and Tyvek substrates, anilox 120/20 performs the
best. For these reasons, anilox 120/20 was chosen for printing on non-paper substrates.

Figure 3.13: SR values for increasing BSA concentration from sensors constructed using
Tyvek with anilox A) 200/14 and B) 120/20
With the number of coats and anilox roll necessary for printing on each substrate,
sensors were created and tested for their ability to detect BSA versus PBS-only
applications. Two paper substrates were tested first: conventional copy paper and
chromatography-grade paper. Copy paper was chosen because it is inexpensive and
readily available. Chromatography paper was chosen for its controlled purity by the
manufacturer, ensuring we could receive the same quality of paper in the future.
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3.3.3.3 Protein detection with paper and non-paper sensors
The first graphene ink biosensors tested with BSA and compared to PBS
applications were printed on 11”x17” copy paper. The average ΔSR for the five devices
tested with BSA was 18 Ω/sq, and the average ΔSR for the five devices tested with just
PBS was 2.3 Ω/sq, seen in Figure 3.14. Due to the large error, no statistically significant
difference was found, meaning there was no reliable way to determine if BSA or PBS
was present on the surface of the sensor. The reason for this is hypothesized to be the
swelling effect of the graphene/cellulose devices. As any liquid is placed on the sensor
surface, the liquid swells the paper and causes sheets of graphene to become separated,
regardless of protein presence.

Figure 3.14: Average SR increase with increasing BSA concentration applications and
PBS applications on three-coat, copy paper devices printed with anilox 70/36
Next, graphene ink biosensors were printed onto chromatography filter paper. The
same BSA versus PBS application test was used for sensors printed on chromatography
paper. The average ΔSR for the five devices tested with BSA was 15 Ω/sq, and the
average ΔSR for the five devices tested with PBS was 6 Ω/sq, seen in Figure 3.15. The
average SR difference between BSA-tested and PBS-tested devices was not significantly
different. This was additional evidence that any liquid on the sensor surface would
produce an SR change, regardless of protein presence. To limit the swelling effect of the
paper-based printing substrate, two non-paper substrates were tested: Tyvek and
poly(ethylene terephthalate).
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Figure 3.15: SR curves for A) BSA and B) PBS tested three-coat, graphene ink devices
on chromatography filter paper
Sensors were printed onto PET film and tested for BSA detection versus PBSonly application. The PET film is extremely hydrophobic, which should reduce the
swelling effect of the paper substrates and allow for the detection of protein presence
based on an increase in the sheet resistivity. The devices with BSA application had an
average ΔSR of 22 Ω/sq, and the devices with PBS-only application had an average ΔSR
of 28 Ω/sq, seen in Figure 3.16. Again, with similar average change in SR between BSA
and PBS-only applications, the devices were not able to detect protein on the surface of
the sensor. This result indicates that the swelling of the porous substrates was not the only
effect causing similar SR changes in the tests. This result shows that any liquid present on
the sensor surface causes the SR to change.

Figure 3.16: SR curves for A) BSA and B) PBS tested one-coat, graphene ink devices on
PET film
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As another control for a non-paper substrate, Tyvek grade 1079 was used for
sensor printing and tested for its detection ability. Devices tested with BSA had an
average ΔSR of 27 Ω/sq, and the devices tested with PBS-only had an average ΔSR of 23
Ω/sq, seen in Figure 3.17. Again, the same result as PET film was obtained with Tyvek
grade 1079. These results combined show that liquid present on the sensor surface is
causing the change in SR, not purely the presence of protein on the surface. One possible
reason for this could be the fact that liquid has the ability to contact the electrical leads
during resistivity measurements, which could alter the electrical performance of the
sensors. To test this theory, hydrophobic wax was printed onto the paper substrates to
create a barrier between the testing region and the electrical leads on the sensor surface,
discussed in Section 3.3.4.

Figure 3.17: SR curves for A) BSA and B) PBS tested one-coat, graphene ink devices on
Tyvek grade 1079
3.3.3.4 Custom graphene ink testing
Custom graphene inks were formulated during a month-long internship at XG
Sciences to increase the compatibility of ink with protein application. Specifically,
poly(acrylic acid) (PAA) was added to the ink formulation solvent to make the resulting
ink more hydrophilic compared to the normal ethyl cellulose used in the ink.
Additionally, a different size of graphene nanoplatelets was used to formulate the ink to
increase the available binding surface area from ~50 m2/g to over 500 m2/g. Three
devices created using the PAA-custom ink were tested with BSA applications (Figure
3.18, solid lines), and two devices created using the same ink were tested with PB only
applications (Figure 3.18, dashed lines). The ΔSR for BSA-tested devices was 1080
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Ω/sq, and PB-tested devices had a ΔSR of 1800 Ω/sq. Although this ink was slightly
more hydrophilic than the standard ink tested, it did not result in acceptable protein
detection.

Figure 3.18: SR curves for PAA-custom graphene ink devices on GP copy paper
Three devices created using the size-custom ink were tested with BSA
applications (Figure 3.19, solid lines), and two devices created using the same ink were
tested with PB only applications (Figure 3.19, dashed lines). The ΔSR for BSA-tested
devices was -7090 Ω/sq, and PB-tested devices had a ΔSR of 13000 Ω/sq. This custom
ink had large variance from device to device, immediately making this ink unsuitable for
repeatable device sensing ability.

Figure 3.19: SR curves for custom-size graphene ink devices on GP copy paper
3.3.4 Wax printing hydrophobic barriers
Printing barriers onto the paper substrates requires the optimization of 3D printing
wax onto the surface of the sensor, and the subsequent heating of the wax to penetrate
through the paper to form a complete barrier. 3D printing was achieved using a
replication rapid prototyper (RepRap) with a heated syringe extruder for printable wax.
The RepRap and the printed wax features to create a liquid flow channel can be seen in
64

Figure 3.20. The RepRap is only capable of printing the heated wax onto the top surface
of the substrate, so additional heating of the wax was necessary to penetrate the wax
through the thickness of the substrate to form the complete hydrophobic barrier.

Figure 3.20: RepRap 3D printer with printed wax lines
After graphene ink lines were printed onto copy paper and chromatography paper
by the flexographic proofer, wax was 3D printed across the graphene ink lines to create
the hydrophobic barriers. To fully penetrate the wax through the graphene ink lines and
paper substrates, the wax was melted at 90°C for five minutes. The fully melted wax
barriers on the graphene lines can be seen in Figure 3.21. With the hydrophobic barriers
in place, the liquid application region is the ~2 mm gap between wax lines.

Figure 3.21: Hydrophobic wax barriers printed onto graphene ink lines
3.3.4.1 Wicking tests
A wicking test was designed to confirm proper wax barrier formation through the
paper substrate and to show the hydrophobicity of both the wax and graphene ink line. A
drop of red-dyed water was applied to one side of the paper substrate, and the time to
cross to the other side of the paper was recorded (Figure 3.22). The wicking test was
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performed on copy paper with and without the graphene line, chromatography paper with
and without the graphene line, and on the cellulose/graphene paper blend from XG
Sciences. As expected, the copy paper without the graphene line had the shortest time to
cross at 10 seconds, and chromatography paper with the graphene line had the longest
time to cross at 30 seconds. The long time to cross is because chromatography paper is
thicker than the copy paper and cellulose/graphene paper blend. Interestingly, the
application of the graphene line caused the time to cross to increase by 10 seconds in the
case of copy paper and chromatography paper, shown in Figure 3.23. During the tests, no
wicking to the outside of the wax lines was observed, confirming that the hydrophobic
barriers were fully formed and retained the liquid between the wax lines. From this test,
the graphene lines with wax barriers were used to electrochemically detect the presence
of protein on the surface without liquid interference on the conductive leads.

Figure 3.22: Wicking test schematic for the wax barriers on various paper substrates
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Figure 3.23: Wicking test results on paper substrates with and without graphene lines
3.3.4.2 Paper substrate device testing with wax barriers
Biosensors were fabricated by three-pass printing graphene ink onto copy paper
and wax barriers were 3D printed onto the surface. Four sensors were tested for their
ability to detect BSA from 0.01 to 5 mg/mL and compared to a control PB-only
application sensor, shown in Figure 3.24. Sensors tested with BSA had an average ΔSR
of 3.3 Ω/sq, and the sensor tested with PB-only had an average ΔSR of 4.3 Ω/sq. As seen
in Figure 3.24, the PB-only sensor fell directly in the same range of SR changes as the
BSA-tested sensors meaning there is no different protein application compared to bufferonly application.

Figure 3.24: SR curves for BSA-tested sensors (1-4) and PB-tested sensor (%) with 3Dprinted wax barriers on copy paper
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Additional biosensors were fabricated by three-pass printing graphene ink onto
chromatography paper and wax barriers were 3D printed onto the surface. Four sensors
were tested for their ability to detect BSA from 0.01 to 5 mg/mL and compared to a
control PB-only application sensor, shown in Figure 3.25. Sensors tested with BSA had
an average ΔSR of 33000 Ω/sq, and the sensor tested with PB-only had an average ΔSR
of 760 Ω/sq. Although the comparison of ΔSR between BSA and PB sensors seems to
suggest there is a significantly large increase in SR for BSA and not PB, the large
variablility between sensors 1-4 is unacceptable for reliable analyte detection.

Figure 3.25: SR curves for BSA-tested sensors (1-4) and PB-tested sensor (%) with 3Dprinted wax barriers on chromatography paper
These results from paper-based sensors with wax barriers indicate that the liquid
contact to the electrical leads is not the dominating effect of SR increase. Regardless of
protein presence on the sensor surface with wax barriers, SR increases. This means the
sensors are not specific enough to what was applied on the surface and the specificity
must be increased for proper analyte detection. One attempt to increase the specificity of
the sensors was by functionalization with primary antibodies.
3.3.5 Functionalization of graphene sensors
Before a complete sandwich ELISA system was constructed on the graphene
biosensor surface, proper immobilization of antibodies on the graphene surface was
tested. As discussed in section 2.1.2.2.2, the immobilization of antibodies onto graphene
is accomplished by π-π stacking an amine-reactive probe onto the graphene surface and
applying antibodies onto the probe for immobilization via EDC-NHS chemistry between
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the NHS probe and primary amine on the FC region of antibodies. The amine-reactive
linker applied to the graphene surface was 1-pyrenebutanoic acid succinimidyl ester
(PBA-NHS) (Figure 3.26A). After linker attachment, donkey anti-goat IgG antibodies
labelled with HRP were applied and immobilized on the surface by EDC-NHS chemistry
(Figure 3.26B). Ethanolamine was used to cap unreacted PBA-NHS linkers (Figure
3.26C). This functionalization procedure was performed in non-stick test tubes by adding
the appropriate liquid component and rocking. After numerous washing steps, a 3,3’,5,5’tetramethylbenzidine (TMB) substrate and hydrogen peroxide was added. TMB is a
colorless chromogenic substrate for HRP which acts as a hydrogen donor during the
redox reaction of H2O2 to water by the enzyme HRP. When HRP is in the presence of
TMB and H2O2, the enzymatic reaction produces a blue colored 3,3’,5,5’tetramethylbenzidine diimine. The reaction is stopped using sulfuric acid which turns the
solution color to yellow and can be read at 450 nm for quantification.

Figure 3.26: Primary antibody immobilization onto graphene sheet
To test the immobilization procedure, sheets of graphene were fully
functionalized and the absorbance at 450 nm was compared to non-functionalized
graphene sheets, sheets with PBA manually pipetted onto the surface, and sheets without
the PBA-NHS linker added. Additionally, plain copy paper was used as a negative
control for functionalization. Functionalized graphene sheets had an average absorbance
of 1.4 ± 0.4 and manually applied PBA functionalized graphene sheets had an average
absorbance of 1.7 ± 0.5, suggesting that the PBA application process does not affect the
immobilization of antibodies, seen in Figure 3.27. Non-functionalized graphene sheets
had an average absorbance of 0.04 ± 0.001, confirming that if no antibodies are added to
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the sheets, no color change is observed. Functionalized plain paper, no PBA on graphene
sheets, and no PBA on plain paper had average absorbances of 1.2 ± 0.6, 0.8 ± 0.3, and
1.4 ± 0.2 respectively. Although these values do lie within the error of fully
functionalized graphene sheets, plain paper would lack the conductivity provided by the
graphene to be viable in electrochemically detecting the antigen. This high absorbance
from functionalized plain paper is likely due to antibodies passively absorbed into the
porous paper. From this functionalization test, it was confirmed that our procedure
immobilizes antibodies onto the graphene sheets.

Figure 3.27: Absorbance measurements of HRP-labelled antibody functionalized
graphene sheets and plain copy paper sheets
3.3.5.1 Sandwich ELISA system design and testing
Once proper immobilization of antibodies onto the graphene sheet was confirmed,
a full sandwich ELISA system was designed and tested for the specific detection of our
analyte of interest, mouse IgG. To functionalize the graphene biosensors, goat anti-mouse
IgG antibodies were immobilized on the surface of the graphene shown in Figure 3.28.
The PBA-NHS linker was applied to the surface of the graphene sensor (Figure 3.28A).
Next, anti-mouse IgG antibodies were applied to the surface to be immobilized by the
NHS on the PBA and primary amines on the FC regions of the antibodies (Figure 3.28B).
BSA was added to the sensor surface to block non-specific binding of the antigen to the
sensor surface itself, and ethanolamine was used to cap unreacted PBA-NHS linkers
(Figure 3.28C). The antigen of interest, mouse IgG, was applied to the surface and
captured by the immobilized antibodies by specific antibody-antigen interactions (Figure
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3.28D). Finally, detecting goat anti-mouse antibodies labelled with a AuNP were applied
to the antigen (Figure 3.28E). The detecting antibodies act as signal-enhancing
molecules as the immobilization of a AuNP-labelled antibody should drastically change
the electrical properties of the sensor surface.

Figure 3.28: Sandwich ELISA system on graphene sheet
To test the functionalized graphene sheets using a sandwich ELISA system, a
constant concentration for the detecting antibody was used at 0.1 mg/mL and an
increasing concentration of mouse IgG was applied to the primary antibodyfunctionalized graphene sheets from 10-5 to 10-1 mg/mL. With an increased amount of
mouse IgG bound to the sensor, which would result in an increase amount of AuNPlabelled detecting antibody, a decrease in the resistivity was expected. The AuNP should
act as an electron-mediator to increase the conductivity of the bound complex when
electrochemically tested. Five sensors were tested, and the SR curves before (black
curve) and after (red curve) detecting antibody application for individual sensors is
shown in Figure 3.29A-E. This data is shown as individual functionalized devices to
show the inconsistent results obtained for changes in the SR as mouse IgG and dAbs
were applied to the surface. Sensors A, C, and D have the expected drop in SR with
increasing mouse IgG concentration, and sensors B and E have an increase in the SR with
increasing mouse IgG concentration. Another issue is that there should be an observable
difference in SR curves before and after dAb application, and there is no such result. This
suggests that the application of a AuNP-labelled species onto the graphene sheets did not
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significantly change the electrical properties. Without a change in the SR during testing,
there is no reliable method to detect the presence of the target analyte.

Figure 3.29: SR curves for 5 functionalized graphene sheets tested using a sandwich
ELISA system for mouse IgG detection

3.4 Conclusions
The results discussed here for the graphene biosensors project show limited
success in the detection of target analytes. Throughout biosensor creation, various
conditions were explored to obtain positive results. Paper and non-paper substrates were
used for biosensor creation with no change in SR when comparing BSA-applications to
buffer-only applications. The number of ink coats, ink conductivity, and graphene sheet
hydrophobicity/size were varied in attempts to change the electrical and chemical
properties of the biosensors without success. Wax barriers were used to reduce swelling
effects of the biosensors also without successful protein detection. Additionally,
functionalization of the graphene sheets with a sandwich ELISA system was performed
which also lead to insufficient data to support the detection of target analytes. Overall,
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with a wide variety of parameters tested for the biosensors project, no positive and
publishable results were obtained. The results discussed in this dissertation should act as
a review of optimization attempts for creating graphene-based biosensors for rapid
analyte detection.
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4 Virus particle detection using various sizes of gold
nanoparticles aggregated by osmolytes
4.1 Introduction
Up to nine different infectious diseases are tested for in blood donations in the
United States [19]. These infectious diseases are detected by confirming the presence of
antibodies to the disease with immunoassays or amplifying the nucleic acid from the
virus itself using a nucleic acid test (commonly polymerase chain reaction). Although
effective, these tests are specific to only one virus at a time, are time consuming, and
expensive. A faster, non-specific test would increase throughput of samples and reduce
costs by being able to confirm the presence of any viral particle in each sample. One
potential way to accomplish this is utilizing gold nanoparticles (AuNPs) in a virus
detection assay.
AuNPs have unique optical properties that can aid in detection and is called
surface plasmon resonance (SPR). SPR dictates the AuNP’s color in solution and changes
with different sizes of AuNPs and their inter-particle distance [187]. SPR is a result of
exciting the cloud of free electrons present near the surface of metals, including AuNPs.
The natural oscillations of the free electrons on the surface of the AuNPs are called
surface plasmons, which exist at the gold metal-dielectric interface [90]. When excited by
light, the surface plasmon oscillations can couple with the incident light, which emits
electromagnetic waves in the visible range [88, 90]. This resonant oscillation between the
incident light and surface plasmons is called SPR [91]. AuNPs with a certain size have a
characteristic ultraviolet-visible (UV-Vis) absorption spectrum and absorbance peak. For
example, 15 nm diameter AuNPs have an absorbance peak at a wavelength of 519 nm,
corresponding to a deep red solution [6].
AuNPs and other metallic nanoparticles are capable of Rayleigh scattering, which
is the phenomenon of elastic scattering of light by particles smaller than the wavelength
of the incident light [188]. Within the Rayleigh scattering range, which is appropriate for
sub-100 nm nanoparticles, the scattering light intensity is proportional to the sixth power
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of the particle diameter [189]. AuNPs light scattering ability can be used to determine
their size using dynamic light scattering (DLS). It has been shown that assays developed
using a light scattering detection system have a lower limit of detection up to four orders
of magnitude compared to absorbance based systems [187]. For this reason, light
scattering-based assays are more appropriate for detecting low concentrations of virus
present in samples, which has been used to detect whole virus particles [97], viral nucleic
acids [94], and viral antibody markers [190].
The detection pathway of these virus detection tests typically occurs in two steps.
First, AuNPs are functionalized with virus-specific nucleic acid probes or capture
antibodies (Figure 4.1A). Then, the functionalized AuNPs aggregate in the presence of
the target viral oligonucleotides or virus particles (Figure 4.1B). This aggregation occurs
when target virus is added because viral particles are symmetrical. The symmetrical
nature of viruses allows multiple antibodies to bind to the same virus, causing a crosslinking like pattern to occur, shown in Figure 4.1B. The same would not occur in the
presence of proteins because proteins cannot bind to multiple antibodies. The aggregation
results in a measurable change in size directly measured using DLS.

Figure 4.1: A) AuNP functionalization with virus-specific antibodies and B) induced
aggregation of AuNPs after the addition of target viral particles
One example of a functionalized AuNPs aggregation assay was detection of
influenza virus with influenza-specific antibody functionalized AuNPs [97]. When
influenza virus was added to a solution of antibody-functionalized AuNPs, aggregation
occurred and was measured by DLS with a limit of detection (LOD) of <100 TCID50/mL,
which was 1-2 orders of magnitude lower than conventional diagnostic kits [97]. These
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tests have shown improved detection ability compared to ELISA-based and PCR-based
tests. However, like these conventional tests, they also depend on the use of nucleic acids
and antibodies that must be immobilized onto the AuNPs, which increases preparation
complexity and cost. Stability issues are also a concern when nucleic acids and antibodies
are used. Thus, an unmodified AuNP, whole viral particle test is desired to reduce the
cost and increase simplicity.
The goal is to create a viral particle assay using unmodified AuNPs. Without
functionalizing the AuNPs, a different aggregation technique must be used. It has been
well studied that NaCl has the ability to aggregate citrate-capped AuNP by neutralizing
the negative charge distribution with Na+ cations in as little as 100 mM NaCl [93, 94].
One assay was developed that utilizes NaCl to aggregate unmodified, non-stabilized
AuNP. In this assay, hepatitis C virus (HCV) RNA was detected based on NaCl-induced
AuNP shown in Figure 4.2 [191]. First, extracted HCV RNA from clinical samples was
added to a tube containing a hybridization buffer with the targeting RNA primer. The
mixture was then denatured and annealed to allow the primer to bind to the HCV RNA.
NaCl and AuNPs were then added to the tube and the color was observed after 1 minute
of incubation (Figure 4.2, Complementary Target). In this case, the primer hybridized
with the target, which left the AuNPs unprotected and thus aggregated by NaCl. In the
case where a non-complementary target RNA was added in the sample tube, the RNA
primers were adsorbed to the surface of the AuNPs through electrostatic interactions
between the nitrogenous backbone of RNA and the AuNPs, which protected the AuNPs
from NaCl-induced aggregation (Figure 4.2, Non-complementary Target). This assay
had a LOD of 50 copies/reaction, which was 1,200 times lower than a conventional
ELISA for the HCV core antigen [191]. Although this assay significantly improved upon
the conventional method, it still utilized oligonucleotide probes that have stability issues.
Additionally, the sample preparation steps to extract HCV RNA are complex.
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Figure 4.2: Colorimetric detection pathway for HCV RNA using unmodified AuNPs via
NaCl-induced aggregation [191]
One different method of causing AuNP aggregation is using osmolytes, which are
known to aggregate viral particles [111, 112]. Osmolytes are water-soluble, naturallyoccurring molecules that are produced by cells to enhance protein stability. Osmolytes
work by combating osmotic stress and other environmental stresses to help cells maintain
their structure by regulating water content within the cell [105, 106]. Osmolytes have
been used for the preferential aggregation of both enveloped (Sindbis virus) and nonenveloped (PPV) viral particles [111, 112]. The theory for this preferential virus
aggregation versus protein aggregation with osmolytes is based on the relative
hydrophobicity between viruses and proteins and the physical structure of the two
macromolecules [6, 111]. When osmolytes are introduced into solutions containing PPV
or proteins, there is a partial dehydration around the biomolecules. This is because
osmolytes have a higher affinity for water molecules than does the protein backbone
[108]. Excess free energy is generated that must be minimized when water molecules are
pulled away from the biomolecule surface. For proteins, their relatively more hydrophilic
and flexible nature allows the excess free energy to be minimized by increased protein
side chain interactions, resulting in protein structure compaction and stabilization [6, 111,
113]. The mechanism of free energy reduction due to osmolyte-induced dehydration in
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the case of viruses is different. It has been shown that viruses are relatively more
hydrophobic and rigid than proteins [113]. Due to the relatively high hydrophobicity of
viruses, they are dehydrated to a greater extent than proteins when exposed to osmolytes.
Since viruses cannot reduce the excess free energy by structure compaction like proteins,
the hydrophobic exposed residues are minimized by virus-virus aggregation [111]. This
difference in free energy reduction mechanism between proteins and viruses gives the
virus detection assay its specificity because AuNP/protein complexes should not
aggregate to the same extent as AuNP/virus complexes when exposed to osmolytes.
This osmolyte-induced, preferential aggregation of viral particles action was used
to develop a PPV and BVDV detection assay [6]. The viral particles were capable of nonspecifically binding to AuNPs through a combination of electrostatic [192] and
hydrophobic interactions [104]. The hypothesized mechanism of this interaction is that
viral particles have surface-exposed, positively charged patches on the capsid which can
electrostatically bind with the citrate-capped AuNPs. After complexing viral particles
with 15 nm AuNPs via these electrostatic interactions, mannitol was used to aggregate
the AuNP/virus complexes. The addition of 1M mannitol dehydrated the viral particles
and caused the complexes to aggregate. This aggregation was detected using DLS. The
AuNP/virus complex size before and after aggregation was measured by DLS and
compared to AuNP/protein complex size before and after aggregation. This resulted in a
LOD of 6 log MTT50/mL for PPV and 4 log MTT50/mL for BVDV [6].
The previous virus detection study using 15 nm AuNPs served as the baseline to
be improved using different sizes of AuNPs in the same aggregation assay. To improve
the virus detection assay, different sizes of AuNPs were synthesized and used to
potentially lower the LOD for the same viruses. To explore how different sizes of AuNPs
interact with viruses and effect the assay, AuNPs with a diameter of 50 nm were used
with BVDV particles (Figure 4.3E), and AuNPs with diameters of 5, 15, and 40 nm were
used with PPV particles (Figure 4.3A-C). These sizes were chosen to have the size ratio
between the AuNP and virus diameters to be <1, ~1, and >1, shown in Figure 4.3. The
diameter ratios between viral particles and AuNPs were expected to change the detection
ability two different ways. First, a diameter ratio >1 should lead to both a larger surface
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for viruses to bind to (Figure 4.3C and F), and an enhanced DLS signal with larger
AuNPs should be observed. This enhanced signal is expected because the intensity of the
scattered signal in DLS to changes in the radius of the AuNPs has the relation of (DLS
intensity ∝ AuNP radius6) [193]. Second, a diameter ratio <1 should cause smaller

AuNPs to electrostatically bind to the viral particles more readily since the positively
charged patches on the virus surface may be hard for larger AuNPs to access. This would
result in the virus surface being more covered by the smaller AuNPs, shown in Figure
4.3A and D. At a diameter ratio of ~1, there are less AuNPs covering the virus surface as
the AuNPs would be electrostatically hindered from completely covering the surface,
shown in Figure 4.3B and E.

Figure 4.3: AuNPs binding to A-C) PPV and D-F) BVDV particles in size ratios of <1, 1,
and 2
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However, from this work, the use of the osmolytes mannitol and glycine as
aggregating agents for the various sizes of AuNP/virus complexes did not result in an
improved virus detection assay, as the LODs for both viruses were unchanged compared
to the original assay using 15 nm AuNPs.

4.2 Materials and methods
4.2.1 AuNP and cell culture materials
Gold (III) chloride trihydrate (≥99.9%), trisodium citrate (ACS grade, ≥99.0%),
bovine serum albumin (≥98%), D-mannitol (≥98%), and sodium phosphate dibasic
heptahydrate (ACS grade, 98.0-102.0%) were purchased from Sigma-Aldrich (St. Louis,
MO). Sodium phosphate monobasic monohydrate (ACS grade, 98.0-102.0%) and sodium
chloride (ACS grade, ≥99.0%) were a gift from MilliporeSigma (Burlington, MA).
Barnstead™ nanopure water (Thermo Scientific, Waltham, MA) with an electrical
resistance of ≥18 MΩ was used to create the aqueous solutions. AuNPs with a diameter
of 5 nm (typical diameter 5.3-5.8 nm) were purchased from Ted Pella (Redding, CA) and
were used without any modification. The 5 nm AuNPs had a particle concentration of
8.3×10-8 M.
Minimum essential medium, Dulbecco’s modified eagle’s medium, fetal bovine
serum (Mexico origin), horse serum (New Zealand origin), 10,000 U/mL penicillin
streptomycin, 0.25% trypsin-EDTA (1X), phosphate buffered saline pH 7.2 (1X), and
sodium bicarbonate (7.5%) for cell culture and virus propagation were from Gibco™
(Grand Island, NY). All solutions were filtered through a 0.2 μm Nalgene™ RapidFlow™ sterile disposable bottle-top filter with PES membrane from Thermo Scientific
into an autoclaved vessel for storage before use.
4.2.2 Virus production and purification
Porcine kidney cells (PK-13) were purchased from the American Type Culture
Collection (ATCC®) (cat# CRL-6489™) and cultured in minimum essential medium
(MEM) supplemented with 10 vol% fetal bovine serum (FBS) and 1 vol%
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penicillin/streptomycin (pen/strep). The cells were incubated at 37°C, 5% CO2, and 100%
humidity. PPV strain NADL-2 was a gracious gift from Dr. Ruben Carbonell at North
Carolina State University (Raleigh, NC). PPV strain NADL-2 was propagated in PK-13
cells as described previously [194]. After PPV propagation in PK-13 cells, the cell lysate
was clarified by centrifugation at 5,000 rpm at 4°C for 15 minutes in a ST16R centrifuge
with a TX-400 swing-bucket rotor (Thermo Scientific). The collected supernatant was
dialyzed using Biotech cellulose ester 1000 kDa dialysis tubing at 4°C with two 4 mM
phosphate buffer (pH 7.2) exchanges over two days. The dialyzed PPV was further
purified using an Econo-Pac 10DG size-exclusion desalting column and used within one
week of purification.
Bovine turbinate cells (BT) were purchased from ATCC (cat# CRL-1390™) and
cultured in Dulbecco’s modified essential medium (DMEM) supplemented with 10 vol%
horse serum and 1 vol% pen/strep [195]. The cells were incubated at 37°C, 5% CO2, and
100% humidity. BVDV strain NADL was purchased from USDA APHIS. BVDV was
propagated in BT cells [6, 196]. After BVDV propagation, the cell lysate was clarified
and stored the same as PPV.
4.2.3 Synthesis and characterization of AuNPs with various sizes
Various sizes of AuNPs were synthesized and characterized. AuNPs ranging from
~27 to 106 nm in diameter were synthesized by the seed-mediated, room temperature
growth method with trisodium citrate (Na3Ctr) and chloroauric acid (HAuCl4) [193]. The
synthesis of larger AuNPs started with monodisperse 15 nm diameter AuNP seeds that
were synthesized by the conventional Turkevich method of adding Na3Ctr to reduce
boiling HAuCl4 [6]. By changing the volume of water and AuNP seed additions to
constant volumes of HAuCl4 and Na3Ctr, different diameters of AuNPs were synthesized
over time at room temperature, shown in Table 4.1 [193]. The concentration of HAuCl4
was 44.7 mM, the concentration of the seed AuNPs was 6.54×1012 particles/mL, and the
concentration of Na3Ctr was 38.8 mM [193].

81

Table 4.1: Reactants volumes for synthesis of AuNPs with various diameter [193]
AuNP size
Vwater
VHAuCl4
Vseed
VNa3Ctr
(nm)
(mL)
(mL)
(mL)
(mL)
22.7
36.220
0.227
3.377
0.176
34.2
38.786
0.227
0.811
0.176
45.7
39.270
0.227
0.327
0.176
57.1
39.432
0.227
0.165
0.176
68.6
39.502
0.227
0.095
0.176
80.0
39.537
0.227
0.060
0.176
91.4
39.557
0.227
0.040
0.176
102.9
39.569
0.227
0.028
0.176
114.3
39.577
0.227
0.020
0.176
4.2.4 Concentration determination of different AuNP sizes
The concentration of AuNPs was determined by the molar extinction coefficient
method after collecting the UV-Vis spectra and size via DLS, which has been shown to
be accurate for AuNPs between 5 and 100 nm [197]. The concentration of AuNPs
calculated from the UV-Vis spectra method was adjusted so that all reactions would have
the same binding surface area across all sizes. The concentration of 3.5 nM was used for
15 nm AuNPs for the detection of PPV and BVDV [6]. Using Equation 4.1, the surface
area was held constant by varying the concentration of AuNPs with different diameter,
𝐶𝐶2
𝐶𝐶1

=

𝐷𝐷

2

� 1�
2

� 𝐷𝐷 2
� 22 �

(4.1)

where C1 is the concentration of the 15 nm AuNPs (3.5 nM), C2 is the desired
concentration of any other sized AuNPs, D1 is the diameter of 15 nm AuNPs (15 nm),
and D2 is the diameter of any other sized AuNPs. This equation shows a higher
concentration of larger diameter AuNPs are necessary for the virus detection assay.
4.2.5 AuNP/virus and protein complex formation
Different concentrations of PPV, BVDV, and BSA were added to the AuNPs of
different sizes to form complexes to be aggregated by osmolyte or salt. PPV from 8 log
MTT50/mL to 4 log MTT50/mL was added in a 1:1 volume ratio (total volume of 1 mL)
with AuNPs and mixed overnight on a Roto-shake Genie rocker (Bohemia, NY) with end
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over end rotation. The same overnight mixing was performed for BVDV from 6 log
MTT50/mL to 2 log MTT50/mL, and BSA at 0, 1 nM, and 1 µM to form AuNP
complexes. For AuNPs with diameter 40 and 50 nm, the complexes were centrifuged at
6000×g for 20 minutes in a ST16R centrifuge with a microliter 30 x 2 mL fixed angle
rotor (Thermo Scientific) to remove un-complexed material in the supernatant, and
resuspended in 1 M mannitol, glycine, or NaCl.
For AuNPs with a 5 nm diameter, the manufacturer did not recommend
centrifugation of the complexes as they are readily aggregated by centrifugation. Instead,
250 µL of 7.0 nM AuNPs and 250 µL of PPV were combined and mixed overnight the
same way as above. The concentration of aggregating agent was doubled to 2 M to allow
for a 500 µL addition to achieve the same final concentration of components with a final
volume of 1 mL after aggregation.
4.2.6 Quantification of aggregated AuNP/virus complexes by DLS
A Malvern Nano ZS Zetasizer (Malvern, UK) was used to collect DLS curves of
intensity versus hydrodynamic diameter (DH) for samples before and after aggregation.
The software-generated Z-average for the size distribution was used as the DH for each
sample. The AuNP material properties were set at a refractive index of 0.20 and an
absorption of 3.32 [198]. The water dispersant properties were set to a temperature of
20°C, a viscosity of 1 cP, and a refractive index of 1.333. Samples were placed in
disposable acrylate cuvettes at a volume of 1 mL.
The quantification of AuNP/virus complexes was achieved using DLS to
determine the DH before and after aggregation by osmolyte or salt. The change in
hydrodynamic diameter (ΔDH) was used to quantify the extent of aggregation, which was
inferred by measuring the change in size of the aggregates using Equation 4.2,
Δ𝐷𝐷𝐻𝐻 = 𝐷𝐷𝐻𝐻,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡 − 𝐷𝐷𝐻𝐻,𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑏𝑏𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡

(4.2)

where DH, complexes after treatment is the hydrodynamic diameter of AuNP/virus complexes
after aggregation by osmolyte or salt (nm), and DH, complexes before treatment is the
hydrodynamic diameter of AuNP/virus complexes before aggregation by osmolyte or salt
(nm).
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4.3 Results and discussion
4.3.1 Virus interaction with various AuNP sizes
The interaction between different sizes of AuNPs and virus particles was
explored. The two model viruses to be detected in the AuNP assay, PPV and BVDV,
have diameters of ~20 nm [199] and ~50 nm [200]. To explore how different sizes of
AuNPs interact with the two viruses, AuNPs with diameters of 5, 15, and 40 nm were
chosen for PPV (Figure 4.3A-C), and AuNPs with a 50 nm diameter were chosen for
BVDV (Figure 4.3D-E). These sizes were chosen to have the size ratio of AuNP to virus
diameters be <1, ~1, and ~2. For AuNPs that are smaller in diameter than the virus
particles, it is believed that the AuNPs surround the virus particles (Figure 4.3A and D).
The size ratio of ~1 for PPV has already been performed and serves as the base line
control to compare the other size ratios (Figure 4.3C) [6]. When sufficiently large
AuNPs are used, the opposite should occur, where many virus particles surround a single
AuNPs (Figure 4.3C and F).
It was hypothesized that the configuration where virus particles surround the
larger AuNPs (ratio ~2) would result in a higher DLS signal, and hence a lower LOD if
enough virus is present to be aggregated by the osmolytes. This is because the interparticle distance decrease of larger AuNPs results in more scattered light than decreasing
the inter-particle distance between smaller AuNPs. Additionally, the larger AuNPs have a
higher accessibility of the virus to bind due to the increased surface area. This should
help ensure the virus particles are complexed with AuNPs prior to aggregation so the
virus can be detected. This hypothesis was tested by measuring the size of AuNP/virus
complexes before and after osmolyte-induced aggregation with DLS. The results
indicated that neither larger AuNPs nor smaller AuNPs resulted in an improved virus
detection assay because the LOD was not reduced.
4.3.2 Synthesis and characterization
After synthesis, the particles were characterized by UV-Vis, DLS, and TEM. The
UV-Vis absorption spectrums for 27, 68, 96, 100, and 106 nm diameter AuNPs are
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shown in Figure 4.4A. A red-shift in absorbance peak is clearly visible due to the
increased size of AuNPs, and the absorbance peaks are very close to the expected
literature values [193]. To determine the size of the different diameter AuNPs, DLS
curves collected shown in Figure 4.4B. The Z-average hydrodynamic diameter collected
during DLS measurements were used as the reported sizes of AuNPs, which is the
diameter at peak intensity. The synthesized AuNPs of different diameter are
monodisperse based on the presence of only one peak on the DLS curves, except for 68
nm particles, possibly due to a small amount of contamination. To confirm the correct
size and shape of AuNPs, TEM images were collected and can be seen in Figure 4.4C
for 68 nm and 100 nm AuNPs. The TEM image confirmed the size of the 100 nm
AuNPs. The peak-broadening of the larger AuNPs (>100 nm) seen in UV-Vis (Figure
4.4A) is caused by dephasing of the surface plasmons from an enhanced mean free path
of electrons, which causes new plasmon modes to appear at higher wavelengths [201203]. The measured sizes of the AuNPs from the TEM images were similar to the sizes
determined by DLS, with a slight over-estimation of the size by DLS. This result has
been observed by others characterizing AuNPs and is due to DLS measuring the
hydrodynamic diameter of the particles, which includes the solvation layer, whereas
TEM measures the absolute size [188].
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Figure 4.4: Characterization of various sizes of AuNPs showing the A) UV-Vis
absorption spectrums, B) DLS curves, and C) TEM images of 68 nm and 100 nm AuNPs
4.3.3 Aggregation of 40 nm AuNP/PPV complexes
AuNPs with a diameter of 40 nm (AuNP40) were complexed with PPV in the
range of 8 log MTT50/mL to 4 log MTT50/mL and aggregated using 1 M mannitol, 1 M
glycine, and 1 M NaCl. 1 nM and 1 µM BSA were used as controls to show the specific
nature of osmolytes to aggregate AuNP40/virus complexes, but not AuNP40/BSA
complexes. Aggregation of the AuNP40/virus and BSA complexes by mannitol, glycine,
and NaCl are shown in Figure 4.5. At 7 log MTT50/mL, there began to be a difference
between AuNP40/PPV complexes before and after treatment with mannitol (Figure 4.5A)
and glycine (Figure 4.5B). Below that concentration, not enough virus was present to be
aggregated and measured. A concentration of 8 log MTT50/mL was necessary to halt saltinduced aggregation of the AuNPs (Figure 4.5C). From the previous assay with AuNP15,
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6 log MTT50/mL was needed to halt salt-induced aggregation [6]. This difference is likely
because of the larger AuNP surface exposed to the salt environment when compared to
using smaller AuNPs. Diameters of ~75 nm (Figure 4.5D) and ~55 nm (Figure 4.5E)
were achieved by aggregating AuNP40/BSA control complexes with mannitol and
glycine, respectively. Using Equation 4.2, ΔDH values of ~25 nm and ~7 nm were
calculated for mannitol-treated AuNP40/BSA complexes and glycine-treated
AuNP40/BSA complexes, respectively. The ΔDH values for BSA complexes represent the
limit of the DLS to distinguish between AuNP/virus and AuNP/BSA complexes
aggregated by mannitol and glycine. ΔDH was calculated for mannitol and glycine
aggregated AuNP40/PPV complexes and compared to ΔDH calculated for aggregated
AuNP40/BSA complexes, showing that the LOD for mannitol-treated complexes was 7
log MTT50/mL (Figure 4.5G, red line). The LOD for glycine-treated complexes was also
7 log MTT50/mL (Figure 4.5H, red line).
The baseline LOD results from the AuNP15/PPV assay was 6 log MTT50/mL for
PPV [6]. Neither mannitol-treated nor glycine-treated AuNP40/PPV complexes led to an
improved LOD. This result did not support the hypothesis that larger diameter AuNPs
would increase the DLS intensity signal at lower concentration of virus.
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Figure 4.5: AuNP40/PPV complexes aggregated by A) 1 M mannitol, B) 1 M glycine, and
C) 1 M NaCl. AuNP40/BSA complexes aggregated by D) 1 M mannitol, E) 1 M glycine,
and F) 1 M NaCl. G) ΔDH as a function of AuNP40/PPV complexes aggregated by
mannitol with the red line representing the LOD. H) ΔDH as a function of AuNP40/PPV
complexes aggregated by glycine with the red line representing the LOD.
4.3.4 Aggregation of 50 nm AuNP/BVDV complexes
AuNPs with a diameter of 50 nm (AuNP50) were complexed with BVDV in the
range of 6 log MTT50/mL to 2 log MTT50/mL and aggregated using 1 M mannitol, 1 M
glycine, and 1 M NaCl. BSA was used as a control. Aggregation of the AuNP50/virus or
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protein complexes by mannitol, glycine, and NaCl are shown in Figure 4.6. At 5 log
MTT50/mL, there began to be a difference between AuNP50/BVDV complexes before and
after treatment with mannitol (Figure 4.6A). At 6 log MTT50/mL, there began a
difference between AuNP50/mL complexes before and after treatment with glycine
(Figure 4.6B). Below these concentrations, not enough virus was present on the AuNP
surface to be aggregated and measured. A concentration of 5 log MTT50/mL was
necessary to halt salt-induced aggregation of the AuNPs (Figure 4.6C), which is lower
than AuNP40 used with PPV likely because of the larger size of BVDV compared to PPV
capable of shielding the NaCl from aggregating the AuNPs. Diameters of ~80 nm
(Figure 4.6D) and ~60 nm (Figure 4.6E) were achieved by aggregating AuNP50/BSA
control complexes with mannitol and glycine, respectively, leading to ΔDH values of ~30
nm and ~6 nm. ΔDH values of ~30 nm and ~6 nm were calculated for mannitol-treated
AuNP50/BSA complexes and glycine-treated AuNP50/BSA complexes, respectively. The
ΔDH values for BSA complexes represent the limit of the DLS to distinguish between
AuNP/virus and AuNP/BSA complexes aggregated by mannitol and glycine. ΔDH was
calculated for mannitol and glycine aggregated AuNP50/BVDV complexes and compared
to ΔDH calculated for aggregated AuNP50/BSA complexes, showing that the LOD for
mannitol-treated complexes was 4 log MTT50/mL (Figure 4.6G, red line). The LOD for
glycine-treated complexes was 6 log MTT50/mL (Figure 4.6H, red line).
The baseline LOD results from the AuNP15/BVDV assay was 4 log MTT50/mL
for BVDV [6]. These results did not improve the LOD compared to when 15 nm AuNPs
were used, which did not support the hypothesis that larger diameter AuNPs would
increase the DLS intensity signal at lower concentration of virus.
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Figure 4.6: AuNP50/BVDV complexes aggregated by A) 1 M mannitol, B) 1 M glycine,
and C) 1 M NaCl. AuNP50 /BSA complexes aggregated by D) 1 M mannitol, E) 1 M
glycine, and F) 1 M NaCl. G) ΔDH as a function of AuNP50 /BVDV complexes
aggregated by mannitol with the red line representing the LOD. H) ΔDH as a function of
AuNP50 /BVDV complexes aggregated by glycine with the red line representing the
LOD.
4.3.5 Aggregation of 5 nm AuNP/PPV complexes
Since larger AuNPs complexed with the virus did not result in a lower LOD, it
was decided to try AuNPs that were smaller than the virus. AuNP5 (5 nm particles) were
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complexed with PPV in the range of 4 to 8 log MTT50/mL with the same osmolytes and
salt. BSA was used as the control. Aggregation of the AuNP5/PPV or BSA complexes are
shown in Figure 4.7. Regardless of the concentration of PPV used to complex with the
AuNP5, the same level of aggregation was observed when mannitol and glycine were
added, shown in Figure 4.7A and B. However, as expected, salt-induced aggregation
was stopped at higher concentration of PPV (6 log MTT50/mL), meaning PPV shields the
AuNPs from being aggregated, as shown in Figure 4.7C. Regardless of the BSA
concentration used, the same degree of aggregation was observed when compared to PPV
samples (Figure 4.7D and E). The ΔDH values calculated for AuNP5/BSA complexes
were ~130 nm for mannitol treated complexes and ~30 nm for glycine treated complexes.
Using these ΔDH values for AuNP5/BSA complexes as the LOD for AuNP5/PPV
complexes, there is no detection ability when aggregated by mannitol or glycine (Figure
4.7G and H, respectively). These results indicated that the AuNP5 were aggregating due
to osmolyte addition regardless of the biomolecule or biomolecule concentration.
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Figure 4.7: AuNP5/PPV complexes aggregated by A) 1 M mannitol, B) 1 M glycine, and
C) 1 M NaCl. AuNP5/BSA complexes aggregated by D) 1 M mannitol, E) 1 M glycine,
and F) 1 M NaCl. G) ΔDH as a function of AuNP5 /PPV complexes aggregated by
mannitol with the red line representing the LOD. H) ΔDH as a function of AuNP5 /PPV
complexes aggregated by glycine with the red line representing the LOD.
To test this theory, AuNP5 were mixed with an equal volume of nanopure water, 1
M mannitol, 1 M glycine, and 1 M NaCl, and DLS curves were collected for each
condition to test if the size increased just with osmolyte treatment without biomolecule
presence. The results are shown in Figure 4.8. The AuNP5 straight from the manufacturer
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and in water showed a DH of ~11 nm, see Figures 4.8A and B. Although the size is larger
than the expected 5 nm, it is common for DLS to over-estimate the true size of the
particles as it is measuring the hydrodynamic diameter, and not true diameter of the
particles [188]. The size of the particles was confirmed with TEM imaging, showing a
size between 6-7 nm, shown in Figure 4.9. AuNP5 mixed with glycine showed only a
slight increase in hydrodynamic diameter to 16 nm, (Figure 4.8C). AuNP5 mixed with
mannitol and NaCl showed an increase in diameter to 113 nm and 950 nm, respectively.
Although the salt-induced aggregation is expected for bare AuNPs, the high degree of
aggregation due to mannitol treatment was unexpected and undesired. One possible
reason for this aggregation by mannitol could be that the high number of hydroxyl groups
present on mannitol can substitute citrate ions on the surface leading to a destabilization
of the AuNPs. This increased hydroxyl group affinity to smaller AuNPs was noticed
when a reducing agent with a high number of hydroxyl groups was more efficient at
synthesizing smaller diameter AuNPs, compared to reducing agents with a lower amount
of hydroxyl groups [204]. Due to the challenge of osmolytes aggregating the plain
AuNP5, they were not investigated for further use in virus detection.
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Figure 4.8: DLS curves showing the size of A) AuNP5 straight from the manufacturer’s
bottle and B) AuNP5 in nanopure water. DLS curves of AuNP5 aggregated by C) 1 M
glycine, D) 1 M mannitol, and E) 1 M NaCl.

Figure 4.9: TEM images of 5 nm AuNPs at two different magnification levels
94

Overall, by utilizing AuNP40 with PPV, AuNP50 with BVDV, and AuNP5 with
PPV, there was no improvement to the virus detection assay previously published using
AuNP15 for PPV and BVDV. The LODs remained at 6 log MTT50/mL for PPV and 4 log
MTT50/mL for BVDV.

4.4 Conclusions and future work
Synthesis of various sizes of AuNPs was performed and characterized for use in a
PPV and BVDV detection assay. AuNP40 were complexed with PPV, resulting in a LOD
of 7 log MTT50/mL when aggregated by 1 M mannitol. AuNP50 were complexed with
BVDV, resulting in a LOD of 5 log MTT50/mL when aggregated by 1 M mannitol.
AuNP5 were used in an attempt to detect PPV, but the high concentrations of osmolytes
used in the aggregation step led to AuNP aggregation regardless of the presence of virus
or control protein. Neither an increase nor decrease in the size of AuNPs lead to an
improved LOD compared to the published work of using 15 nm AuNPs in the same
detection assay. These results indicate that the size of AuNPs used in the virus detection
assay do not play a critical role in detection.
Future work for the AuNP project includes using 100 nm AuNPs (AuNP100) to
test if a size ratio between AuNP and BVDV of 2 would improve the detection ability.
The size ratio of 2 between PPV and AuNPs40 did not lead to an improved LOD, but
BVDV is a larger virus that could complex with a few number of AuNP100. By
complexing with fewer, larger AuNPs BVDV could be detected due to the increase in
scattered light intensity with larger AuNPs.
The system pH could be varied to improve the virus detection assay. Since the
virus pI dictates the surface charge on a virus particle, the system pH could be lowered to
cause more electropositive patches to be present. With more electropositive patches
present, the electrostatic interaction may become stronger between citrate-capped AuNPs
and virus particles. The stronger electrostatic interaction may lead to the ability to use a
lower concentration of virus particles to bind to AuNPs, and thus a lower amount of virus
would be needed for osmolyte-induced aggregation.
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Additionally, other osmolytes such as alanine and trehalose have been shown to
aggregate enveloped and non-enveloped viruses, which could be used to aggregate the
AuNP/virus complexes [111, 112]. Alanine is an amino acid with a hydrophobic side
chain that may be able to aggregate viral particles more effectively. Alanine residues in
protein molecules are normally buried within the protein structure to protect it from
solvent exposure [205]. This effect could be exploited for the aggregation assay because
the hydrophobic residues from alanine could aid in stabilization and enhanced
aggregation of the dehydrated hydrophobic patches of virus particles. Trehalose is a sugar
with two molecules of glucose linked by an α, α-1,1-glucosidic bond [206]. Trehalose has
a high affinity for water due to multiple hydrogen bonding events between its two
glucose rings and water molecules [207]. The high affinity for water would rapidly
dehydrate the virus surface, potentially causing more virus aggregates to form as more
and more water is pulled away from the virus surface. This could improve the AuNP
assay by allowing a lower concentration of osmolyte to be used in the aggregation step,
or to dehydrate a smaller concentration of virus particles due to the strong dehydration
ability of trehalose.
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5 Continuous downstream purification of viral products
using an aqueous two-phase system
5.1 Introduction
Vaccination remains the best method to prevent the transmission of
communicable human diseases. According to the World Health Organization (WHO), in
2018, 86% of infants worldwide (116.3 million) received three doses of the diphtheriatetanus-pertussis vaccine. But that left 14% of children under the age of 1 (19.4 million)
unvaccinated [208]. One reason for this is due to vaccine supply shortages. Over the past
15 years, significant manufacturing problems have led to numerous vaccine shortages.
These shortages have led to the inability for even the United States to meet past demands
of vaccines for hepatitis A/B, rabies, and influenza [209, 210]. The ever-expanding world
population will continue to increase the demand for vaccines. The biomanufacturing
industry must develop and implement novel production methods to supply the market
quickly and reliably with vital virus-containing biotherapeutics. One such solution is to
switch to continuous operation.
The switch to continuous operation would increase profits by increasing
productivity and flexibility, while decreasing capital and operating costs [211-213]. This
switch requires a fully integrated, end-to-end, continuous biomanufacturing process.
Upstream unit operations that operate continuously are currently in operation [214, 215],
but truly continuous downstream processes are still being developed. Truly continuous
downstream processes must also handle the increasing titers produced in the bioreactor to
purify viral products safely and quickly.
Current semi-continuous downstream processes are focused on simulated moving
bed (SMB) chromatography. There are only a limited number of SMB virus purification
processes due to the complex nature of designing an SMB process [139, 141, 216]. One
SMB chromatography process purified human influenza virus from a serum-free MDCK
cell culture supernatant. The process resulted in 89% virus recovery, 52% protein
removal, and 99.7% DNA removal using a quaternary amine anion exchange monolith
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[139]. However, to achieve the FDA-required DNA maximum amount of 10 ng/dose, a
Benzonase®-treatment was necessary and adds an addition step of Benzonase® removal
later in the process. In addition, a 10% column load was required to keep contaminant
protein and DNA levels low [139]. This low of a column load leads to higher processing
time and cost due to under-utilized column resin. Another SMB chromatography process
used size-exclusion chromatography (SEC) to purify adenovirus from a filtered harvest of
Triton X-100 and Benzonase®-treated HEK-293 cell media. Use of the two-column SEC
technique resulted in 86.3% virus yield, 90% DNA removal, and 89% host cell protein
(HCP) removal [144]. These two SMB chromatography processes show promise for
operating a semi-continuous downstream purification, since most SMB processes are
continuous loading and semi-continuous elution. Since SMB processes are not fully
continuous and resin costs remain high, other unit operations need to be explored.
Aqueous two-phase systems (ATPSs) can be run as fully continuous processes.
An ATPS is a liquid-liquid extraction technique that is used to partition molecules
between two semi-miscible liquid phases and is typically comprised of a polymer and salt
for biomolecule separations [147, 149]. Water is the major component in ATPS, making
the materials inexpensive and environmentally-friendly compared to common
chromatography resins [217]. ATPSs have been tested extensively in batch-mode to
separate and purify proteins [161, 163], phages [175], and viruses [7, 154, 173]. ATPS
was used for the separation and purification of porcine parvovirus (PPV) with an
infectious titer recovery of 79%, DNA removal of 78%, and high protein removal using a
mixture of poly(ethylene glycol) (PEG) and citrate [7].
There have been several continuous ATPS designs used for the recovery of
proteins [158, 161, 163] and enzymes [165, 166, 218]. Two vital considerations for
continuous ATPS operation are effective mixing and phase separation. The most common
designs for continuous ATPSs include the use of column contactors, such as rotating disk
contactors (RDC) and mixer-settlers [170]. The key difference between these types of
designs are how mixing is achieved. RDC uses mechanically spun plates to form mixing
vortices between plates and in-line turbulence generators mix the ATPS in mixer-settles.
One continuous ATPS used an RDC to extract α-lactalbumin from a mixture of α- and β98

lactalbumin [158]. This was performed by spiking α- and β-lactalbumin into the citraterich phase, then a PEG-rich phase was flowed through the bottom of the citrate-rich
phase inside the RDC. Adequate contact between phases was provided and 86% of the αlactalbumin was recovered in the PEG-rich phase with an 86% purity. Although high
recovery and purity of the product was achieved using the RDC, two hours was required
to achieve steady-state operation while flowing at 3 mL/min [158]. Another draw-back to
column contactors is the issue of column flooding, which decreases separation
performance [170].
Mixer-settlers avoid issues of flooding and mechanical failures by employing
various in-line static mixer designs, such as a tube filled with glass-bead or baffles. These
types of mixers use in-line obstacles to disrupt the streamlines of the flowing phases,
creating droplets of each phase. Continuous ATPSs with a polymer as one of the phase
forming components will typically operate in the laminar flow regime due to the high
viscosity of the polymer. For this reason, in-line mixers are appropriate because they can
blend the two phases by disrupting the flow pattern and creating convective radial
mixing. Separation of mixed phases is achieved using long lengths of tubing and
decanters. Continuous ATPS using a mixer-settler was used to study the partitioning of
bovine whey protein isolate (WPI) proteins (α- and β-lactalbumin) between PEG-rich and
phosphate-rich phases [163]. After 12 minutes of continuous operation, 72% of the initial
total protein was partitioned to the phosphate-rich phase, while 30% of the total protein
was collected in the PEG-rich phase [163]. Although the purity of the collected phases
was not quantified, SDS-PAGE gels showed the phosphate-rich phase contained only
bands corresponding to β-lactalbumin, demonstrating that a high purity was achieved
[163]. This study demonstrated the ease of scale-up from batch mode experiments to a
fully continuous separation process.
In this work, we developed a fully continuous ATPS for the purification of PPV
and human immunodeficiency virus type-1 group antigen virus-like particles (HIV VLPs)
from crude cell supernatant without pre-treatment. Optimizations of mixer types was
performed to achieve proper mixing of phases and partitioning of viral particles to the
PEG-rich phase while partitioning most contaminant proteins and DNA to the citrate-rich
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phase. Recovery and purity of each viral product was determined over approximately 40
minutes.

5.2 Materials and methods
5.2.1 Materials
Poly(ethylene glycol) 12,000 (MWavg 11,000-15,000) , citric acid monohydrate
(ACS grade ≥98%), sodium dodecyl sulfate (BioReagent, ≥98.5%), sodium citrate
tribasic dihydrate (ACS reagent, ≥99%), and 2-mercaptoethanol were from SigmaAldrich (St. Louis, MO). Minimum essential medium, fetal bovine serum (Mexico
origin), 10,000 U/mL penicillin streptomycin (pen-strep), 0.25% trypsin-EDTA (1X),
phosphate buffered saline pH 7.2 (1X), and sodium bicarbonate (7.5%) for cell culture
and virus propagation were from Gibco™ (Grand Island, NY). Thiazolyl blue tetrazolium
bromide (98%) was from Alfa Aesar (Ward Hill, MA). SeeBlue™ Plus2 prestained
standard, NuPAGE™ 3-(N-morpholino)propanesulfonic acid (MOPS) sodium dodecyl
sulfate (SDS) running buffer (20X), SimplyBlue™ SafeStain, and NuPAGE™ 4-12%
Bis-Tris gels were from Invitrogen (Carlsbad, CA). Pierce™ lithium dodecyl sulfate
(LDS) sample buffer non-reducing (4X) was from Thermo Scientific (Waltham, MA).
Barnstead™ nanopure water (Thermo Scientific) with an electrical resistance of ≥18 MΩ
was used to create all solutions. All solutions were filtered through a 0.2 μm Nalgene™
Rapid-Flow™ sterile disposable bottle-top filter with PES membrane from into an
autoclaved vessel for storage before use.
5.2.2 Methods
5.2.2.1 Cell maintenance
Porcine kidney cells (PK-13) were purchased from the American Type Culture
Collection (ATCC®) (cat# CRL-6489™) and cultured in minimum essential medium
(MEM) supplemented with 10 vol% fetal bovine serum (FBS) and 1 vol% pen/strep. The
cells were incubated at 37°C, 5% CO2, and 100% humidity. PPV strain NADL-2 was a
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gracious gift from Dr. Ruben Carbonell at North Carolina State University (Raleigh, NC).
PPV strain NADL-2 was propagated in PK-13 cells as described previously [194]. After
three freeze-thaw cycles, the cell lysate was clarified by centrifugation at 5,000 rpm at
4°C for 15 minutes in a ST16R centrifuge with a TX-400 swing-bucket rotor (Thermo
Scientific). The PPV-containing supernatant was stored at -80°C until use.
5.2.2.2 MTT assay for PPV titer
The titer of PPV was found by the MTT colorimetric cell viability assay [219].
PK-13 cells at a seeding density of 8×104 cells/mL were placed in 96-well plates and
incubated overnight. The next day, the cells were infected with PPV by serially diluting
across the plate at a ratio of 1:5 and placed back in the incubator for 6 days. 6 days after
infection, 5 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) salt in 1X pH 7.2 PBS was added to each well to allow living cell’s mitochondrial
reductase to reduce the MTT to (E,Z)-5-(4,5-dimethylthiazol-2-yl)-1,3-diphenylformazan
(formazan). The solubilizing solution, consisting of 10 w/v% sodium dodecyl sulfate
(SDS) with 0.01 M hydrochloric acid (HCl), was added to dissolve the formazan. The
absorbance at 550 nm was measured with a Synergy™ Mx microplate reader from
BioTek (Winoski, VT), and the 50% viral infectious dose was determined in units of
MTT50/mL.
5.2.2.3 Fluorescence measurements for HIV VLP detection
The HIV VLPs were expressed in proprietary Hansenula polymorpha cells
donated by Esperovax (Plymouth, MI). The fluorescence from the GFP was recorded
with a Synergy™ Mx microplate reader in a black, flat-bottom 96-well plate at an
excitation wavelength of 485 nm and emission of 509 nm.
5.2.2.4 ATPS formation
Unpublished work in our lab from an ATPS tie line study using a 12 kDa
PEG/citrate ATPS determined the highest recovery of PPV in the PEG-rich phase at a tie
line length (TLL) of 32 w/w% and tie line ratio (TLR) of 0.5. For this reason, this system
of PEG and citrate was chosen as the ATPS to be run continuously. To form the TLL
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32%/TLR 0.5 system, stock solutions of 45 w/w% PEG (ρ = 1.065 g/mL), 30 w/w%
citrate (ρ = 1.158 g/mL), and nanopure water were mixed to achieve starting system
concentrations of 18 w/w% PEG, 12 w/w% citrate, and 70 w/w% water. To achieve these
starting system concentrations, 41% of the total volume was 45 w/w% PEG, 38% of the
total volume was 30 w/w% citrate, 11% of the total volume was viral product, and 11%
of the total volume was water.
5.2.2.5 Mixer-settler construction
An air-powered mixer operating at 1,500 rpm with a 5 cm diameter Cowles blade
was used to mix ATPS components. This mixer was used as the positive control of
mixing for the in-line mixers. Two in-line mixer designs were tested for their ability to
sufficiently mix the PEG, citrate, and water prior to testing the separation ability and
ATPS formation of the full system. The first mixer was constructed by filling a 15 cm
length of Tygon S3 E-LFL (Saint Gobain, Malvern, PA) polyvinyl chloride (PVC) tubing
(6.35 mm inner diameter) with approximately 150, 3 mm outer diameter glass beads from
Fisher Scientific (Waltham, MA) until fully packed. This was designated the “glass bead
mixer”. The second mixer was assembled by inserting 2, 12-element helical blades (4.76
mm outer diameter) from Cole-Parmer (Vernon Hills, IL) into a 15 cm length of 4.76 mm
ID Tygon S3 E-LFL PVC tubing, which was designated the “helical mixer”.
After each in-line mixer, 45.7 cm of 2 mm ID Tygon tubing was shaped into a
spiral by winding around a 100 mL graduated cylinder (9.5 cm outer diameter) to begin
phase separation before the settler. The settler was a 15 mL centrifuge tube with 2 mm
OD holes drilled into the top of the cap, direct bottom of the tube, and half-way up the
vertical wall of the tube for PEG-rich phase collection, citrate-rich phase collection, and
feed inlet lines, respectively. Each hole was sealed with DAP® RapidFuse® Fast Curing
All Purpose Adhesive with Plastic Primer glue to prevent leaking. The full system
process flow diagram and in-lab set-up are shown in Figure 5.1A and B, respectively.
Close-up images of the helical mixer and the separator section of the continuous ATPS
set-up are shown in Figure 5.1C and D, respectively.
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Figure 5.1: A) Process flow diagram of continuous ATPS and B) in-lab bench scale setup. C) Close-up picture of the in-line helical mixer and D) separator section.
5.2.2.6 COMSOL Multiphysics simulation of helical mixer
COMSOL Multiphysics was used to further evaluate the helical mixer
performance. The program simulated the two-phase laminar flow through the helical
mixer (Figure 5.1C). A schematic of the numerical model and the associated
computational grid are shown in Figures 5.2A and B, respectively. A finite-element
approach was employed as implemented in COMSOL Multiphysics to solve the
incompressible Navier-Stokes equations for the two-phase flow of the PEG-rich (stream
1) and the citrate-rich (stream 2) mixture [220, 221]. A phase-field approach was adopted
to model the interaction between the two immiscible components [222]. The governing
equations were solved iteratively, where within each iteration first velocity and pressure
fields were calculated together directly, and then the phase-field variable was computed
in the same manner. The fluid flow and phase-field equations were discretized via P2+P1
scheme and quadratic elements, respectively. Tetrahedral elements were used to mesh the
computational domains (see Figure 5.2B), and the grid was chosen such that the changes
in the results due to the mesh refinement were marginal.
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Figure 5.2 : COMSOL Multiphysics modelling of in-line helical mixer showing the A)
mixer geometry and B) mesh pattern used in the simulation
The flow within the helical mixer was driven in the simulation by applying inlet
and outlet boundary conditions upstream and downstream of the mixer. Consistent with
stream 1 and steam 2 in the experiments, the fluid velocity (measured in m/s ) and the
phase-field variable are specified as
4.0404 × 10−3 𝒆𝒆𝑧𝑧 𝑓𝑓𝑓𝑓𝑓𝑓 𝑥𝑥 > 𝑅𝑅
1 𝑓𝑓𝑓𝑓𝑓𝑓 𝑥𝑥 > 𝑅𝑅
and Φ = �
𝒖𝒖𝑖𝑖𝑖𝑖 = �
−3
−1 𝑓𝑓𝑓𝑓𝑓𝑓 𝑥𝑥 ≤ 𝑅𝑅
2.869 × 10 𝒆𝒆𝑧𝑧 𝑓𝑓𝑓𝑓𝑓𝑓 𝑥𝑥 ≤ 𝑅𝑅

at the inlet (see Figures 5.4A and B) and the outlet pressure is fixed to zero.

Additionally, no-slip and 90° contact angle conditions were imposed on wetted walls.
Furthermore, the properties of PEG-rich and citrate-rich phases, and the surface tension
between them were set to µPEG = 0.0912 Pa∙s, ρPEG = 1015 kg/m3, µcitrate = 0.001 Pa∙s,
ρcitrate = 1068 kg/m3, and γ = 0.000463 N/m, respectively.
5.2.2.7 Continuous ATPS operational procedure
A mass balance was performed around the mixer to determine proper flow rates
of the stock PEG, citrate, and water into the mixer to achieve the desired TLL 32% TLR
0.5 ATPS (Appendix Figure A.1). To confirm the proper ATPS was formed by the
mixer, physical property measurements of the PEG-rich and citrate-rich phase after
separation were performed on the density, dynamic viscosity, and refractive index, as
described previously [7]. Density measurements were performed by weighing a 1 mL
sample on a Mettler-Toledo analytical balance (Columbus, OH). Dynamic viscosity
measurements were performed with an SV-10 sine-wave vibro viscometer from A&D
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(Tokyo, Japan). Refractive index measurements were performed using a Digital Brix/RIChek refractometer from Reichert Technologies (Depew, NY). These measurements were
used to compare batch-mode and continuous-mode phase samples to confirm proper
ATPS formation.
To equilibrate the continuous ATPS, 45% PEG, 30% citrate, and water were
pumped through a mixer at 1.45 g/min (ρ=1.065 g/mL), 1.45 g/min (ρ=1.158 g/mL), and
0.73 g/min (ρ=1.0 g/mL), respectively, for a total mixture flow rate of 3.63 g/min
(ρ=1.209 g/mL). The PEG, citrate, and water flowed through the entire system for 15
minutes to allow for steady-state operation prior to introducing any viral product. After
system equilibration, the water line was switched to a crude viral product tube for
purification for continuous operation. PEG-rich and citrate-rich fractions were collected
by two individual peristaltic pumps set at different flow rates (typically between 1.0-1.5
mL/min) to keep the interface of the phases within the separator at the same level.
Fractions were collected every 2 minutes for 10 seconds. After fraction collection, PPV
was quantified by MTT assay to assess recovery in both phases. Recovery of PPV in the
PEG-rich and citrate-rich phases was calculated using Equation 5.1:
𝑃𝑃𝑃𝑃𝑃𝑃 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 (%) = �

10𝑇𝑇𝑃𝑃,𝐶𝐶 ∙ 𝑉𝑉𝑃𝑃,𝐶𝐶
� 𝑇𝑇𝑀𝑀
10 ∙ 𝑉𝑉𝑀𝑀 � ∙ 100

(5.1)

where T is the titer of PPV (log10 MTT50/mL) in the PEG-rich phase (P), citrate-rich
phase (C), or PPV starting material (M), VP,C is the volume of the fraction collected for
10 seconds (mL), and VM is the volume of starting material flowed into the system for the
total testing time (mL).
Recovery of the HIV VLPs in the PEG-rich and citrate-rich phases was calculated
from fluorescence measurements using Equation 5.2:
𝐻𝐻𝐻𝐻𝐻𝐻 𝑉𝑉𝑉𝑉𝑉𝑉 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅 (%) =

𝑅𝑅𝑅𝑅𝑈𝑈𝑃𝑃,𝐶𝐶 ∙ 𝑉𝑉𝑃𝑃,𝐶𝐶
𝑅𝑅𝑅𝑅𝑈𝑈𝑀𝑀 ∙ 𝑉𝑉𝑀𝑀

∙ 100

(5.2)

where RFU is the constant-volume relative fluorescence units per 100 μL of the PEG-rich
phase (P), citrate-rich phase (C), or starting HIV VLP material (M), and V is the phase
volume measured (μL).
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5.2.2.8 SDS-PAGE, Bradford assay, PicoGreen DNA assay
Contaminant protein partitioning was visualized using sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE). The gels were run using 4-12% BisTris 1.0 mm 12-well NuPAGE™ gels with NuPAGE™ MOPS running buffer in an
XCell SureLock Mini-Cell from Life Technologies (Carlsbad, CA). Samples were
prepared and denatured by mixing 25 μL of sample in 25 μL 4X sample buffer with
addition of 4 μL of 2-mercaptoethanol. Samples were placed in a dry block heater at
95°C for 5 minutes prior to loading. The SeeBlue Plus2 pre-stained protein ladder (19114 kDa) was used as the protein band standard. 10 μL of protein standard and sample was
loaded into the gel and ran at a constant 200 V for 50 minutes. Gels were stained with
SimplyBlue™ SafeStain as per the manufacturer’s microwave protocol for a 5-ng
detection limit.
Contaminant proteins present in each ATPS phase were quantified using the
Pierce™ Bradford Coomassie assay from Thermo Scientific according to the
manufacturer’s microplate protocol. The concentration of virus present in samples is
much lower than the limit of detection for the Bradford assay and therefore did not
interfere with contaminant protein quantification. To eliminate interference from high
concentrations of PEG and citrate present in samples, PEG-containing samples were
diluted 1:33 in nanopure water and citrate-containing samples were diluted 1:22 in
nanopure water prior to addition of assay reagents. Contaminant protein recovery was
calculated using Equation 5.3:
𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 (%) =

𝐶𝐶𝑃𝑃,𝐶𝐶 ∙ 𝑉𝑉𝑃𝑃,𝐶𝐶 ∙ 𝐷𝐷𝐹𝐹
𝐶𝐶𝑀𝑀 ∙ 𝑉𝑉𝑀𝑀 ∙ 𝐷𝐷𝐷𝐷

∙ 100

(5.3)

where C is the protein concentration (μg/mL) in the PEG-rich phase (P), citrate-rich
phase (C), or PPV starting material (M). DF is the dilution factor for each sample.
DNA content in the PEG-rich and citrate-rich samples was quantified using the
Quant-iT PicoGreen dsDNA kit from Thermo Scientific. Standard curves were created by
diluting the stock λ DNA standard in a range of 1-10 ng/mL in 2 w/w% PEG and 0.24
w/w% citrate diluted in 1X TE buffer for quantitating dsDNA in PEG-rich and citraterich samples. A standard curve from 10-200 ng/mL in 1X TE buffer was created to
quantitate starting viral product dsDNA content. The PEG-rich samples were diluted in
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1X TE buffer to 2 w/w% PEG according to the manufacturer’s recommendation, and
citrate-rich samples were diluted in 1X TE buffer to 0.24 w/w% citrate to reduce assay
interference. Samples were compared to the total amount of dsDNA present in the crude
starting PPV to quantify DNA removal. DNA recovery was calculated using Equation
5.4:
𝐷𝐷𝐷𝐷𝐷𝐷 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 (%) =

𝐶𝐶𝑃𝑃,𝐶𝐶 ∙ 𝑉𝑉𝑃𝑃,𝐶𝐶 ∙ 𝐷𝐷𝐷𝐷
𝐶𝐶𝑀𝑀 ∙ 𝑉𝑉𝑀𝑀 ∙ 𝐷𝐷𝐷𝐷

∙ 100

(5.4)

where C is the DNA concentration (ng/mL) in the PEG-rich phase (P), citrate-rich phase
(C), or PPV starting material (M).

5.3 Results and discussion
5.3.1 Model virus and virus-like particles
PPV and HIV VLPs were used as viral products to test the ability of continuous
ATPS to partition viral products to the PEG-rich phase while leaving contaminant
proteins and host-cell DNA in the citrate-rich phase. PPV was chosen as a model nonenveloped virus for purification due to its small size and physicochemical properties
making it difficult to recover from traditional filtration or chromatographic techniques.
The physicochemical properties of PPV are summarized in Table 5.1.
HIV VLPs were expressed by genetically modified Hansenula polymorpha cells
donated by Esperovax. These VLPs are created for their potential use as an oral vaccine
candidate. The VLPs self-assemble after the core HIV-1 structural polyprotein gag is
made by the cells and bud through the cell membrane (Appendix Figure A.2). The
physicochemical properties of the HIV VLPs are summarized in Table 5.1. The pI of the
VLPs is unknown but is likely less than 7 for two reasons: first, the pI of the proteins
present in the gag polyprotein are less than 7 [223, 224], and second, glycoproteins
comprising the Hansenula polymorpha cell membrane have high-mannose type Nglycans. The envelope proteins terminate with mannose residues that have excess
hydroxyl groups, likely resulting in a pI well below 7 [225]. The enveloped HIV VLP
was chosen to demonstrate the flexibility of the continuous ATPS to purify a potential
vaccine candidate.
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Table 5.1: Virus and VLP physicochemical properties
Virus
PPV
HIV VLP

Model For

Genome

Human B19 parvovirus ssDNA
[226]
[227]
HIV oral vaccine

None

Shape

Envelope

Icosahedral
[228]
Pleomorphic spherical
[230]

No
[228]
Yes
[230]

Size
pI
(nm)
18 – 26 4.8 – 5.1
[227]
[229]
80 – 120
<7
[137] [223, 224]

5.3.2 Selection of in-line mixer
The first unit operation to be designed was the in-line mixer. The chosen mixer
needed to produce a homogeneous mixture of the PEG, citrate, water, and viral particles
to allow for proper mass transport of viral particles to each phase. The in-line mixer
performance was evaluated by comparing each one to the mixing ability of an airpowered Cowles blade mixer. The air-powered mixer (Figure 5.3A) was used as the gold
standard for mixing the components, as it produces turbulent mixing with a spinning
blade for high shear rates. A straight length of tubing the same length as the in-line
mixers was used as the negative control to demonstrate no mixing, as the system was run
in laminar flow (Figure 5.3B). Both in-line mixers (Figure 5.3C and D) were compared
to the air-powered mixer’s ability to create a homogeneous mixture. Due to the high
viscosity of PEG and low flow rate of the system, the helical mixer and glass bead mixer
were tested, which are both capable of dispersing high viscosity fluids in the laminar flow
regime [231, 232]. A helical static mixer redistributes fluid in the radial and tangential
directions using only the process stream’s energy, which achieves mixing by disrupting
the streamlines in laminar flow [233].
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Figure 5.3: Collage of different mixing modes for continuous ATPS. Mixing ATPS with
an A) air-powered mixer, B) straight length of tubing, C) glass bead mixer, D) and helical
mixer.
The two in-line mixers, the glass bead mixer and the helical mixer, were tested for
their ability to produce a homogeneous mixture at their outlet, and for proper phase
separation after mixing. Mixing and settling was visualized with the addition of neutral
red. Neutral red was added to the citrate phase and then partitioned to the PEG-rich
phase. Mixing the ATPS components with the air-powered mixer for 5 minutes resulted
in a completely homogeneous mixture shown in Figure 5.3A at 0 minutes of settling
time. After 20 minutes of settling time, the neutral-red dye partitioned to the PEG-rich
top phase, leaving the citrate-rich bottom phase clear seen in Figure 5.3A. The mixing
and partitioning shown in Figure 5.3A was used as the benchmark for the in-line mixers
to determine if proper mixing was achieved.
A flow rate of 3 mL/min (3.63 g/mL) was chosen as a starting basis to flow
through the glass bead mixer and the helical mixer. The glass bead mixer was expected to
produce a highly homogeneous mixture due to flow distribution as the liquid components
encountered the beads [163]. Mixing is achieved in a glass bead mixer because as the
laminar flow streamlines encounter a bead, they are deflected around the bead causing
crowding between phases next to the sphere. This crowding results in a change in the
velocity of the streamlines close to and far away from the bead. The difference in
109

streamline velocity causes convective mixing [234]. However, the glass bead mixer did
not produce a fully homogeneous mixture as there is a clear interface between the phases,
indicating that proper mixing was not achieved, seen in Figure 5.3C (red arrow) at 0
minutes of settling time. Additionally, a high pressure drop was observed across the glass
bead mixer during testing due to the high viscosity of PEG. This high pressure drop, even
at a relatively low flow rate of 3 mL/min, excluded it for further scaled up experiments.
The helical mixer was able to produce a more homogeneous mixture (Figure 5.3D, 0
min) which was similar in appearance to the air-powered mixer. This successful mixing
was achieved because the helical elements in the mixer disrupt and disperse the laminar
flow streams radially towards the tube wall to induce convective mixing [233]. By redistributing laminar flow streams radially, striations, or unmixed regions, are minimized
[232]. The mixing action of the helical mixer was greater than the glass bead mixer
possibly because in the glass bead mixer, especially in the creeping flow regime, the
streamlines may not have been sufficiently dispersed radially. additionally, the helical
mixer does not have the issue of generating a high pressure drop since most of the mixer
is an open channel compared to the glass bead mixer.
The helical mixer was able to closely replicate the mixing ability of the airpowered mixer, and for this reason, was chosen as the in-line mixer type for the
continuous ATPS. A still image from a video of the helical mixer action is shown in
Appendix Figure A.3. The video shows a neutral red dye being dispersed evenly
throughout the mixture as it travels down the length of the mixer.
5.3.3 Helical mixer performance simulated in COMSOL Multiphysics
A simulation of the helical mixer was generated in COMSOL Multiphysics to
further confirm mixing action of the PEG and citrate phases. The steady-state flow
structure inside the mixer was visualized by plotting the magnitude of the fluid velocity
contours at several cross-sections along the tube and by drawing streamlines originating
from the inlet, shown in Figure 5.4A. The tortuous paths of the flow streamlines
highlighted the critical role of advection in facilitating mixing. Additionally, the degree
of mixing along the tube was visualized in the form of cross-sectional contours of the
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phase-field variable, shown in Figure 5.4B. The simulation revealed that the red colored
PEG phase and blue colored citrate phase are efficiently blended by the helical blades. By
10th element of the helical mixer, the red and blue color are nearly completely mixed,
represented by the green color shown in Figure 5.4B. These results illustrated how well
the PEG and citrate phases were blended efficiently by flowing it through a properly
designed static mixer consisting of a tube embedded with a series of twisted blades.
Overall, numerical calculations corroborated nicely with the experimental observations,
and provide further confirmation of the excellent performance of the helical mixer.
This simulation will be helpful in future scale-up designs of the continuous ATPS
to simulate increased flow rates, different phase forming concentrations, and tubing sizes
without extensive experimental trials.

Figure 5.4: COMSOL Multiphysics modelling of in-line helical mixer showing the A)
mixer geometry and B) mesh pattern used in the simulation. C) Streamlines and fluid
velocity magnitude contours and D) phase field contours
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5.3.4 Settler design
A settler must be used to allow the PEG-rich and citrate-rich phases to separate
after mixing. From the experimental study of the different in-line mixers, 20 minutes of
gravity-driven settling time was necessary to achieve phase separation in batch systems.
This settling time was achieved in the settler section of the bench scale set-up, seen in
Figure 5.1D. The first part of the settler section used a straight length of tubing to begin
phase separation. The second part of the settler section was a separator column to allow
for phase hold-up before collection. Half of the separation time was achieved with a 15
mL tube separator, and the other half of the separation time was achieved using tubing
between the mixer and settler. To achieve the separation time, 3 m of 2.0 mm ID tubing
was used.
To determine if the continuous settler section was allowing the phases to separate
properly, refractive index (RI), dynamic viscosity, and density of the PEG-rich was
collected and compared to the batch ATPS. For the citrate-rich phase comparison
between batch and continuous modes, only density was measured, as viscosity and RI
measurements are unaffected by varying citrate concentrations. The comparison between
batch mode and continuous mode measurements, along with the percent difference
between the measurements can be seen in Table 5.2. The physical property
measurements confirmed that the proper PEG-rich and citrate-rich phases were obtained
after separation evidenced by low percent difference values.
Table 5.2: Physical property measurement comparison between batch mode and
continuous mode ATPS TLL 32% TLR 0.5
System
Batch
Continuous
% Difference

PEG-rich Density Citrate-rich Density
(g/mL)
(g/mL)
1.015 ± 0.009
1.018 ± 0.005
0.20

1.068 ± 0.008
1.070 ± 0.016
0.10

PEG-rich Viscosity
PEG-rich
(mPa·s)
Refractive Index
320 ± 130
310 ± 31
4.5

1.3852 ± 0.0001
1.3847 ± 0.0002
0.03

5.3.5 HIV VLP recovery and purification
The HIV VLPs were first introduced as the viral product to be purified by the
continuous ATPS due to the simple detection of the GFP label. Purification of HIV VLPs
was achieved using the continuous ATPS set-up shown in Figure 5.1B. After 15 minutes
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of system equilibration without HIV VLP flow, HIV VLP was continuously injected into
the system for 40 minutes to test HIV VLP partitioning to the PEG-rich and citrate-rich
phase. 10 minutes after HIV VLP injection, HIV VLPs began to partition to the PEG-rich
phase more favorably compared to the citrate-rich phase, shown in Figure 5.5A.
Although the expected residence time through the separator section was 20 minutes, HIV
VLPs were collected in the outlet sooner possibly because the first HIV VLPs to enter the
filled separator column could travel quicker through the PEG-rich phase due to unhindered transport. After 20 minutes of operation, the partitioning between the two
phases reached a plateau, indicating 20 minutes was the proper separation time to reach
steady-state, which matched the batch system separation time. HIV VLP flow was
stopped at 40 minutes to demonstrate the ability of the system to achieve equilibrium
again after HIV VLP flow stopped (Figure 5.5A, vertical dashed line). No HIV VLP was
collected in either phase 20 minutes after HIV VLP flow was stopped, indicating a 20minute residence time. For the 40 minutes of continuous operation with HIV VLP flow,
69 ± 1% of the HIV VLP was recovered in the PEG-rich phase and 41 ± 7% of the HIV
VLP was recovered in the citrate-rich phase. The recovery and purification of HIV VLPs
are summarized in Table 5.3.
This was an unoptimized system using partitioning parameters that were
established for PPV in batch-mode. With ATPS parameters specifically determined for
the HIV VLPs, recoveries of the VLPs would likely increase.
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Figure 5.5: A) HIV VLP recovery in the PEG-rich and citrate-rich fractions collected
over 60 minutes of continuous separation, B) PPV recovery in the PEG-rich and citraterich fractions collected over 30 minutes of continuous separation, C) DNA recovery in
the PEG-rich and citrate-rich fractions collected from HIV VLP purification, D) DNA
recovery in the PEG-rich and citrate-rich fractions collected from PPV purification, E)
SDS-PAGE gel showing contaminant protein content in the PEG-rich and citrate-rich
phases from HIV VLP purification, and F) SDS-PAGE gel showing contaminant protein
content in the PEG-rich and citrate-rich phases from PPV purification.
Table 5.3: Recovery and purification of PPV and HIV VLPs summary
Virus

PEG-rich Recovery (%)

DNA Removal
(%)

Protein Purity

HIV VLP
PPV

69 ± 1
107 ± 56

73 ± 1
96 ± 3

Pure by SDS
Pure by SDS

The partitioning of host cell dsDNA was observed by quantifying the DNA in
each PEG-rich and citrate-rich fraction using the PicoGreen assay. With the high
concentration of PEG and citrate present in the samples, PEG-rich samples were diluted
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to a final concentration of 2 w/w% PEG, and citrate-rich samples were diluted to a final
concentration of 0.24 w/w% citrate. The DNA partitioning over 40 minutes of continuous
operation of the ATPS can be seen in Figure 5.5C. The DNA recovery in the PEG-rich
phase was 27 ± 1%, and DNA recovery in the citrate-rich phase was 78 ± 5%. This
demonstrates cATPS can remove a majority of host cell DNA in single step.
The purity of the collected HIV VLP product in the PEG-rich phase was
visualized with SDS-PAGE. Protein bands from PEG-rich and citrate-rich fractions
collected during continuous separation of VLPs can be seen in Figure 5.5E, with all
detectable proteins partitioning to the citrate-rich phase. The figures show that the PEGrich phase containing the HIV VLP product is highly purified from contaminant proteins.
5.3.6 PPV recovery and purification
With the successful recovery and purification of HIV VLPs, PPV was introduced
into the continuous ATPS as the viral product. However, initial trials showed low
recovery of PPV in the PEG-rich phase using the same continuous ATPS used for HIV
VLPs. Typical PPV recovery was 10-15% in the PEG-rich phase, and 60-80% in the
citrate-rich phase, which was not expected. Batch experiments using the same ATPS
concentrations had over 70% recovery in the PEG-rich phase, with rarely any PPV in the
citrate-rich phase, as it was readily salted-out of the citrate when mixed with a vortex
mixer [7]. It was hypothesized that PPV takes longer to partition to the PEG-rich phase
compared to HIV VLPs due to the difference in pI (5 for PPV and likely <5 for HIV
VLPs), and differences in the viral surface affinity to the relatively more hydrophobic
PEG-rich phase. The pI of the viral product in ATPS directly effects the salting-out
ability of the citrate. The net negative surface charge on PPV at a system pH of 7 is of
less magnitude when compared to the net negative surface charge on the HIV VLPs
because of the lower pI. This makes the HIV VLPs electrostatically repulsed out of the
citrate-rich phase with more force than PPV. Additionally, HIV VLPs have a lipid bilayer
which is hydrophobic due to the presence of many mannose N-glycans on the lipid
surface [235]. This allows the HIV VLPs to have a higher affinity to the relatively more
hydrophobic PEG-rich phase compared to PPV, which has been shown to be slightly
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more hydrophobic than common proteins [113]. It was hypothesized that HIV VLPs were
quickly salted-out from the citrate-rich phase to the interface and pulled into the PEGrich phase by hydrophobic interactions between the HIV VLP lipid bilayer and high MW
PEG.
A different mixing strategy was implemented for the PPV-containing ATPS to
ensure PPV had time to partition to the PEG-rich phase after being salted-out from the
citrate-rich phase. This was achieved by mixing a 250 g system with 10 vol% PPV in a
glass bottle with a stir bar and flowing directly into the continuous settler. This design
change for PPV purification can be seen in Figure 5.6 (note the change from the helical
mixer in Figure 5.1B).

Figure 5.6: Mixer set-up for ATPS TLL 32 TLR 0.5 with 10 vol% PPV for continuous
purification
After the 250 g system was mixed in the glass bottle with a stir bar for 10
minutes, the PPV-containing ATPS was continuously flowed through the separator
tubing and settler sections. PPV favorably partitioned to the PEG-rich phase as expected
during the 30 minutes of continuous operation, shown in Figure 5.5B. For the 30 minutes
of continuous operation, 107 ± 56% of the PPV was recovered in the PEG-rich phase and
0.9 ± 0.3% of the PPV was recovered in the citrate-rich phase. The recovery and
purification of PPV are summarized in Table 5.3.
The DNA recovery in the PEG-rich phase was 1.1 ± 2.7%, and the DNA recovery
in the citrate-rich phase was 85 ± 10%, shown in Figure 5.5D. The high recovery of
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DNA in the citrate-rich phase is consistent with another study that recovered plasmid
DNA in the salt-rich phase of ATPS [167]. Thus, this continuous ATPS is a good unit
operation for the removal of DNA from viral products and increased mixing may assist in
DNA removal from the PEG-rich phase.
SDS-PAGE was performed on every other collected fraction to visualize the
purity of the PEG-rich and citrate-rich phase, shown in Figure 5.5F. The main
contaminant in the crude PPV injected into the system was BSA. The PPV was made
with 10 vol% FBS added to the cell culture media, which contains 3-5 g/dL of total
protein [236]. The citrate-rich fractions contained a majority of the contaminant proteins,
with only minimal amounts of protein seen in the PEG-rich fractions. The protein band
present in the PEG-rich fractions correspond to BSA present in the sample with high
concentration of PEG. Proteins present in high concentrations of PEG are known to cause
smearing and protein band migration [237], which was also tested by spiking known
concentrations of BSA into water and PEG to compare the protein band locations
(Appendix Figure A.4).
The Bradford assay was used to attempt to quantify the protein content in the
PEG-rich and citrate-rich phases. Due to high concentrations of PEG and citrate in the
samples, 27 w/w% and 24 w/w% respectively, samples were diluted to 1 w/w% to
minimize the interference. However, batch-mode experiments showed diluting the
samples to 1 w/w% PEG caused the protein concentration to be below the lowest limit of
detection possible by the assay at 2.5 μg/mL. This resulted in <56% protein recovery in
the PEG-rich phase, however, the true protein content is expected to be much lower in the
PEG-rich phase. Protein recovery in the citrate-rich phase was 15 ± 7%, with the
remaining protein likely trapped in the interface between the PEG- and citrate-rich
phases. While it was difficult to quantify, high levels of proteins were removed from the
stock PPV.

5.4 Conclusions
This is the first demonstration of continuous ATPS for viral particle purification.
This system was able to purify both an enveloped (PPV) and non-enveloped (HIV VLP)
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virus from their contaminants. The continuous ATPS was able to recover 107 ± 56% of
PPV in the PEG-rich phase with high protein and DNA removal. The system was also
able to recover 69 ± 1% of HIV VLPs in the PEG-rich phase with similar contaminant
removal. The scale up and continuous operation of this ATPS was achieved by ensuring
continuous mixing and settling of the ATPS components was achieved. Mixing was the
critical step to partition the viral product to the PEG-rich phase while leaving the
contaminants in the citrate-rich phase. HIV VLPs were readily partitioned to the PEGrich phase when mixed by the helical mixer, but PPV required the use of a mechanical
mixer to ensure adequate phase contact between ATPS components. This difference in
partitioning ability between the two viral products was hypothesized to be due to the
difference in physicochemical properties of the virus. The pI of the viral products dictated
the salting-out ability of the citrate-rich phase and the presence of a lipid bilayer envelope
of HIV VLPs allowed them to easily partition to the PEG-rich phase. With further scaleup and optimization of the continuous ATPS for a target viral product, this purification
process has the potential to be used in large-scale, fully continuous downstream
processing trains in vaccine manufacturing.
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6 Conclusions and future work
6.1 Conclusions
This dissertation discussed the development of two novel virus detection methods
and one virus purification method. The first detection method used graphene biosensors
and was discussed in Chapter 3. The second virus detection method utilized gold
nanoparticle (AuNP) aggregation and was discussed in Chapter 4. The virus purification
technique was a scaled up continuous aqueous two-phase system (ATPS) and was
discussed in Chapter 5.
Graphene ink printed biosensors were created for potential use as inexpensive
point-of-care devices. The goal was to flexographically print electrochemical biosensors
that were capable of distinguishing between analyte-containing samples compared to
buffer-only samples. The sheet resistivity (SR) on the sensor surface was monitored as
different concentrations of analyte was applied and compared to the SR changes due to
buffer-only applications. Biosensors created with paper and non-paper substrates showed
no ability to distinguish between either sample applied to the surface. The number of ink
coats, ink conductivity, and graphene sheet hydrophobicity/size were varied in attempts
to change the electrical and chemical properties of the biosensors without success. Each
set of tested biosensors resulted in the same conclusion: SR changes were due to applying
any liquid to the surface, independent of what biomolecule was present in the sample.
This conclusion led to the strategy of applying hydrophobic wax barriers on the graphene
surface to contain the liquid sample in a testing region without contacting the electrical
leads. However, wax barriers were reduced the swelling effects of the biosensors but
were also unsuccessful at protein detection. Additionally, functionalization of the
graphene sheets with a sandwich enzyme linked immunosorbent assay (ELISA) was
performed which also lead to insufficient SR differences to detect target analytes.
Overall, with a wide variety of parameters tested for the biosensors, no positive and
publishable results were obtained.
The virus detection ability of the AuNP aggregation assay was studied using
different sizes of AuNPs. The original assay utilized 15 nm AuNPs for the detection of
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porcine parvovirus (PPV) to 6 log MTT50/mL and bovine viral diarrhea virus (BVDV) to
4 log MTT50/mL when aggregated by 1 M mannitol. The goal was to synthesize other
sizes of AuNPs and use them in the assay to lower the limit of detection (LOD). Seedmediated, room temperature synthesis of 27, 68, 96, 100, and 106 nm diameter AuNPs
was successfully performed. The AuNPs were characterized by ultraviolet-visible
spectroscopy (UV-Vis), dynamic light scattering (DLS), and transmission electron
microscopy (TEM). The different sizes of AuNPs were used to explore how the LOD of
the assay would change based on the differences in interactions between AuNPs and viral
particles. AuNPs with a 40 nm diameter were complexed with PPV, resulting in a LOD
of 7 log MTT50/mL when aggregated by 1 M mannitol. AuNPs with a 50 nm diameter
were complexed with BVDV, resulting in a LOD of 5 log MTT50/mL when aggregated
by 1 M mannitol. AuNPs with a diameter of 5 nm were used in an attempt to detect PPV,
but the high concentrations of osmolytes used in the aggregation step led to AuNP
aggregation regardless of the presence of virus or control protein. Neither an increase nor
decrease in the size of AuNPs lead to an improved LOD compared to the published work
of using 15 nm AuNPs in the same detection assay. These results indicated that the size
of AuNPs used in the virus detection assay do not play a critical role in detection.
A novel continuous virus purification technique using an aqueous two-phase
systems (ATPS) was developed. The goal was to scale up a batch ATPS and confirm the
recovery and purification of PPV and human immunodeficiency virus-like particles (HIV
VLPs) was not lost. The continuous mixing section of the ATPS was identified as the unit
operation that influenced proper viral particle partitioning to the poly(ethylene glycol)
(PEG) rich phase. Different in-line mixer types were tested for their ability to properly
mix the citrate salt and viscous PEG components. The components flowing through the
system were in the laminar flow regime due to the low flow rate tested for the benchscale operation and high viscosity PEG. Testing revealed that an in-line helical mixer was
able to disperse the phases in the laminar flow regime. HIV VLPs were readily
partitioned to the PEG-rich phase when mixed by the helical mixer, but PPV required the
use of a mechanical mixer to ensure adequate phase contact between ATPS components.
This difference in partitioning ability between the two viral products was hypothesized to
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be due to the difference in physicochemical properties of the virus. The pI of the viral
products dictated the salting-out ability of the citrate-rich phase and the presence of a
lipid bilayer envelope of HIV VLPs allowed them to easily partition to the PEG-rich
phase. The continuous ATPS was able to recover 107 ± 56% of PPV in the PEG-rich
phase with high protein and DNA removal. The system was also able to recover 69 ± 1%
of HIV VLPs in the PEG-rich phase with similar contaminant removal. With further
scale-up and optimization of the continuous ATPS for a target viral product, this
purification process has the potential to be used in large-scale, fully continuous
downstream processing trains in vaccine manufacturing. This work was the first
demonstration of continuous ATPS for viral particle purification.

6.2 Future work
This dissertation contains numerous tests to develop a graphene biosensor for
rapid analyte detection, an optimization strategy for the AuNP virus detection assay, and
a scale up design of a continuous ATPS. However, there are other experiments that can
be performed to further improve each method.
To improve the graphene biosensors for analyte detection, the graphene ink
properties could be altered. Results were discussed from biosensors created with a
different ink binder and graphene nanoplatelet grade, but other binds and grades of
graphene could be used. For example, a more hydrophilic ink binder could be used during
the formulation of the ink which could provide biomolecules a more suitable graphene
ink surface during sample application and testing.
The LOD of the AuNP aggregation assay was not improved using different sizes
of AuNPs. This indicated that AuNP size was not the main influencer in virus detection.
Many other system parameters exist that could influence the detection ability. The system
pH could be lowered closer to the virus pI, which would create more positively charged
patches on the virus surface. With more positively charged patches, the negatively
charged citrate-capped AuNPs could electrostatically bind to the AuNPs more readily.
With more AuNPs complexed with the virus, the light scattering ability of the aggregated
complexes with less viral particles could be improved, leading to a lower LOD. One
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possible issue with this change would be the stability of the AuNPs at a lower pH, as the
change in pH could cause the citrate-capped AuNPs to aggregate. Different shapes of
AuNPs also exist, such as gold nanorods (AuNRs), gold nanostars (AuNSts), and gold
nanocubes (AuNCs). The different shapes of AuNPs have different characteristic UV-Vis
spectra and light scattering ability. For example, AuNRs have a characteristic two-peak
UV-Vis spectra due to the longitudinal and transverse surface plasmon resonance (SPR)
properties due to the large aspect ratio of rods compared to spheres [238]. This could be
exploited because as AuNRs aggregate, one of their characteristics peaks could disappear
due to losing that characteristic aspect ratio of monodisperse AuNRs. Additionally,
different osmolytes could be used to induce aggregation in the assay. Other osmolytes
such as alanine and trehalose have been shown to aggregate enveloped and nonenveloped viruses, which could be used to aggregate the AuNP/virus complexes [111,
112]. Alanine is an amino acid with a hydrophobic side chain that may be able to
aggregate viral particles more effectively. Alanine residues in protein molecules are
normally buried within the protein structure to protect it from solvent exposure [205].
This effect could be exploited for the aggregation assay because the hydrophobic residues
from alanine could aid in stabilization and enhanced aggregation of the dehydrated
hydrophobic patches of virus particles. Trehalose is a sugar with two molecules of
glucose linked by an α, α-1,1-glucosidic bond [206]. Trehalose has a high affinity for
water due to multiple hydrogen bonding events between its two glucose rings and water
molecules [207]. The high affinity for water would rapidly dehydrate the virus surface,
potentially causing more virus aggregates to form as more and more water is pulled away
from the virus surface. This could improve the AuNP assay by allowing a lower
concentration of osmolyte to be used in the aggregation step, or to dehydrate a smaller
concentration of virus particles due to the strong dehydration ability of trehalose.
The ATPS was the first of its kind technique for continuous viral particle
purification, which leaves it open for numerous optimization opportunities and future
work to make it a complete and robust process. The current system could be improved by
implementing a true continuous mixer for PPV purification. One possible way to
accomplish this would be to use the same glass bottle/stir bar configuration but purchase
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another 3-channel pump to flow the stock components into the mixer. The current system
could also benefit from additional scale-up beyond 3 mL/min. At an increased flow rate,
the helical mixer should have increased performance as turbulence is reached in the
mixer. If sufficient mixing is not achieved with the single 12-element helical mixer,
additional mixers could be put in series, or a larger-diameter helical mixer could be
constructed from larger inserts. Proper quantification of contaminant proteins in the PEGrich and citrate-rich phases also needs to be performed. Attempts to quantify the protein
in both phases using the Bradford assay, microBCA, and UV adsorption were mostly
unsuccessful due to the high concentrations of PEG and citrate interfering with the assay
reagents. One quantification technique that may possibly work is densitometry from
SDS-PAGE gels. This technique has been used before in a PEG 400 Da-potassium
phosphate ATPS, and could be implemented for our PEG 12,000 Da-citrate ATPS [179].
Ideally, in-line biomolecule quantification techniques should be implemented because
this is a fully continuous ATPS. With robust in-line quantification techniques, industrial
implementation of a continuous ATPS could be realized. This is because industrial
bioprocesses are under strict regulatory guidelines that require quantification of the
bioproducts at each stage of the manufacturing process. One possible in-line
quantification technique could utilize nanoparticle tracking analysis (NTA), but issues of
resolution to detect viral particles is a concern. Additional changes to the ATPS itself
could result in improved recovery and processability. Unpublished work in the Heldt lab
has shown the addition of osmolytes to ATPS improves the recovery of the viral product
on a lower TLL. A lower TLL means a lower w/w% PEG-rich phase is collected, which
has a much lower viscosity without a loss of recovery. This change would increase the
processability of the PEG-rich product containing phase for further downstream
processes. One of these downstream processes is the recovery of the viral product out of
the PEG-rich phase. Two methods for recovering the viral product out of the PEG-rich
phase are back extraction using a second stage of ATPS or filtering the viral product out
of the PEG-rich phase. Back extraction is the technique to partition the product from the
PEG-rich phase into the citrate-rich phase using a different ATPS that more favorably
partitions the virus to the citrate-rich phase. This technique has been used before to purify
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and back extract foot-and-mouth disease virus in a batch system [174]. Lastly, to
convince industry to implement a continuous ATPS for virus purification, an economic
analysis should be performed.
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Appendix for Chapter 5
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Figure A.1: Mass balance and schematic of 32% TLL 0.5 TLR ATPS. The green boxes
are boxes that should be changed for each run to ensure the density of PEG and citrate
result in the correct flow rate.
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Figure A.2: TEM images of HIV gag-GFP VLPs purified by ultra-centrifugation

Figure A.3: Helical mixer video still showing neutral red dye dispersing through the
phases
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Figure A.4: SDS-PAGE of 0.01-4 mg/mL BSA in water and 33 w/w% PEG showing
band migration
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Fig. 1. Simplify scheme of continuous
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Fig. 1. Graphene paper microdevice.
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Fig. 1. Schematic diagram of a
colorimetric assay based on unmodified
AuNPs for detection of full length HCV
RNA.
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